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ABSTRACT
Total N-acetylneuraminic acid (NANA) and lipid-bound 
sialic acid (LSA) were evaluated as indicators of 
tumour burden in a range of human tumours and also an 
animal model system.
For human bladder carcinoma, both serum and urinary 
total NANA were found to lack the sensitivity 
required for use as markers for small tumour burden. 
However, serum NANA levels were significantly 
elevated in cases of advanced disease, thereby 
implying a role for this marker as a supplementary 
parameter in the clinical mdnitoring of high stage 
bladder carcinoma.
In the evaluation of total serum NANA as an indicator 
of human prostate tumour burden, NANA levels were 
monitored m  10 patients undergoing treatment for 
advanced disease over periods ranging from 3 - 6  
months. Individual isolated NANA determinations did 
not always reflect tumour burden. This marker 
displayed characteristics of an acute-phase reactant, 
whereby a large incidence of false positive results 
indicated a deficiency in the specificity of NANA as 
an indicator of tumour burden. However, serial 
determination of NANA was found to be useful as a 
means of monitoring patient response to therapy.
Using an animal model system, both total serum NANA 
and serum LSA were evaluated as tumour markers for 
Landschutz ascites tumour (LAT). Prolonged
monitoring of serum NANA and LSA levels showed that 
LSA more accurately reflected the extent of tumour 
burden•
À modified thiobarbitunc acid micro-assay (VGR- 
Micro) was developed and used to determine total 
plasma NANA levels. The modifications introduced in 
the VGR-Micro assay, while increasing the safety 
factor and reducing the time required for analysis, 
did not adversely affect the performance 
characteristics of the original (Warren) assay.
A murine monoclonal antibody (A5F9) was produced 
against the EJ human bladder carcinoma cell line. 
This antibody recognises an antigen not present on 
either normal tonsillar lymphocytes or blood 
leucocytes. Analysis of A5F9 ascitic fluid (by 
ELISA) showed that this antibody can detect the 
presence of EJ cells at dilutions m  excess of 1 : 
7000.
AN OUTLINE OF THE AIMS OF THI8 CURRENT PROJECT
The objective of this project was to evaluate the 
tumour marker potential of sialic acid, using 
biochemical and immunological investigations, in a 
range of tumours differing in nature and in species 
of origin.
Biochemical investigations involved thorough 
evaluation of sialic acid, both total NANA and LSA, 
as markers for animal and human tumours.
During the course of this research, significant 
problems were encountered with the Warreo 
thiobarbitunc acid (TBA) assay (the hitherto 
standard method of analysis for total NANA). These 
persistent problems inspired the development of a 
modified TBA assay. The modified assay was developed 
to achieve the following:
1. Reduction of interference from 2-Deoxynbose 
(2-DOR).
2. To replace cyclohexanone with a less toxic 
chromophore stabiliser, thereby making the 
modified assay more "operator friendly".
3. To include a degree of automation, thereby 
reduce the time required for analysis.
4. To replace dual wavelength analysis by single 
wavelength analysis (at 560 nm), enabling 
NANA determination from a standard curve.
A modified thiobarbitunc acid micro-assay (VGR- 
Micro) was developed and used to determine total 
plasma NANA levels. The modifications introduced in 
the VGR-Micro assay, while increasing the safety 
factor and reducing the time required for analysis, 
did not adversely affect the performance 
characteristics of the original (Warren) assay.
r
A murine monoclonal antibody (A5F9) was produced 
against the EJ human bladder carcinoma cell line 
This antibody recognises an antigen not present on 
either normal tonsillar lymphocytes or blood 
leucocytes. Analysis of A5F9 ascitic fluid (by 
ELISA) showed that this antibody can detect the 
presence of EJ cells at dilutions in excess of 1 . 
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SECTION 1
INTRODUCTION
The Clinical Potential of Sialic Acid 
as a Tumour Marker.
NOMENCLATURE, STRUCTURE AND DISTRIBUTION OF SIALIC 
ACIDS
1 1
Faillard (1989) stated that "although sialic acids 
are probably more than a million years old, they 
were discovered only half a century ago, and can 
therefore hardly be regarded as an object of 
historical research" Nevertheless, based on the 
special degree of interest shown in this group of 
sugars over the past 50 years, it is possible to 
state that sialic acids have been the subject of 
extensive research
The term "sialic acid" first appeared m  the 
literature in 1952 (Blix aJL ) The standard 
method of nomenclature of sialic acids, adopted by 
consensus, was also proposed by Blix ££. ¿1 (1957),
whereby neuraminic acid was designated as the 
unsubstituted parent structure (Figure 1) and sialic 
acid as the generic name for the family of related 
derivatives having an acyl group on the amino 
nitrogen and frequently O-substituents elsewhere 
The extreme diversity of this group of sugars is 
generated by the different types of O-substitutions 
(usually O-acetyl esters) at the 4-,7-,8- and 9- 
hydroxyl positions of the parent molecule 
(neuraminic acid) Prior to the introduction of the 
standard method of nomenclature, various sialic 
acids were previously referred to by other names, 
including hemataminic acid (Yamakawa and Suzuki, 
1952) and gynaminic acid (Zilliken ££. al , 1955).
The most common of the naturally occurring sialic 
acids is N-acetylneuraminic acid (NANA), which has 
the systematic name 5-acetamido-3, 5-dideoxy-D-
1
glycero-D-galacto-nonulosonic acid (when named as an 
open-chain compound)
Another widely distributed sialic acid is N- 
glycolylneuraminic acid (NGNA). These two species, 
NANA and NGNA, comprise the structural backbone for 
the majority of known sialic acids They occur in 
the pyranose ring form when glycosidically linked to 
other sugars, and this is also the preferred 
conformation in the free state (Figure 2, Ledeen and. 
Yu, 1976)
The sialic acids are widely distributed m  nature, 
either free or as components of homo- and 
heterosaccharides, glycoproteins and glycolipids 
(Tuppy and Gottschalk, 1972) They have been 
reported in viruses, bacteria, invertebrates, 
primitive chordates and vertebrates (including 
fishes, amphibians, reptiles, birds and mammals), 
with sialic acid being ubiquitous in tissues of all 
mammalian species studied to date (Ng and Dain, 
1976) Within the eukaryotic cell, essentially all 
of the sialic acid is m  a bound form incorporated 
in g l y c o p r o t e i n s  and g l y c o l i p i d s  
(sialoglycoconjugates), and these are, to a large 
extent, components of the cell membranes. Sialic 
acids are usually in terminal positions at the non­
reducing ends of oligosaccharide moieties of 
sialoglycoconjugates. In general, the concentration 
is highest in the plasma membrane, lower in the 
smooth endoplasmic reticulum (and possibly Golgi 
apparatus), and lowest in the rough endoplasmic 
reticulum and nucleus (Warren, 197 6).
2
BIQW QIQhh FUNCTIONS OF NANA
1 2
The sialic acids are an extremely versatile group of 
sugars, with numerous biological functions The 
following section describes the principal functions 
of sialic acids and includes a discussion of their 
biological significance.
In 1962, Forrester silL performed micro-
electrophoretic studies on clones of normal and 
polyoma-transformed hamster fibroblasts Treatment 
of both cell types with neuraminidase, prior to 
electrophoresis, resulted in significant reductions 
in electrophoretic mobilities These results 
indicated that approximately 35% of the surface 
charge (of both cell types) arose from surface 
sialic acid moieties In further electrophoretic 
investigations of the same cell types, Forrester 
al (1962) found that while untreated transformed 
cells showed greater electrophoretic mobility than 
their normal counterparts, neuraminidase treatment 
resulted in indistinguishable electrophoretic 
mobilities m  an electric field This observation 
demonstrated that the increased electrophoretic 
mobility of the transformed clone was due to the 
charge enhancing property resulting from increased 
concentration of surface NANA. Cook and Jacobson 
(1968), in a two year study, investigated the 
electrophoretic mobilities of normal and leukaemic 
murine cells so as to characterise and compare the 
chemical nature of their surface charges Exposure 
of normal and leukaemic cells, to neuraminidase, 
lowered their electrophoretic mobilities by 27% and 
4 9%, respectively. These results indicated that 
both cell types possessed significant amounts of 
NANA at their peripheries Confirmation of reduced
3
surface NANA, as the principal cause of reduced 
electrophoretic mobilities, was demonstrated by the 
biochemical detection of liberated NANA in the 
supernatants of enzyme-treated cells More
specifically, since neuraminidase is an a-
glycosidase, therefore unlikely to generate any 
cationic groups, the loss of electrophoretic 
mobility as a result of treatment with this enzyme 
was attributed to removal of the carboxyl groups of 
NANA Kojima and Maekawa (1970) in a similar study, 
performed comparative studies on the effect of 
neuraminidase removal of NANA on the cellular 
electrokinetic charge of rat ascites hepatoma 
While suggesting that NANA may not be the only 
factor responsible for the negative surface charge 
of cells (other factors not specified), results 
again indicated that observed reductions in 
electrophoretic mobility were caused by enzymatic 
removal of the carboxylic groups of cell surface 
NANA Finally, Latner and Turner (1974), using 
electrophoresis, investigated surface modification 
of normal and transformed baby hamster kidney cells 
(BHK21 - C13 and BHK21 C13 Py6, respectively)
Results from Py6 demonstrated that removal of 
surface NANA molecules did not expose an equal 
negative charge, thereby implying that NANA 
molecules constitute a significant proportion of the 
overall negative surface charge of the cell
Other research has shown that the presence of 
terminal NANA residues can influence the lifetime of 
a range of circulating biomolecules Morell fit al 
(1971), using an animal model system, found that the 
viability of many serum glycoproteins and 
gonadotropic hormones depends on the presence of 
their normal complement of NANA residues Removal 
of NANA results in exposure of terminal, non­
4
reducing galactosyl residues, thereby facilitating 
their recognition and removal by the liver Reuter 
et al (1980) suggested that O-acetylation of NANAs 
could also influence the lifetime of red blood 
cells
Vaheri al (1972) were the first to demonstrate 
the stimulation of DNA synthesis and cell division 
of density-inhibited cells by exposure to 
neuraminidase (as evidenced by an increase in 3H- 
thymidme incorporation, mitotic index and cell 
counts), whereby enzyme levels of only 0 02 ^ig/ml 
were sufficient to cause a detectable degree of 
stimulation Neuraminidase treatment also resulted 
in increased sugar uptake These results provided 
direct evidence that control of cell growth is 
regulated by NANA residues on the cell surface 
Chandrakant and Bernacki (1975) suggested a possible 
role for NANA in the increased drug resistance of 
the murine leukaemic cell line, L1210, to 
guanylhydrazone, due to competitive uptake of 
spermidine by NANA (acting as a receptor) Surface 
NANA was considered to be a contributing factor to 
increased drug resistance since its removal from the 
leukaemic cells (by exposure to neuraminidase), 
which greatly reduced spermidine uptake, was 
accompanied by increased growth inhibition (from 
guanylhydrazone) Van Heyningen (1974) showed that 
LSAs act as receptors for certain toxins Tetanus 
toxin, which acts on the central nervous system 
(CNS), was shown to be found by at least three LSAs 
in nervous tissue, each differing from the other by 
NANA content The ability of LSAs to bind tetanus 
toxin, which increased with increasing NANA content, 
did not result in loss of toxicity In marked 
contrast, LSAs were found, not only to bind cholera
5
toxin, but also to inhibit its action in the small 
intestine and the skin
Berwick and Coman (1962) suggested that surface NANA 
affects specific physical properties of cells on 
finding that neuraminidase cleavage of NANA resulted 
in decreased "stickiness" of cells to siliconised 
glass Raz ££. (1980), who found that removal of
surface NANA reduced homotypic aggregation of B16 - 
F10 murine melanoma cells, suggested that peripheral 
NANA is also involved in cell aggregation. 
Similarly, Hara aL ai. (1980) demonstrated, from 
experiments involving neuraminidase, that surface
NANA is the essential carbohydrate moiety required 
*for' the platelet - aggregating activity of tumour 
cells Since other research has indicated that 
platelets play an important role in the process of 
metastatic seeding, by causing cell adherence to 
vessel walls (Hilgrad, 1973), and also metastatic 
establishment, by secretion of growth factors (Hara 
et a 1 , 1979), these observations concerning
platelet aggregation imply a role for NANA in the 
promotion of metastatic growth
Extensive research has shown that NANA also may have 
the ability to mask specific recognition sites on 
molecules and cells, resulting in supression of 
antigenicity The ability of NANA to "deamplify" 
antigenic expression can provide a means of immune 
response inhibition, thereby allowing certain types 
of sialylated cells (including cancer cells) to 
evade a host's defence mechanisms
Currie and Bagshawe (1968) attempted to elucidate 
the role of surface NANA in inhibiting the detection 
of the murine LAT by the immune system On finding 
that trypsin sensitive components of the antigenic
6
determinant group were protected from the active 
centre of the trypsin molecule by neuraminidase - 
susceptible NANAs, it was suggested that antigenic 
sites could be protected from immunocompetent cells 
of the host in a similar fashion. Suggested 
protection mechanisms were steric hindrance (due to 
the physical dimensions of the NANA molecule) and 
inhibition by the electrostatic effects of ionised 
carboxyl groups in the region of the sensitive site 
Using a range of neuraminidase enzymes (with 
different sites of action on the NANA substrate), it 
was found that the masking ability of NANA required 
a specific type of linkage to the cell surface, with 
cleavage of a (2-6)-O-glycosidic linked NANA being
essential for unmasking of antigenic sites Urdal 
and Hakamon (1983) found that murine lymphoma cells 
treated with neuraminidase were 6-10 times more 
sensitive to complement-mediated lysis (by a 
specific monoclonal antibody) than were untreated 
cells, clearly indicating that tumour cell 
antigenicity is influenced by sialylation of 
membrane components The importance of surface NANA 
as a modifier of the immune response was further 
demonstrated by Frohman and Cowing (1985), who 
examined the potential functional relevance of the 
differential glycosylation of la molecules (class 2 
major histocompatibility complex, MHC, 
glycoproteins) on the antigen presenting function of 
resting B cells Alteration of surface
glycosylation, by treatment with neuraminidase, 
resulted in a 25-fold increase in B cell antigen 
presentation to T cells Powell et al (1985) 
demonstrated that cell surface NANA influences 
tumour cell recognition, in that a B cell lymphoma 
(AKTB-lb) failed to stimulate thymic lymphocytes 
unless pretreated with neuraminidase In agreement 
with the earlier work of Currie and Bagshawe, it was
7
found that neuraminidase-dependent stimulation of 
lymphocytes is due to the desialylation of specific 
membrane structures (as opposed to total
desialylation), with removal of a (2-6)-linked NANA
being a prerequisite for tumour recognition, 
Schauer (1985) proposed partial loss of NANA from 
the surface of cells, or molecules, as one of the 
causes of autoimmune disease Sarna fit (1988)
successfully used Cis-dichlorodiammine platinum 2 
(cisplatin) in the treatment of mice with syngeneic 
transplantable fibrosarcoma. Ciplatin indirectly 
stimulates the immune response by increasing the 
antigenicity of tumour cells, thereby increasing 
their susceptibility to phagocytosis Since
incubation of tumour cells, with cisplatin, resulted 
in release of NANA, it was concluded that NANA plays 
a major role in the regulation of antigenic 
expression Finally, Benoist fit. &1- (1988)
demonstrated the importance of NANA in masking 
natural killer (NK) target recognition structures, 
whereby neuraminidase treatment of cells resulted in 
enhanced susceptibility to NK-mediated lysis 
However, while the immunostimulatory effects of 
neuraminidase-treated cells and their role in 
rejection of established tumours is well 
authenticated, there has been some controversy as to 
whether neuraminidase effects transplantability. 
Smyth fit. al. (1977) investigated the effects of 
neuraminidase treatment on the transplantability of 
LAT cells (using 3 different mouse strains). While 
neuraminidase treatment reduced tumour 
transplantability at certain inoculum levels, no 
effect was observed, in any of the mouse strains, 
when greater than 106 LAT cells were inoculated. 
Nevertheless, in 2 of the 3 mouse strains tested, 
neuraminidase treatment was found to significantly 
reduce tumour transplantability when inoculum levels
8
of less than 106 cells were used, thereby implying 
that NANA removal resulted in increased LAT 
immunogenicity Furthermore, the failure of NANA 
removal to inhibit LAT growth, on injecting large 
numbers of tumour cells, may have been due to the 
inablity of the murine immune system to cope with 
the large tumour inoculum
1 3
METHODS FOR DETERMINATION OF TOTAL NANA. PROTEIN- 
BQUNP HfiM ft
One of the earliest, and subsequently most commonly 
used, methods of NANA determination is the 
colorimetric thiobarbitunc acid (TBA) assay of 
Warren (1959) The basis of this assay is the 
periodate oxidation of NANA to form |J-
formylpyruvate, following liberation of bound NANA 
using acid hydrolysis (by cleavage of O-ketosidic 
linkages), with chromophore formation and extraction 
using TBA and cyclohexanone, respectively The 
major problem with this assay is interference from 
2-deoxyribose (2-DOR), a constituent of DNA 
Aminoff (1961) then developed an alternative TBA 
method for NANA determination. NANA was cleaved 
from sialoglycoconjugates using either acid 
hydrolysis or the enzyme neuraminidase. Deviations 
from the Warren assay included faster periodate 
oxidation at 37°C (as opposed to room temperature) 
and the replacing of cyclohexanone by acidified 
butan-l-ol (for chromophore extraction) Aminoff 
claimed that this modified TBA assay had greater 
sensitivity and also was less prone to interference 
when dealing with complex biological systems 
Despite these claims, the method of choice for
9
colorimetric determination of NANA over the past 30 
years has been the Warren TBA assay However, the 
problem of interference by the ubiquitious 2-D O R  
persisted Roboz al (1981) developed a modified 
TBA assay whereby it was claimed that interference 
by 2-DOR was eliminated by pH-dependent extraction 
with cyclohexanone. The procedure involved prior 
removal of the 2-DOR chromophore by cyclohexanone 
extraction at pH 5 6 - 6 0 After readjusting the 
pH to 1 7  - 1.9, the NANA chromophore was then
quantitatively extracted, again using cyclohexanone. 
Svennerholm & Svennerholm (1958) devised a 
quantitative method of NANA analysis using paper 
partition chromatography, incorporating a solvent 
system of n-butanol/n-propanol/O IN HC1 (1 2 1, 
v/v) After identification of NANA bands, using 
either the resorcmol or Ehrlich's reagent, followed 
by further extraction, NANA was analysed by the 
resorcmol reaction This method of analysis, with 
an accuracy of ± 3%, was not extensively used, one 
of the reasons being the length of time required to 
perform the assay (the paper chromatography 
separation step alone required a minimum of 18 
hours)
In more recent times, the development of 
sophisticated analytical techniques has resulted in 
a wide range of highly sensitive and highly specific 
methods for determination of NANA. Hammond & 
Papermaster (1975) developed a fluorometric 
microassay based on fluorescence of the TBA reaction 
product of periodate-oxidised NANA, using excitation 
and analysing emission wavelengths of 550 nm and 570 
nm, respectively. This method, with its 500-fold 
increase in sensitivity over previously described 
colorimetric procedures, could detect picomolar 
(10~12M) levels of NANA Interference by 2-DOR was
10
also minimised since its major emission band is 
narrow and centred at 550 nm
High performance liquid chromatogaphy (HPLC) has 
also been employed for NANA quantitation Silver ££. 
al (1981) determined NANA levels using a rapid 
isocratic HPLC method, with separation achieved 
using an Aminex HPX-87 cation-exchange resin This 
method is much more reliable than the conventional 
TBA assay and has a significantly improved maximum 
sensitivity of 0 8 nmol/ml The rapid improvement 
in the analytical ability of HPLC, when applied to 
quantitation of NANA, was demonstrated when Shukla 
et aX (1986) developed a method whereby it was 
possible, following separation on a strong anion- 
exchange resin, to determine a minimum amount of 
0 6 pmol (200 pg) NANA The low limit of detection 
allowed direct determination of NANA, thereby 
eliminating prior sample purification or
concentration An additional advantage was the time 
required for analysis (approximately 10 minutes per
sample) The authors stated that this HPLC method
is not subject to problems encountered when using 
colorimetric assays, whereby results (from the
latter) may be influenced by saponification and 
migration of the O-acetyl groups due to the time and 
chemical conditions required for analysis
Analysis of NANA was further improved by the 
introduction of chromatographic techniques, 
particularly gas chromatography (GC), coupled with 
mass spectrometry (MS) Sugawara (1983)
determined NANA levels by GC-MS, using selected ion- 
monitoring technique, with a stable isotope (N- 
[ 2H3 ]-ANA) as an internal standard This highly 
specific and highly quantitative method of analysis, 
with its low limit of detection (several hundred
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pg) , has additional advantages of minute sample 
requirement (nL quantities), simplicity and speed of 
operation, with very accurate and reproducible 
measurements Sugiyama aX (1988) modified the 
method of Sugawara to determine levels of free NANA 
in human serum, using capillary GC-MS with selective 
ion monitoring and specific separation on a Sep Pak 
silica cartridge Using this method, the
measurements were again specific, accurate and 
reproducible, with the mass fragmentogram of serum 
showing a good signal to noise ratio (indicative of 
low background interference) This method could 
also be used to determine free NANA levels in 
seminal fluid, cerebrospinal fluid, ascites and 
urine, thereby presenting a powerful analytical 
technique for routine clinical monitoring of free 
NANA levels m  patients with disease (especially 
cancer) However, the use of these sophisticated 
analytical techniques, as routine methods of NANA 
determination, may be limited by the high cost of 
required instrumentation
Research, particularly over the past five years, has 
resulted in the production of a range of enzymatic 
assays for NANA determination, many of which are 
available commercially. Boehringer Mannheim have 
produced one such enzymatic kit This method 
incorporates a cascade reaction system, involving 
the enzymes neuramindase, NANA-aldolase and pyruvate 
oxidase, ultimately resulting in the formation of 
hydrogen peroxidase (H2O2 ), the amount of the latter 
being equivalent to NANA content H2O 2 is then 
converted to a dye (using peroxidase) and determined 
colorimetrically at 550 nm The main disadvantage 
of this method is that one of the series of 
reactions results m  the production of pyruvic acid, 
a naturally occurring constituent of body fluids
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For example, the concentration of pyruvate in serum, 
usually between 6 and 12 mg/L (Ogasahara al , 
1985), is equivalent to between 21 and 42 mg NANA/L, 
respectively, thereby resulting m  a potentially 
significant source of interference in the assay 
This particular method is also subject to 
interference from ascorbic acid (Vitamin C) Chien 
et al (1991) developed an enzyme system for NANA 
determination in serum and urine, involving the use 
of two immobilised enzyme pairs which were 
separately immobilised onto 1,12-diamino-dodecane 
agarose (a substance with high coupling capacity) 
While this method has the advantages of enhanced 
enzyme activity, reagent stability and overall 
operational stability, it is also subject to 
interference from pyruvate as a direct result of 
incorporating a pyruvate-forming step in its 
sequence of reactions Ironically, a superior 
enzymatic assay for determination of NANA in serum 
was developed somewhat previously, by Teshima al
(1988) The principal advantage of this method was 
the removal of the pyruvate forming reaction with 
concommitant elimination of its interference 
Additional advantages of this method included a 
highly sensitive endpoint, excellent linearity of 
the dilution curve (extending to approximately 3000 
mg NANA/L) and elimination of ascorbic acid 
interference (by addition of ascorbate oxidase).
Protein-Bound NANA_&__LSA
A method utilising the acidic ninhydrin reaction, 
specifically designed to determine protein-bound 
NANA, was developed by Yao ££. al (1989) This 
simple direct method requires mixing of the sample 
solution with glacial acetic acid and acid ninhydrin
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reagent (2 5%, w/v, ninhydrin in acetic acid/HCl, 
60 40, v/v) Following heating in a boiling
waterbath (10 minutes) and rapid cooling, the O D s 
were recorded at 470 nm Protein-bound NANA levels 
were determined from a standard curve (constructed 
using fetuin, a sialoglycoprotein), linear in the 
range 20 Jig to 3 mg. The rapidity of this method^rt *
makes it ideal when many samples are to be analysed 
simultaneously A method used to determine LSA 
levels was developed by Katopodis & Stock (1980) and 
later modified (Katopodis & Stock, 1982) . It 
involved ganglioside extraction using cold 
chloroform/methanol (2.1, v/v), followed by
precipitation with phosphotungstic acid (Ig/ml) 
After chromophore development, and extraction with 
butyl acetate/n-butanol, 85 15 (v/v) , 0 D s were
recorded at 580 nm LSA levels were determined from 
a standard curve developed from a standard sample of 
NANA Unquestionably, the procedure of Katopodis & 
Stock has been the method most extensively used for 
the determination of LSA levels in both serum and 
plasma However, m  recent years this method has 
been the subject of vociferous criticism The main 
criticism of the method has been that the 
recommended extraction procedure results in 
extraction, not only of gangliosides, but also 
significant amounts of protein-bound NANA Because 
of the discrepancy between amounts of extracted LSA 
(using the method of Katopodis & Stock) and the 
content of pure serum gangliosides, Voigtmann fit. al
(1989) analysed the composition of extracted LSA, 
using immunochemical techniques. The "LSA" fraction 
was found to contain considerable quantities of 
sialoglycoproteins, including acid-a-l-glycoprotein, 
anti-trypsin, haptoglobin and anti-chymotrypsin 
Furthermore, a strong correlation existed between 
elevated LSA levels and the content of acid-a-1-
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glycoprotein in the sera of patients with 
malignancy On the basis of their results, the 
authors suggested that the term LSA, as applied to 
the method of Katopodis and Stock, is misleading, 
since the major contributor to LSA elevations is, in 
fact, a sialoglycoprotein. Similarly, Berra fit. 
(1986) stated that the procedure of Katopodis & 
Stock results in incomplete extraction of LSA from 
serum, followed by an overestimation of this 
fraction in the pellet, after phosphotungstic acid 
precipitation, because of the presence of 
glycopeptides (many containing NANA) Consequently, 
a modified procedure was developed, whereby LSA, 
extracted with chloroform/methanol (2 1, v/v), was 
partitioned in di-isoprophylether, 1-butanol and 
50mM NaCl (6 4 5, v/v) , thereby facilitating 
improved separation of LSA and sialoglycopeptides 
Tautu fit. al (1989), also critical of the afore­
mentioned method, developed an alternative procedure 
for determination of serum LSA, which allegedly 
e x t r a c t e d  all LSA while e x c luding  
sialoglycoprotems This method involves prior 
removal of proteins and glycoproteins (including 
s i a l o g l y c o p r o t e i n s )  by p r e c i p i t a t i o n
(chloroform/methanol, 1 2 v/v) and centrifugation 
The supernatants, containing LSA, are then dried 
under vacuum. Following resuspension in distilled 
water, LSA levels are determined using a modified 
method of the periodate-resorcinol procedure 
(Jourdian fit ai,, 1971) Hess and Rolde (1964)
devised a microflurometric assay for the 
determination of LSA in human brain tissue, based on 
the reaction of LSA with 3,5-di-aminobenzoic acid 
(DABA) in hot dilute HC1 (yielding a product with 
intense green fluorescence) . Excitation and 
emission wavelengths were 405 nm and 510 nm, 
respectively The use of these wavelengths
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minimised interference from contaminating 
fluorochromes, with the main source of interference 
being hexoses (which gave 1 6% as much fluorescence 
as sialic acid on a molar basis) LSA levels were 
determined from a standard curve, linear over the 
range 0-5 nmoles LSA/100 |XX DABA
1.4
STRUCTURAL STUDIES AND CHARACTERISATION OF NANA
In addition to NANA determination, analytical 
techniques have also been employed in the study of 
NANA metabolism, with additional applications 
including identification and characterisation, 
thereby providing invaluable detailed analytical and 
clinical information concerning this important 
biomarker For example, Reuter ££. al (1980) were 
the first to present unambiguous and unequivocal 
evidence, using GC-MS for structural analysis, that 
9-O-acetyl-NANA is the almost exclusive NANA of 
Balb/c mouse erythrocytes In a separate
investigation, Reuter £JL &X (1980), again using GC- 
MS for structural elucidation, also identified a new 
NANA (4-0-acetyl-9-0-lactyl-NANA) present in horse 
submandibular gland glycoproteins Beau ££. ai 
(1980) used thin-layer chromatography (TLC) to study 
the metabolism of 4-O-methyl-NANA (a synthetic NANA 
derivative containing a stable methoxyl substituent 
at C-4) Their results confirmed that substitution 
of the hydroxyl group at C-4 of NANA strongly 
hinders the degradation of sialogylcoconjugates, 
thereby enabling study of the biological influence 
of such modified NANAs when bound to glycoconjugates 
or cells Hutchins al. (1988) demonstrated the 
presence of mono-, di- and tri-O-acetylated NANAs on 
human colon cells using radiochromatrographic and
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chemical techniques (including ion-exchange 
chromatography, paper' chromatography and fast-atom 
bombardment mass spectrometry) Their investigation 
showed that aberrant expression of O-acetylated- 
NANAs was associated with adenocarcinoma of the 
colon, resulting in almost complete loss of di- and 
tri-O-acetylated NANAs It was suggested that the 
loss of O-acetylation in NANA molecules expressed on 
human colon cells could be used as a sensitive 
indicator of early malignancy change, thereby 
enabling a possible screening method for cancer of 
the colon
Monoclonal antibodies have also been used in 
characterisation studies of NANA * Their unique 
degree of target specificity enables distinction 
between closely related antigens, where the 
difference between antigenic epitopes may involve a 
single sugar residue or the type of sugar linkage 
Miyake ££. al (1988) generated two murine monoclonal 
antibodies against GM2 gangliosides associated with 
lung carcinoma in order to identify the molecular 
species of the glycolipid Using these antibodies 
(MK2-34 and MK1-16, directed against NGNA and NANA, 
respectively), it was shown that significant amounts 
of NANA occurred m  several types of lung cancer, 
whereas NGNA was not found in any glycolipid 
fractions from the same origins It was also found 
that the appearance of NANA on the GM2 ganglioside 
correlated well with the degree of differentiation 
of the cancer cells in patients with squamous cell 
carcinoma and adeno-carcinoma of the lung Kannagi 
fii. &JL (1988), who performed both quantitative and 
qualitative characterisation of human cancer- 
associated serum glycoproteins (expressing closely 
related "sialoepitopes"), showed that subtle 
differences m  the linkage of NANA residues (to
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proteins) greatly affect the cancer specificity of 
carbohydrate antigens Cheresh fit al (1984), also 
using a monoclonal antibody (01 l)f were able to 
demonstrate the presence of an O-acylated NANA on 
human melanoma-associated gangliosides, occurring 
possibly as a result of aberrant O-acetylation 
caused by the malignancy
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MECHANISMS SUGGESTING A ROLE EQB^SIALIC ACID AS A 
TUMOUR MARKER
As previously stated (Section 1 1), NANA is mainly 
located at the cell surface (Warren, 1976) . NANA 
aroused the interest of oncologists when it was 
found that levels were significantly elevated on the 
surfaces of many tumour cells (Warren fit al , 1975, 
Van Beek fit , 1975, Yogeeswaran fit SlL r 1978)
Black fit &I. (1983) stated that, in tumour cells, 
shedding of highly sialylated glyconconjugates 
occurs continuously, into body fluids (such as blood 
or urine), in a disregulated way, with the turnover 
of peripheral sugars (including NANA) being 
significantly higher than that of core structures 
This finding implied a possible role for NANA as a 
marker for presence of tumour Feizi (1984), using 
monoclonal antibodies, revealed saccharide 
structures (including NANA residues) of 
glycoproteins and glycolipids as differentiation and 
tumour-associated antigens, Singhai and Hakomori
(1990), in their review of molecular change in 
carbohydrate antigens associated with cancer, stated 
the abnormalities in the profiles of cell surface 
carbohydrates have been found in essentially all 
human cancers and that these include significant
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conformational changes at the cell surface caused by 
the addition of NANA residues The following 
results, from clinical research, provide direct 
evidence that increased surface NANA levels, of 
tumour cells, are due to altered rates of NANA 
biosynthesis and/or altered activity of the enzyme 
sialyltransferase (which attaches NANA to endogenous 
membrane receptors). Evans e t a 1 (1980)
demonstrated that both serum and liver 
sialyltransferase activity increased dramatically 
after implantation of the R3230 AC rat mammary 
tumour It was also shown that, when growth of the 
primary tumour was controlled by chemotherapy, no 
elevation in enzyme activity was detected, 
suggesting that size, or growth rate, of the tumour 
may be a determining factor in alterations of 
sialyltransferase activity Dobrossy fit. ¿2. (1981),
in their study of murine B16 melanoma, found that 
the degree of lung implantation (one of the steps in 
the metastatic process) correlated with the amount 
of tumour cell surface NANA accessible to 
neuraminidase and also tumour cell surface 
sialyltransferase (ectosialyltransferase) activity 
Ivanov fi_t (1985), using [14C] -N-acetyl-
mannosamine as the precursor of NANA, found that the 
biosynthesis rate of NANA was higher in chicken 
hepatoma (Mc-29) than in normal liver cells. 
Hakomori (1985) stated that aberrant glycosylation 
(including sialylation) of glycolipids is a 
ubiquitous property of cancer cell membranes In a 
study of murine colon adenocarcinoma (Kijima-Suda fit. 
al / 1986), the metastatic potential of various
sublines was found to correlate with neuraminidase- 
susceptible (surface) NANA and also 
sialyltransferase activity Baker fit. ¿lL (1987), 
who studied the granulocytes of patients with 
chronic myelogenous leukemia (CML), found that
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elevated activity of a specific sialyltransferase 
(2 8 times higher than that of normal cells) was 
responsible for the aberrant sialylation of O-linked 
membrane oligosaccharides in CML cells, suggesting 
that the resulting increase in sialylation could 
contribute to the pathophysiological behaviour of 
CML granulocytes
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TQTMi .MARKER FORJHMOHB-BnBOHti
The use of total NANA as an indicator of tumour 
burden has been a contentious issue for several 
decades, with numerous claims and counterclaims 
concerning its diagnostic and prognostic potential, 
as applied to oncology Ryan fit. aX (1980) , who 
evaluated total serum NANA (using the Warren assay) 
and carcinoembryonic antigen (CEA, a glycoprotein of 
mol wt approx 200,000 containing 40 - 50%
carbohydrate, Bates and Longo, 1987) as markers for 
human breast cancer, found significantly elevated 
NANA levels in cancer patients which correlated with 
tumour stage CEA was found to be an unsuitable 
marker since, in all stages of disease, a lower 
proportion of patients had elevated CEA levels 
Silver fit. al (1981) evaluated serum NANA and CEA as 
markers for carcinoma of the ovary, a disease 
difficult to clinically diagnose because of its 
diffuse intraperitoneal location Whereas both 
markers were found to lack the specificity required 
for diagnosis, NANA was found to be a better 
indicator of tumour burden in patients with 
established disease, whereby NANA levels increased 
with increased tumour presence Furthermore, in the 
majority of patients with progressing disease,
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significant NANA elevations predated other clinical 
signs of increasing tumour burden by between 1 and 
21 weeks, thereby implying a possible role for total 
NANA as a potentially valuable prognostic indicator 
for ovarian cancer In their study of the total 
NANA content of both cancerous and healthy human 
liver tissue, Alhadeff and Holzinger (1982) found 
that NANA levels were increased ( 1 4 - 7 2  fold) in 
cases of metastacy when compared to their non- 
malignant counterparts Silver £_fc_ (1983)
employed a proportional hazards model to examine 
nine factors, including total serum NANA, as 
possible predictors of malignant melanoma 
recurrence In this capacity, 5 of the 9 factors 
(age, sex, primary site, tumour diameter and tumour 
stage) were found to be unsuitable Of the four 
factors giving positive results, only 2 were 
independent (measured tumour depth and total serum 
NANA) The combined use of these markers, as 
opposed to each one separately, greatly increased 
predictive ability of recurrence, whereby patients 
with lesions greater than 1 75 mm and total NANA 
greater than 2 ^mol/ml were found to have a 12-fold
greater risk of recurrence, within 2 years, than 
those with lesions less than 1 75 mm and total NANA 
below 2 |imol/ml Colli fit al (1989) evaluated the
diagnostic accuracy of total NANA in the diagnosis 
of malignant ascites It was found that NANA could 
be regarded as an accurate marker for neoplastic 
involvement of the peritoneum, in that, a 
statistically significant difference (P < 0 001) 
existed, in NANA levels, between malignant and non- 
malignant ascites The sensitivity, specificity and 
overall diagnostic accuracy of the test were found 
to be 70%, 90% and 82%, respectively
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Neoplastic transformation is not always accompanied 
by elevations in total NANA Ohta fit aX (1968) 
determined total NANA levels of normal and malignant 
cells, using the Warren assay (following liberation 
by either treatment with neuraminidase or acid 
hydrolysis) All the virally transformed cell lines 
were found to have slightly lower amounts of NANA 
than their respective normal counterparts. 
McClelland and Bridges (1973) determined the total 
NANA content of normal and lymphatic leukaemic 
lymphocytes (human origin) A highly statistically 
significant difference (P < 0 001) was found between 
the average total NANA content of the two groups, 
whereby normal levels were approximately ten times 
greater than those obtained for cancerous 
lymphocytes from chronic lymphatic leukaemic (CLL), 
with mean levels being 0 33 |ig/106 cells and
0 04|lg/106 cells, respectively Furthermore, 
decreased lymphocyte total NANA levels, of the same 
magnitude as that observed in CLL patients, were 
also found in cases of acute lymphatic leukaemia 
(ALL) In a similar study, O'Kennedy fit (1982),
who found a 60% reduction in the total NANA content 
of CLL cells (relative to normal peripheral 
lymphocytes) and also a diminution in surface 
(neuraminidase - susceptible) NANA, suggested that 
the observed reduction in NANA levels was probably 
due to the B cell nature of CLL cells
Other research has indicated that total NANA is 
unsuitable for use as an indicator of tumour burden. 
Hoon fit ¿lL (1985) performed both XXL vivo and in 
vitro experiments, using a range of cell lines, to 
determine whether the release of bound NANA was 
related to mammary tumour metastasis The NANA was 
considered to be in bound form, since acid 
hydrolysis was required to release it for HPLC
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analysis From in vivo experiments, where animals 
were injected with 1 - 5 x 106 cells, serum NANA 
levels were found to increase with tumour burden up 
to day 10, after which time, despite further tumour 
growth, levels began to plateau la vitro studies 
confirmed the findings of the animal experiments, 
namely, that the phenotypic expression of bound NANA 
shedding did not correlate well with the metastatic 
potential of the mammary tumour lines, suggesting 
that while NANA could possibly be used as a marker 
for the presence of tumour, it was an unsuitable 
indicator of tumour-burden Moran ££. aL (1985) 
also suggested that the extent of tumour burden may 
not necessarily be reflected in total NANA levels 
A modified Warren assay was used to determine total 
serum NANA levels m  patients with various types of 
malignant disease While statistically significant 
NANA elevations occurred in cases of CLL, no such 
elevations were found in serum NANA of patients with 
either primary or secondary breast cancer 
O'Kennedy ¿1 ¿1 (1991), in their comprehensive
evaluation of NANA determinations in the diagnosis 
of malignancy, found that extent of tumour burden 
was not always reflected in total serum NANA levels, 
thereby limiting its application as a tumour marker
A commonly expressed reservation concerning the use 
of total NANA as a tumour marker arises as a result 
of the fact that, unlike lipid-bound NANA, 
significant elevations in total NANA occur in many 
non tumour-associated disorders, thereby implying 
NANA to be an acute-phase reactant (the latter being 
a substance which responds to various types of 
injury and inflammatory conditions by an increase in 
the rate of synthesis) This observation casts 
doubts on the clinical reliability of NANA 
determinations, since stimulators of an acute-phase
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reaction include surgery, trauma and bacterial 
infection, the latter condition often associated 
with cancerous disease as a result of the impaired 
capability of immune system mechanisms in cancer 
patients. For example, Kiersnowska - Rogowska 
al. (1978), who found elevated serum NANA levels in
patients with acute micromyeloblastic leukaemias, 
readily admitted that the observed increases may 
have been partly due to accompanying inflammatory 
processes (caused by increased susceptibility to 
infection) . Silver ££. al* (1979) found that total 
serum NANA was higher among melanoma patients than 
among aged and sex-matched normal controls, with 
levels tending to increase with tumour burden. 
However, when compared to normal controls, highly 
significant (P < 0.001) NANA elevations were also 
observed in patients with active rheumatoid 
arthritis. It was suggested that at least part of 
the observed increase in serum NANA levels was due 
to contributions from non-specific acute-phase 
reactants such as oci-acid-glycoprotein. Plucinsky
al_. (1986) found significantly (P < 0.001)
elevated NANA levels in patients with 
gastrointestinal and breast cancer, and also 
carcinoma of the pancreas and cholangiocarcinoma. 
While the sensitivity of the test was adequate to 
allow the use of NANA as a monitor of tumour burden 
(especially in cases of severe malignancy), the 
specificity was found to be lacking, since levels 
were also significantly elevated (P < 0.01 - P < 
0.001) in non-tumour pathological controls, 
including intestinal, breast and regional enteritis. 
Shamberger (1984) also reported elevated total serum 
NANA levels in Crohn's disease (a chronic non- 
cancerous intestinal disorder) and psoriasis. 
Stefenelli ££_ al. (1985) evaluated total serum NANA 
levels in patients with malignant tumours, bacterial
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infections and chronic liver diseases From this 
extensive study, involving over 2,000 patients, 
total NANA levels were found to be of limited value 
as a diagnostic test for malignant neoplasms 
Inflammatory diseases (including tuberculosis) 
stimulated elevated NANA levels to such an extent 
that evaluation of simultaneously existing 
neoplastic processes was prevented Therefore, a 
prerequisite for accurate interpretation of test 
results, m  the diagnosis, prognosis and follow-up 
of malignant tumours, is the ability to ensure the 
exclusion of bacterial infections or other acute 
inflammatory disorders (including tuberculosis and 
rheumatoid arthritis) as the cause of elevated NANA
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PROTEIN-BOUND NANA AS A TUMOUR„MARKER
Protein-bound NANA (protein associated NANA, PA- 
NANA) has also been investigated as a possible 
tumour marker Macbeth and Bekesi (1962) evaluated 
plasma levels of several protein-bound 
carbohydrates, including hexoses (galactose and 
m a n n o s e ) , hexosamines (glucosamine and 
galactosamine), fucose and PA-NANA in patients with 
malignant and non-malignant disease* PA-NANA was 
found to be the most useful marker with significant 
plasma elevations occurring in all cases of 
malignant disease. Warren (1975), who
compared glycopeptides derived from surface and 
internal membrane glycoproteins of a murine melanoma 
with those of normal tissues (using double-label 
elution patterns from Sephadex G-50 columns), found 
a marked increase in NANA-nch, fucose-containing 
glycopeptides of melanotic cells These increases
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in PA-NANA occurred both in malignant cells grown in 
vitro and in solid melanotic tumours jjx vivo. The 
contribution of PA-NANA to tumour glycoproteins was 
further verified by the significant reduction in 
size (of tumour glycopeptides) after treatment with 
neuraminidase. Van Beek ££. al (1975) performed 
molecular exclusion chromatographic analysis of 
tumour cell surface glycopeptides isolated from 
peripheral blood of patients with either active 
leukaemia or leukaemic transformation of 
lymphosarcoma Whereas untreated tumour
glycopeptides eluted ahead of the controls (normal 
peripheral blood lymphocytes), neuraminidase 
treatment (prior to chromatography) eliminated the 
difference between the elution profiles of normal 
and tumour samples, thereby indicating that the 
structural difference found in the fucose-containmg 
glycopeptides of tumour cells could be attributed to 
an increased PA-NANA content. Van Beek e t 
a L (1973), again using molecular exclusion 
chromatography to compare a range of malignant cells 
with their normal counterparts (including 
lymphoblast baby hamster kidney cells and mouse 
fibroblasts), also found that neuraminidase 
treatment resulted m  coinciding elution profiles, 
further confirming that the aberrant elution pattern 
of tumour cells was due to increased surface PA-NANA 
content Bernaki and Kim (1977) found elevated serum 
PA-NANA levels in rats with spontaneously 
metastasizing mammary tumours, with no elevation 
occurring in non-malignant disease Yogeeswaran fit 
¿I (1978) investigated the cell surface organisation 
of sialoglycoconjugates of mouse melanoma variant 
lines with either a high (F10) or low (FI) degree of 
lung implantation. F10 cells in culture showed an 
increase of 16 5%, in surface-exposed (neuraminidase 
susceptible) PA-NANA Furthermore, studies of
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short-term cultured la vivo tumour cells showed a 
quantitative increase in at least 4 major surface 
sialoglycoproteins in F10 cells relative to FI 
cells Therefore, these results suggested that 
highly tumourigenic and metastatic mouse melanoma 
cells are enriched with highly sialylated 
glycoproteins Arakawa al. (1989) using HPLC,
determined the ratio of PA-NANA to PA-NGNA in 
glycopeptides isolated from rat colonic tumour and 
normal mucosa The results showed that PA-NANA/PA- 
NGNA ratios were significantly elevated 
(approximately 55 fold) in cases of colonic tumour, 
with these elevations caused, to a large exent, by 
PA-NANA levels in tumour glycopeptides
However, as in the case of total NANA, the clinical 
potential of PA-NANA, as a tumour marker, may be 
limited Carroll (1988) stated that increased 
sialylation of membrane proteins is not unique to 
tumour cells Rothbard &1 (1982) found that
embryonic neural cellular adhesion molecules also 
contain large amounts of PA-NANA, in direct contrast 
to the adult forms of these proteins Furthermore, 
other research has shown that elevated levels of 
protein-bound carbohydrates occur in cases of active 
metabolic and acute inflammatory diseases. For 
example, Waalkes ££. &1 (1978) suggested, despite a 
95% incidence of elevated serum PA-NANA levels in 
patients with metastatic breast cancer, that in 
relation to tumour burden, the guaranteed absence of 
other types of non-malignant disease is a 
prerequisite for accurate clinical interpretation of 
PA-NANA levels.
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LSA AS A MARKER OF TUMOUR BURDEN
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In more recent times, the emphasis has shifted from 
measuring total levels of NANA to determining the 
levels of the lipid-bound sub-fraction of NANA. 
Extensive research has been (and continues to be) 
carried out to evaluate lipid-bound sialic acid 
(LSA) as an indicator of tumour burden. Commonly 
used abbreviations for this marker include the 
afore-mentioned LSA, LASA (JLipid-associated ¿ialic 
acid, P-LASA and LASA-P (the final 2 abbreviations 
referring specifically to p.lasma levels of this 
marker) LSA levels are also referred to as levels 
of "gangliosides" (gangliosides being glycolipids 
containing NANA) The method most commonly used to 
determine serum or plasma levels is that of 
Katopodis and Stock (1980) and, unless otherwise 
indicated, all LSA determinations referred to in 
this section were obtained by this method
The evaluation of serum and plasma NANA as a tumour 
marker has encompassed a broad spectrum of cancers 
Horan (1982), who studied both total serum NANA and 
serum LSA levels in a range of malignancies (nature 
of malignancies not specified), found LSA to be a 
superior marker for the presence of disease (in 
terms of sensitivity and specificity) Elevations 
in serum LSA levels were found in cases of mild 
neoplastic disease (Stage 1), whereas no change 
occurred in total NANA. It was also found that 
overlapping occurred when total NANA levels of 
cancer-bearing and non-malignant disease patients 
were compared. However, on comparing serum LSA 
levels, for the same groups, no such overlapping 
occurred Musset ££. ¿LL (1986) , in their study of 
advanced prostatic cancer, compared the tumour
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marker potential of serum LSA with two other 
markers, CEA and PAP (prostatic acid phosphatase) 
The sensitivity of LSA was found to be 94 2%, 
whereas those of PAP and CEA were only 36 5% and 
25 0%, respectively, thereby indicating that serum 
LSA may be a useful marker for malignancy 
Echenique ££. al (1988) evaluated serum LSA and CA- 
19-9 (a sialylated oligosaccharide found on cell 
surface glycoproteins) as potential tumour markers 
for renal cell carcinoma Whereas CA-19-9 was found 
to be unsuitable (all patients tested had values 
below the upper limit of normal), serum LSA was 
found to be a suitable marker for the presence of 
residual or metastatic disease, with a test 
sensitivity of 70% and a specificity of 82% 
However, poor correlation was found between serum 
LSA levels and staging of the disease, whereby no 
statistically significant differences were found 
when LSA levels of patients with varying stages of 
renal cell carcinoma were compared Mack £_£. 
al (1985), using an animal model system, evaluated 
total serum NANA and serum LSA as markers for 
malignancies of the liver, colon and breast 
(chemically induced) Whereas total serum NANA was 
found to be an unreliable marker of tumour burden 
for all 3 malignancies investigated, very good 
correlation was found between serum LSA levels and 
occurrence of tumour Furthermore, LSA was found to 
be a very good marker for early stages of hepatic 
tumour Santamaria £&_ al (1987) studied serum LSA 
as a means of early diagnosis and clinical 
monitoring of laryngeal cancers All incidences of 
cancer, including cases of small tumour burden, 
showed a positive correlation with elevated levels 
of LSA, with 100% specificity and 96% sensitivity 
The diagnostic potential of this tumour marker was 
reaffirmed m  that, where clinical examination
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suggested metastases, normal LSA levels would often 
predict negative results from histological tests 
Hirshaut ££. al (1985) found that plasma LSA levels 
reflected the clinical status of patients suffering 
from Hodgkin's disease Sawitsky £t a! (1985) found 
positive correlation between plasma LSA levels and 
tumour activity in patients with CLL, with increases 
in LSA levels often preceeding clinically apparent 
progression of disease by 4 - 6 weeks
The potential use of LSA as a marker for 
gynaecological neoplasms has also been extensively 
studied Schwartz al (1985, 1986 & 1987), who
evaluated serum LSA as a marker for cancers of the 
ovary, cervix and uterus, found positive correlation 
between LSA levels and the clinical course of these 
diseases, and furthermore, LSA could be used to 
detect disease recurrence prior to surgical or 
clinical realisation Tseng ai (1989), in their 
study of uterine papillary serous carcinoma, found 
correlation between plasma LSA levels and extent of 
disease, with increasing LSA levels indicating 
disease progression and reductions in plasma levels 
indicating a more favourable prognosis (disease 
regression) Ovarian cancer is a disease which 
eventually develops in one out of every 70 newborn 
females (Cutler & Young, 1975) Patsner e t
al (1987) found that plasma LSA performed as well as 
CA-125 (an antigenic high molecular weight 
glycoprotein expressed by over 80% of non-mucinous 
ovarian adenocarcinomas) in terms of sensitivity, 
specificity and reflection of tumour burden It was 
also found that plasma LSA could be used to monitor 
patients suffering from invasive cancer of the 
ovary, as well as being able to predict the outcome 
of second look surgery In a similar study of 
advanced ovarian cancer, Vardi £t ¿JL- (1989) also
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found that serial determination of plasma LSA levels 
could be used as an additional clinical parameter to 
monitor the course of disease during treatment 
Another finding was that, m  many cases, rising LSA 
levels were the only sign of disease recurrence 
(prior to surgical investigation). However, in 
marked contrast to the positive findings of Vardi 
and co-workers, Stratton fit. ai (1988) found serum 
LSA to be an unsuitable marker for gynecological 
malignancies Whereas the specificity of serum LSA 
was very high, with few false positive reactions, 
the sensitivity was found to be lacking, in that the 
test failed to identify the majority of tumour- 
bearing patients LSA levels reflected disease 
status m  only 6 of 45 patients, representing a test 
sensitivity of 13%
LSA has also been studied in relation to cancer of 
the breast, a disease which can be successfully 
treated if detected in the early stages, but has a 
low cure rate in cases of metastacy (Brinkley & 
Haybittle, 1984) In their study of breast cancer, 
Dnistnan fit. al (1982) suggested that while serial 
determinations of serum LSA could be of use as a 
means of assessing established disease progression, 
isolated LSA determinations lacked the sensitivity 
required for use as a method of screening, either of 
initial stages of the disease or early stages of a 
recurrence. The inability of LSA to distinguish 
between non-malignant and malignant disease, in 
certain cases, suggested that LSA also lacked the 
specificity required for use as a tumour marker 
Rae fit. (1987) also found serum LSA to be lacking 
in sensitivity when used as a marker for carcinoma 
of the breast Whereas the magnitude of LSA 
elevations increased with tumour stage, the high 
degree of false negative results indicated that
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normal levels of LSA could not be used to exclude 
carcinoma However, LSA was found to be useful when 
used in conjunction with another clinical parameters 
for this particular cancer, whereby women with 
breast lumps and elevated serum LSA levels were 
found to be at very high risk for breast carcinoma, 
with the recommended action in such cases being 
immediate biopsy
Bone marrow is a selective site for metastasis of 
many epithelial carcinomas, especially breast 
cancer For example, Ginsbourg aJ_ ( 1 986)
determined plasma LSA levels and the presence of 
heterotopic cells in the bone marrow using a 
monoclonal antibody-based assay They found a 
strong statistical correlation (P < 0 005) between 
these distinct markers, thereby reaffirming a 
clinical role for LSA as a marker for metastatic 
breast cancer
In addition to the positive findings implying a 
clinical role for both serum and plasma LSA as an 
autonomous tumour marker, other research has shown 
that diagnostic and prognostic accuracy can be 
increased when LSA is used m  conjunction with other 
established tumour markers Studies by Vardi ££ 
al (1989), who measured the levels of plasma LSA and 
serum CA-125 m  patients with advanced ovarian 
cancer, showed that the ability to predict the 
clinical status of patients' was enhanced by 
combining the results obtained when both markers 
were determined. All patients who showed 
significantly elevated levels of both markers were 
subsequently found to have surgical evidence of 
disease Furthermore, the predictive value for 
negative results (i e a normal level of tumour 
marker predicting absence of disease) also
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increased, from 80% for plasma LSA alone, and 55% 
for CA-125 alone, to 8 9% for both markers combined
The use of LSA (in serum or plasma), as opposed to 
other tumour markers, was found to have additional 
advantages which suggested a greater clinical 
significance for LSA as an aid in the diagnosis and 
prognosis of neoplastic disease. Santamaria £t 
al (1987) found that, unlike CEA, serum LSA levels 
were not correlated to age, sex, menstrual cycle, 
smoking habits or body weight Katopodis
(unpublished data) also found that LSA levels did 
not correlate with sex, age, stage of menstrual 
cycle or menopausal status It was also found that, 
unlike total NANA or protein-bound NANA, LSA levels 
were in the normal range in patients with 
inflammatory disease such as rheumatoid arthritis 
(Katopodis and Stock, 1980), thereby indicating that 
LSA does not behave as an acute phase reactant
It is therefore ironic that the major reservation 
concerning the use of LSA as a marker of tumour 
burden arises as a result of the problems (discussed 
in Section 1 3) associated with the principle method 
of LSA determination, namely, that of Katopodis & 
Stock
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SECTION 2 
Materials and Methods
MATERIALS FOR NANA EXPERIMENTS
2.1
2.1.1
REAGENTS AND CHEMICALS
NANA standard (type 8, 98% pure, from sheep
submaxillary gland) and Pnstane were purchased 
from Sigma Chemical Co., Poole, Dorset, England. 
Sodium arsenite (general purpose reagent, GPR) , 
sodium periodate (analar) , thiobarbitunc acid 
(GPR) , orthophosphonc acid (analar) and sodium 
sulphate (GPR) were purchased from BDH Chemicals, 
Poole, Dorset, England. Phosphotungstic acid, 
hydrochloric acid, sulphuric acid, chloroform, 
methanol (all reagents GPR) Änd cyclohexanone 
(pure) were purchased from Riedel-de Haen, 
Aktiengesellschaft, Wunstorfer Str. 40, D-3016
Seelze 1, Hanover, Germany. Ethanol (analar) was 
purchased from James Burrough, Fine Alcohols 
Division, 60 Montford Place, London SE11 5DF, 
England. PBS tablets, pH 7 3, were purchased 
from Oxoid Limited, Basingstoke, Hampshire, 
England. An enzymatic kit (Cat. No. 784192) for 
NANA determination was purchased from Boehnnger 
Mannheim, Diagnostics and Biochemicals Ltd., Bell 
Lane, Lewes, East Sussex BN7 1LG, England.
2.1.2 
LAT CELLS
LAT cells were obtained from Dr. Honor Smyth, 
Department of Biochemistry, University College, 
Dublin.
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2 1.3 
SAMPLES
Urine, serum and tissue samples from patients 
with either bladder or prostate cancer were 
obtained from Dr Aiden O'Brien, Department of 
Urology, The Meath Hospital, Heytesbury Street, 
Dublin. Human plasma samples (status of donors 
not specified) were obtained from St Vincent's 
Hospital and St. James’s Hospitals, Dublin
2.2
MATERIALS FOR CELL CULTURE EXPERIMENTS
2.2 1
CELL LINES
The EJ human bladder cell line was obtained from 
Ms Mary Freshney, The Beatson Institute, 
Glasgow. All other cell lines were purchased 
from the American Type Culture Collection (ATCC), 
12301 Parklawn Drive, Rockville, Maryland 20852, 
U S.A.
2 2 2 
ANIMALS
Balb/c and Schofield mice were obtained from 
Dublin City University
2 2 3
REAGENTS AND CELL CULTURE ACCESSORIES 
All materials were purchased from Sigma 
Chemicals, Poole Dorset, England, unless 
otherwise indicated. All cell culture media and 
reagents were purchased from ICN-Flow, Irvine,
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Scotland Culture flasks, plates and other
disposable plastics were purchased from Sterilin 
Limited, Feltham, England, Sterile needles and 
syringes were purchased from Becton Dickinson, 
Dun Laoghaire, Co. Dublin. SDS was purchased 
from Aldrich Chemical Company, Gillingham, 
Dorset, England. Pipette tips were purchased 
from Monoject Scientific (Athy) and LIP (Galway). 
EDTA, TEMED, PEG (M.W. 1540), acetic acid, sodium 
carbonate, 2-Mercaptoethanol and broraophenolLblue 
were purchased from Riedel-de Haen, Aktiengesell­
schaft, Wunstorfer Str. 40, D-3016 Seelze 1,
Hanover, Germany- Sodium azide, TRIS, sucrose 
and ammonium persulphate were purchased from BDH 
Chemicals Ltd., Poole, Dorset, England.
2 3
SIALIC ACID METHODS
2.3.1 
LAT CELLS
LAT cells were maintained by passage in Schofield 
mice as l.p. ascitic tumours. These tumours were7established by l.p. in}ection of 1x10 (in 1.0ml 
PBS ) into Schofield mice, aged between 12 and 15 
weeks. After 7-10 days cells were harvested into 
20mls of PBS and washed twice in PBS before use. 
Alternatively, LAT cells were stored m  liquid 
nitrogen until required (Section 2.4.10).
2.3.2
TAIL BLEEDING OF MICE
At specified times blood samples were obtained
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from mice by tail bleeding. A mouse was placed 
in a cage under a 300 watt bulb. This resulted 
in increased blood flow to the animal's 
extremeties, including the tail. After five to 
eight minutes the mouse was transferred to a 
restrainer. A small incision was made m  a major 
artery of the tail using a sterile scalpel blade. 
The blood was collected into a 1.5ml epmdorph 
tube. Having obtained the sample (approx. 1.0ml) 
the tail was then swabbed in alcohol to prevent 
infection. Care was taken at every stage in this 
procedure to ensure that minimum distress was 
caused to the animal.
2.3.3
TREATMENT AND STORAGE OF SERUM SAMPLES
Blood samples from human patients or from mice, 
obtained by tail bleeding (Section 2 3.2), were 
allowed to clot at room temperature. Following 
centrifugation at 5000 r.p.m., for ten minutes, 
the serum was removed using a micropipette. lOul 
aliquots were stored at -20 C, as recommended by 
O'Kennedy et al. (1991).
2.3.4
DETERMINATION OF TOTAL SERUM AND URINARY SIALIC 
ACID (NANA) LEVELS BY THE WARREN THIOBARBITURIC 
ACID ASSAY
The thiobarbitunc acid method of Warren (1959) 
was used to determine total serum and urinary 
NANA levels.
Principle:
In the Warren colorimetric assay, NANA is first
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subjected to periodate oxidation, resulting in 
the formation of ^-formylpyruvic acid. This 
reacts with two molecules of thiobarbitunc acid 
(TBA) to form a pink chromophore with maximum 
absorbance at 549nm. This chromophore is 
extracted into cyclohexanone, which results in 
greater colour stability and intensity. 
2-Deoxyribose, a constituent of DNA, causes 
significant interference in this assay. To 
correct for this interference, Warren deduced a 
correction formula based on the extinction 
coefficients and involving an additional reading 
at 532nm;
umoles NANA per sample =
0.D.c ,o x C. - O.D.r-io x C0 549nm 1 532nm 2
The values for the constants (C^  & C^) were
determined by the initial sample size:
SAMPLE SIZE (ml) C1 C2
0.2 0.090 0.033
0.5 0.097 0 035
Sample Preparation:
Serum sample volumes were either lOul or 50ul. 
Urine sample volumes were 50ul. The samples were 
diluted to a final volume of 0.2ml, for a lOul 
sample, or to 0 5ml, for a 50ul sample, with 0 IN 
HCl.
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Preparation of NANA standards
NANA standard solutions were prepared from a 1 
umole/ml stock solution of NANA, preheated to 
70°C, as follows.
NANA Volume of Volume of
STD. SOLUTIONS standard 0.1N HC1
(nmoles) (Ml) (Ml)
0 (blank) 0 200
10 10 190
20 20 180
Procedure:
The blank, NANA standards, and samples were 
hydrolysed m  0.1N HC1 for one hour at 80°C to 
liberate bound-NANA from sialoglycoconjugates. 
Oxidation was carried out using 0 1ml periodate 
(0. 2M sodium periodate in 9. 0M orthophosphonc 
acid) . This reaction was carried out, with
constant shaking, at room temperature for 25 
minutes. Oxidation was stopped by the addition 
of 1 0ml arsenite (10%, w/v, sodium arsenite in 
0.5M sodium sulphate/0 IN H^SO^). Vigorous 
vortex mixing was required to ensure complete
neutralisation of the periodate by the arsenite. 
Otherwise, precipitation occurred on addition of 
the TBA. Following addition of 3.0ml TBA (0 6%, 
w/v, TBA in 0. 5M sodium sulphate: freshly
prepared and preheated to 70°C), a pink 
Chromophore was developed by heating m  a boiling 
water-bath for 25 minutes. Immediately after 
heating, the chromophore was extracted into an 
equal volume of cyclohexanone. Centrifugation at 
3000 r.p.m. for 10 minutes ensured complete 
separation of the aqueous and organic phases
( c y c l o h e x a n o n e )• The upper organic phase,
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containing the chromophore, was then removed
using a Pasteur pipette. To prevent the 
formation of cloudiness m  the extracted 
chromophores it was necessary to place tubes, 
containing samples and standards, in a 37 C
water-bath. A spectrophotometer (PU8625 uv/vis, 
Philips) was zeroed with cyclohexanone and the 
optical densities then recorded at 549nm and 
532nm. Average values for corrected O.D.s 
(average sample reading minus average reading for 
the reagent blank) were then inserted into the
correction formula to determine total NANA
levels. The blank solution and the standards 
were assayed in duplicate, whereas samples (serum 
or urine) were assayed either in duplicate or in 
triplicate.
2.3.5
DETERMINATION OF LIPID-BOUND SERUM SIALIC ACID 
(LSA) USING THE METHOD OF KATOPODIS AND STOCK
The procedure of Katopodis and Stock (1980) was 
used to determine serum LSA levels. 50#Jl of 
serum were extracted on ice with 3.0ml ice-cold 
chloroform/methanol (2:1, v/v). Tubes were put 
on ice for five minutes. The lipid extract was 
partitioned with 0.5ml cold water (ultrapure). 
The ultrapure water was prepared by distillation, 
followed by filtration under pressure, using the 
Elgastat UHP system. The tubes were then spun at 
1100 r.p.m. for ten minutes. Having removed the 
aqueous phase, containing the sialolipid 
fraction, LSA was precipitated with 50jj1 of 
phosphotungstic acid (lg/ml). After
centrifugation, (3000 r.p.m. for 5 minutes), the 
supernatant was aspirated and the precipitate 
resuspended in 0.5ml HC1 (0.1N). Following acid
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hydrolysis at 80°C for 60 minutes, NANA in 
solution was determined by the Warren assay 
(Section 2.3.4) .
2 . 3 . 6
DETERMINATION OF TOTAL PLASMA NANA BY A MODIFIED 
THIOBARBITURIC ACID ASSAY: THE VGR ASSAY
This method was developed at Dublin City 
University (DCU) and was named the VGR assay. 
Preliminary results have been published (Kinsella 
et a l ., 1991).
Principle:
As m  the Warren TBA assay, NANA is oxidised with 
periodate and the oxidation product is reacted 
with TBA. Unlike the Warren assay, which 
requires the use of cyclohexanone, this 
modified assay uses a solution of 5% (v/v) HC1
in ethanol to extract, intensify and stabilise 
the chromophore. A single wavelength (560nm) 
is used for O.D. measurements At this 
wavelength there is considerable absorbance due 
to NANA, whereas that of 2-deoxynbose is 
reduced. Consequently, there is no need to use a 
correction formula and NANA levels are determined 
from a standard curve.
Sample Preparation:
Plasma samples (10/il) were brought to a final 
volume of 200^1 with 0.1N HC1.
Preparation of NANA standard curve 
A 1/Jmole/ml NANA solution, preheated to 70^C, was 
used to prepare a standard curve as follows:
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\NANA 
STD. SOLUTIONS 
(nmoles)
Volume of 
NANA std 
(Ml)
Volume of 
0 IN HCl 
(Ml)
0 0 200
10 10 190
20 20 180
30 30 170
40 40 160
50 50 150
Procedure:
The blank, NANA standards, and plasma samples 
were hydrolysed m  0.1N HCl for one hour at 80^C 
to liberate bound-NANA from sialoglycoconjugates. 
Oxidation was carried out using 0.1ml periodate 
(0.2M sodium periodate in 9.0M orthophosphonc 
acid). This reaction was carried out, with 
constant shaking, at room temperature for 25 
minutes Oxidation was stopped by the addition 
of 1.0ml arsenite (10%, (w/v), sodium arsenite m
0 5M sodium sulphate/ 0.1N f^SO^ . Vigorous 
vortex mixing was required to ensure complete 
neutralisation of the periodate. Failure to do 
so resulted m  precipitation on addition of TBA. 
Following addition of 3.0ml TBA (0.6%, w/v, TBA 
in 0 5M sodium sulphate: freshly prepared and
preheated to 70^C), a pink chromophore was 
developed by heating in a boiling water-bath for 
25 minutes. Immediately after colour
development, tubes containing the blank and 
standard solutions each received 4.3mls of a 
solution containing 5% (v/v) HCl in ethanol.
These tubes fcere placed in a 50°C water-bath, so 
as to prevent the formation of cloudiness m  the
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chromophore, until the 0 D.s were recorded. 
After colour development, tubes containing the 
samples were centrifuged at 2200 r.p.m. for 10 
minutes. This was necessary to remove
precipitation which formed during colour 
development. After centrifugation 2ml of each 
(clear) supernatant were then added to an equal 
volume of a 5% (v/v) HC1 in ethanol solution.
The tubes were then placed in a 50°C 
water-bath (again to prevent cloudiness) . The 
spectrophotometer (PU8625 uv/vis) was zeroed 
using the 5% (v/v) HC1 m  ethanol solution. The 
O.D.s of the blank the standards and the samples 
were recorded at 560nm. All O.D. readings were 
corrected for interference by subtracting the 
average reading for the reagent blank from all 
standard and sample readings. Plasma NANA levels 
were determined from the standard curve. The 
blank and standard solutions were assayed m  
duplicate, whereas the plasma samples were 
assayed either m  duplicate or m  triplicate.
2.3.7
A MODIFIED VGR ASSAY, INCORPORATING A 
MICRO-SAMPLE DETECTION SYSTEM, FOR DETERMINATION 
OF TOTAL PLASMA NANA
Principle;
The principle of this assay is the same as that 
of the VGR assay. It was modified so as to 
reduce the time required for O.D. measurements, 
and involved recording O.D.s in 96-well 
microtitre plates.
Procedure:
The procedure was very similar to that described
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in Section 2.3.6 However, it contained the 
following alterations:
Having stabilised the chromophores with the 5% 
(v/v) HC1 in ethanol solution, 180/Jl samples from 
each of the tubes were placed m  wells of a 
96-well microtitre plate. The plate was placed 
in the 50°C incubator of the microti tre plate 
reader (Titertek Twmreader plus: type 381,
ICN-Flow). Samples were allowed to equilibrate 
at the required temperature for 25 minutes. The 
spectrophotometer was zeroed at 560nm using a 5% 
(v/v) HC1 in ethanol solution. 0. D . s were then
measured over a period of 30 seconds. All 
readings were corrected for interference by 
subtraction of the average value obtained for the 
blank. As in the VGR assay, plasma NANA levels 
were determined from an NANA standard curve.
2,4
CELL CULTURE METHODS
2.4.1
PREPARATION OF STOCK MEDIUM
Basic cell culture medium can be obtained in 
either concentrated or readily usable form. 
Concentrated medium (usually lOx), obtained as 
powder or liquid, is easier to prepare and much 
cheaper per unit than its lx equivalent. The 
following method is for preparation of Dulbecco's 
Modified Eagle's (DME D5280) liquid medium. 
Ultra-pure water was used as diluent. 4. 5L of
water were dispensed into a 5L conical flask. 
The powdered DME medium (D5280) was added to the 
water, then gently stirred (without heating) 
until completely dissolved. The package was then 
rinsed with 250mls of water to remove all traces
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of powder 475mls of DME medium were dispensed 
into ten 500ml Duran bottles , followed by 
autoclaving at 121°C for 20 minutes. Each bottle 
then received 15mls of sterile 7.5% (w/v) sodium 
bicarbonate m  water, and lOmls of hepes buffer 
(1M solution). The latter reagent is an optional 
buffer system. The pH was adjusted to between
7.2 and 7.4, if necessary, with sterile acid (1M 
HC1) or base (1M NaOH) . The stock medium was 
stored at 4°C until required.
2.4.2
PREPARATION OF MEDIUM FOR CULTURE
The following method was used to prepare a range 
of complete cell culture media ("complete" 
meaning that FCS had been added to the medium) . 
They include.
1 Dulbecco1s Modified Eagle 1s Medium
A. DME-D5280 (Sigma: Section 2.4.1)
B. DMEM IX (ICN-Flow: Cat. No. 12-332-54)
2 Rosewell Park Memorial Institute Medium 
(RPMI-1640 medium: lx)
(ICN-Flow: Cat. No. 12-602-54)
1 Hams-F12 Nutrient Rich Medium 
(Hams-F12 medium: lx)
(ICN-Flow: Cat. No. 12-442-54)
99mls of lx medium were dispensed aseptically 
into a sterile bottle. To this was added 1ml of 
1-glutamine (200mM), 2.0ml of hepes buffer (1M)
and 1.0ml amphotericin B ("Fungizone" :250/ig/ml). 
The following were also added if required: 2.0ml 
penstrep (penicillin; 5000 IU/ml and 
streptomycin; 5000 Mg/ml) or 50#jg
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gentamicin (lOmg/ml) Addition of antibiotics to
culture medium is not advisable as it masks the
presence of bacterial contamination. This could
have more serious consequences since other less
conspicuous forms of contamination, including
Mycoplasma (Section 2.4.12), could also be
present. In any case, proper aseptic technique
eliminates the need for any antibiotics. lOmls
of FCS (Mycoplasma screened) were then added and
the pH adjusted to between 7.2 and 7.4, with
sterile 1M NaOH or 1M HC1, if necessary. A
sample of the culture medium was tested for
sterility by incubation (5% C0o, v/v, / 37^C) for
0at least 7 days. The medium was stored at 4 C 
until required L-glutamme and FCS were
replenished every 12 days.
2.4.3
NSO MYELOMA CELLS
NSO cells were obtained from the ATCC. This is a 
Balb/c mouse myeloma cell line, developed by 
Milstein et al. (1981) , which does not express 
IgG.
NSO cells were maintained in DMEM supplemented 
with 10% FCS. As this cell line is mildly 
adherent, harvesting and sub-culturing of these 
cells required procedures described m  Section 
2.4.6. NSO cells, and all other cell lines, were 
incubated m  a humid 5% (v/v) C00 atmosphere at
37°C .
2.4.4
EJ BLADDER CELL LINE
EJ cells were kindly donated by Ms. Mary
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Freshney, The Beatson Institute For Cancer 
Reseasch, Glasgow, Scotland. The EJ cell line is 
a human bladder carcinoma, developed by Harris et 
al. (1983) , and has an epithelial-like
morphology.
As this bladder carcinoma is strongly adherent, 
harvesting and sub-culturing of these cells 
required procedures described in Section 2.4.7. 
EJ cells were also grown in large scale culture 
using a roller-bottle system (Section 2.4.8).
2.4.5 
NRK CELLS
The NRK cell line was obtained from the ATCC. 
This is a normal rat kidney cell line and was 
first described by Duc-Nguyen et aJL. (1966) .
This cell was maintained in DMEM supplemented 
with 10% (v/v) PCS. As a strongly adherent cell 
line it required trypsinisation (Section 2.4.7) 
for harvesting and sub-culturing of cells.
2.4.6
SUBCULTURING AND MAINTENANCE OF MILDLY ADHERENT 
CELL LINES
Many cells, when grown in culture, are mildly 
attached to the bottom of the culture container 
and can be removed by flushing with medium. 
Cells are usually harvested when they have grown 
to approximately 75% confluency.
All medium was removed from the culture 
container, thereby removing detached (dead) 
cells. Fresh serum-free medium was then added 
and the cells removed by flushing with medium,
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with the aid of a sterile Pasteur pipette The 
contents of the culture vessel were transferred 
to a sterile universal (30ml) and centrifuged at 
2000 r.p.m. for five minutes. A cell count was 
taken (Section 2.4.9). The original culture was5re-seeded at a concentration of 1x10 cells/mlf
ousing 5mls of complete culture medium per 25cm 
flask. Cells were allowed to adhere overnight at 
37°C m  5% (v/v) C02. An additional 5mls of
complete culture medium were then added and the 
culture returned to the incubator (37^C/ 5%, v/v, 
C02). The remaining harvested cells were used to 
initiate new cultures. Excess cells were stored 
in liquid nitrogen ( Section 2 4.10).
2.4.7
SUBCULTURING AND MAINTENANCE OF STRONGLY ADHERENT 
CELL LINES
Unlike mildly adherent cells (Section 2.4.6) 
there are cells that firmly adhere to the bottom 
of the culture container and therefore cannot be 
removed by flushing with medium. To harvest and 
subculture cells of this type requires the use of 
trypsin or similar proteolytic agents.
All culture medium was removed from the culture 
flask. FCS, present in the medium, contains a 
trypsin inhibitor and, therefore, prevents 
enzymatic removal of adhered cells. Trypsin 
(2.5%. w/vf heated to 37°C) was added to the 
flask, which was then placed in an incubator (5%, 
v/v, CO^/ 37°C) . After five to ten minutes the 
flask was returned to the laminar flow, and 
complete culture medium was added, thereby 
preventing further enzymatic digestion. The 
contents of the flask were transferred to a 
sterile universal (30ml) and centrifuged at
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2000 r.p.m.for five minutes. The cells were
5seeded at 1-5x10 cells/ml, using 5mls complete2culture medium per 25cm flask.
2.4.8
LARGE SCALE CULTURE OF EJ CELLS Jvr rA *
In order to obtain large cell numbers, large - 
scale culture of the EJ bladder carcinoma cell 
line was carried out in roller-bottles.
EJ cells (Section 2.4.4) were obtained by either 
trypsinisation of an actively growing culture 
(Section 2.4.7) or recovery from liquid nitrogen 
(Section 2.4.11) . A viable cell count was 
performed (Section 2.4.9). A roller-bottle was7seeded with a total of 1x10 viable cells in 
30mls of complete culture medium (DMEM with 10%, 
v/v, FCS and 2%, v/v, Hepes buffer) The culture 
vessel was placed m  an incubator (37^C) on a 
roller-bottle apparatus (manufactured by Bellco) 
at one revolution per minute, and the cells were 
allowed to adhere overnight. An additional 70mls 
of DMEM were then added and the culture was 
returned to the incubator (37^0 . When the 
culture was approximately 80% confluent the cells 
were harvested as follows. All medium was 
removed from the roller-bottle. Trypsin (2.5%, 
w/v, 15mls at 37°C) was added and the culture was 
returned to the incubator, on the roller-bottle 
apparatus, for 5-10 minutes. Complete culture 
medium was then added to prevent further 
enzymatic digestion. The contents of the 
roller-bottle were transferred to a sterile 50ml 
centrifuge tube. A sample was taken (20/j1-30jj1) 
and a viable cell count was performed (Section
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2 4.9). Cells were centrifuged at 3000r p m. for 
10 minutes to obtain a cell pellet 1x10 viable 
cells were used to maintain the parent culture, 
and the remainder were stored m  liquid nitrogen 
until required (Section 2.4.10).
2.4.9
CELL COUNTS AND VIABILITY STAINING
Cell counts were performed on an improved 
Neubauer haemocytometer slide. Two dye exclusion 
methods, with either trypan blue or acridme 
orange/ ethidium bromide, were routinely used. 
The viability of a cell suspension was determined 
as follows*
% VIABILITY = NUMBER OF VIABLE CELLS
________________________ X 100%
TOTAL NUMBER OF CELLS
Acridme Orange/ Ethidium Bromide 
The main advantage of this method is that colour 
contrast, between living and dead cells, is 
very good. However, it does require a
fluorescence microscope, and care must be taken 
as both chemicals are carcinogens.
The stain solution (light sensitive) contained 
O.lmg acridme orange and O.lmg ethidium bromide 
in 100ml PBS. 20-30/il of a cell suspension were 
mixed with an equal volume of AO/EB in an 
epindorph tube. The cells were then examined by 
U .V . fluorescence microscopy. Live cells stained 
green while dead cells stained orange.
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VTrypan blue exclusion
The m a m  advantage of this method over AO/EB is 
that it is cheaper (no fluorescence microscopy). 
However, as a result of using light microscopy
the colour contrast is not as good as that
obtained using AO/EB. This method is also 
hazardous as trypan blue is a teratogen and a 
possible carcinogen,
A volume of cell suspension (20-30#j1 ) was mixed 
with an equal volume of trypan blue in an 
epmdorph tube, followed by thorough vortexing. 
After 2-3 minutes the cells were counted under a 
light microscope. Live cells were clear while 
dead cells stained blue. In order to prevent
uptake of the dye by healthy cells it was
necessary that the count was taken within 5 
minutes of mixing the trypan blue and cell 
suspension.
2.4.10
FREEZING CELLS IN LIQUID NITROGEN
The freezing mixture contained FCS supplemented 
with 5% (v/v) DMSO (a cryoprotectorant) . It
was prepared by dropwise addition of DMSO to 
ice-cold FCSf followed by sterile filtration 
(0.2fi filter; Gelman) . This reagent was stored 
at -20°C. When required it was thawed in a 37°C 
water-bath, then placed on ice for 30 minutes 
before being used.
Cells were removed from culture vessels either by 
flushing with medium (Section 2.4.6) or 
trypsinisation (Section 2.4.7). A viable cell 
count was performed (2.4.9). Washed cells were 
resuspended at 1-I0xl0 6 cells/ml freezing
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mixture. One ml aliquots were placed m  sterile 
cryotubes. Cells were frozen at a rate of 
approximately 1°C per minute to -70°C on a 
freezing tray (Union Carbide) before being placed 
in liquid nitrogen.
2.4.11
RECOVERY OF CELLS FROM LIQUID NITROGEN
Successful recovery of cells from liquid nitrogen 
requires rapid removal of DMSO, as it can have 
adverse effects on the cells.
0 *The contents of a cryotube were thawed, in a 37 C 
water-bath, until only approximately 5% of the 
cells remained frozen They were transferred to 
a sterile universal (30ml) and 5mls of ice-cold 
serum free medium were added dropwise while 
gently shaking the universal. After
centrifugation {2000 r p.m for 5 minutes) the 
cells were given a further two washes. Culture 
medium was used when the cells were required for 
growth in culture, whereas cells for immunisation 
were washed in sterile PBS. Cells removed 
correctly from liquid nitrogen were approximately 
90% viable.
2.4.12
MYCOPLASMA DETECTION; HOECHST-33258 FLUORESCENCE 
ASSAY
Hoechst 33258 fluorescence stain was used to 
detect the presence of Mycoplasma m  the cellular 
cytoplasm. This method, employing the DNA 
mtercalator bisbenzimid (Hoechst 33258), was 
first described by Chen (1977). The following
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method is an adaptation of this procedure by M. 
Dooley and M. Clynes, Dublin City University 
(personal communication)
3A 5x10 cells/ml suspension of Mycoplasma-free 
NRK cells (Section 2.4,5) was prepared. Sterile 
coverslips, placed m  1 0mm p e t n  dishes, received 
1 .0ml of the cell suspension, and the cells were 
allowed to grow overnight. 1 .0ml of culture
supernatant from cells being tested (free of 
cells and debris) was then added to the NRK 
cells. A negative control (complete culture 
medium) was also included. NRK cells and 
supernatants were reincubated for a further 2-3 
days, during which time the NRK cells continued 
to grow. The coverslips were then washed 3 times 
in PBS, followed by cell fixation for six minutes 
in a 1:1 (v/v) methanol•acetone solution (-20°C). 
After fixation, the coverslips were rinsed three 
times in PBS The cells were stained for 10 
minutes using Hoechst 33258 stain (0.025/Jl/ml) m  
PBS Coverslips were washed twice in PBS,
air-dried, and finally mounted on clean slides. 
The cells were stored in the dark until examined 
by fluorescence microscopy (40x or lOOx with oil 
immersion). Defined spots of green fluorescence 
m  the cell cytoplasm indicated a positive result 
(presence of Mycoplasma). If such a result was 
found in the negative control (culture medium) 
the assay was deemed invalid.
2.5
IMMUNIZATION OF BALB/C MICE FOR THE PRODUCTION OF 
MONOCLONAL ANTIBODIES
For the production of monoclonal antibodies,
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Balb/c mice were immunized with whole EJ cells.
The human bladder carcinoma cells were freshly
harvested from actively growing cultures by
trypsinization (Section 2.4.7) and washed in PBS.
A viable cell count was taken (Section 2.4.9). 
71x10 cells in 1. 0ml of PBS were administered by 
intraperitoneal injection (l.p.) into Balb/c mice 
aged between eight and twelve weeks. The routine 
immunization regimen involved l.p. injection of 
cells on days 0, 7, 14, 21, and a final boost on 
day 28. Three days after the final boost the 
splenocytes were harvested. The spleen cells 
were then either used in a fusion experiment on 
that day or stored m  liquid nitrogen (Section
2.4.10) until required
2.6
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
A protocol for the setting up and performance of 
a solid-phase enzyme-linked immunosorbent assay 
(ELISA) is described for use with fixed cells as 
antigens.
2 .6 . 1
CELL FIXATION FOR USE IN ELISA
Method li
In this method, cells to be fixed were obtained 
from actively growing cultures. This procedure 
was also used to fix normal human blood and 
tonsillar lymphocytes.
Flat bottomed flexible (PVC) plates (Cat. 
No.7717305, ICN-Flow) were washed 3 times 
in PBS, followed by treatment with 
poly-l-lysine (0.1%, w/v, in PBS: lOOfil per
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well). The latter reagent was re-used up to 10
times. After incubating for 1 hour at 37°C the
poly-l-lysine was removed and the plates were
5again washed 3 times m  PBS. 50/j1 of a 5x10 
cells/ml (PBS) suspension, of either washed cells 
obtained by trypsinisation (Section 2.4.7), or 
lymphocytes, were then added to each well. After 
one hour at 4°C, 150/Jl of glutaraldehyde <GA;
0.1%, v/v, in PBS) were added to each well *to > 
give a final concentration of 0.075% (v/v) GA.
It was important, during GA addition, that the 
cell layer was not disturbed and that no air 
bubbles were present in any of the wells. After 
10 minutes (max.) at 4°C, the plates were washed 
three times m  PBS. Glycine (lOOmM in PBS; 
100/Jl/well) was added to block any remaining GA. 
Having incubated the plates at 37^C for 30 
minutes they were washed three times in PBS. 
150pil of storage/blocking buffer (1% BSA, w/v, in 
PBS containing 0.1%, w/v, azide as preservative) 
were then added to each well The plates were 
thoroughly sealed (to prevent evaporation of 
storage/blocking buffer) and then placed at 4°C. 
Under these conditions it was possible to store 
the plates for up to six months with no apparent 
loss of activity.
Method 2:
A second method of fixation was also used. This 
method was used exclusively to fix cells that 
grew in culture and was not used to fix
lymphocytes. Cells were seeded in sterile
96-well tissue culture plates and then allowed to
grow in complete culture medium. When the
required density was reached the cells were 
fixed. One advantage of this method over method 
1 is that it requires fewer cells, thus
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increasing efficiency The operator also has
greater control over experimental conditions, m  
that it is possible to examine the cells under a 
microscope prior to fixation. A minor
disadvantage of this method is that preliminary 
stages must be carried out in a laminar flow hood 
under aseptic conditions.
The procedure used was as follows: Cells were
obtained by trypsinization (Section 2.4.7). A
viable cell count was taken (Section 2.4.9).
Pelleted cells were resuspended m  complete
4culture medium at a concentration of 5x10
cells/ml. Each well received 100/jI of the3suspension (5x10 cells) The plates were
sealed, placed in an incubator (5%, v/v, C00 at 
037 C) and examined daily. The time interval 
between seeding of cells and fixation depended on 
the growth rate of the cell line. Cells were 
usually ready for fixing after 2-3 days Having 
reached approximately 80% confluency the cells 
were fixed as follows: plates were washed 3
times m  PBS. 150^1 of GA (0.1%, v/v, m  PBS) 
were added to each well to give a working 
concentration of 0.075% (v/v) GA. The remaining 
steps in this procedure were exactly the same as 
those of method 1 (previously described) 
regarding the addition of glutaraldehyde.
2.6.2
ELISA
In this indirect, non-competitive ELISA system 
the antigen is coated onto microtitre plates 
(Section 2 .6 .1 ) and antibody binding is detected 
using an enzyme-labelled second antibody.
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Antigen coated plates were washed 3 times m  0.1% 
(v/v) Tween-20 in PBS Non-specific binding 
sites were blocked with 1% (w/v) BSA m  PBS with 
0 ,1% (w/v) azide (1 0 0 /il/well) , for one hour at
37^C. Having re-washed the plates 3 times m  
PBS-Tween, 50/j1 of either control or test sample 
were added to specified wells. Each assay
included a range of controls. The screening of 
hybndomas and clones against a target antigen 
required a positive control (serum from the mouse 
m  which the antibodies were raised) and also a 
negative control (serum from a non-immunised 
mouse). To eliminate interference caused by FCS 
present m  culture media a sample of seruny-free 
medium was also tested. A PBS control was also 
included to ensure that non-specific binding of 
labelled second antibody did not occur. A 
monoclonal antibody (H12), obtained from 
Bernadette Lannon, Applied Biochemistry Group, 
Dublin City University) , highly reactive with 
lymphocytes, was used as a positive control in 
the screening of hybridomas and clones against 
normal cells. Samples of serum free medium and 
PBS were also tested. Plates were incubated at 
4°C for 30 minutes followed by one hour at 37^C. 
Unbound antibodies were removed by washing with 
PBS-Tween. 50/il of enzyme-labelled second
antibody ( 1/500 dilution of
j5-galactosidase-l inked sheep anti-mouse Ig, 
Fiab'Jg fragment) were added to each well. 
Plates were again incubated (30 minutes at 4^C 
followed by one hour at 37°C). Having washed the 
plates to remove unbound second antibody, 1 0 0/il 
of substrate solution (freshly prepared) were 
added to each well. This solution contained 3mM 
O-nitrophenyl-0-galactopyranoside (ONPG) in PBS
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containing lOmM MgCl0 and 0 1M 2-mercaptoethanol
0The colour was developed at 37 C for 1-2 hours 
The reaction was stopped with 1M sodium carbonate 
(50/Jl/well) . This reagent also increased colour 
intensity, O.D.s were recorded at 405nm, against 
a PBS blank, using a microtitre plate reader.
2.7
SOMATIC CELL FUSIONS AND RELATED PROCEDURES
2.7.1
AZAGUANINE TEST FOR HAT SENSITIVITY OF MYELOMA 
CELLS
t
NSO myeloma cells were grown in complete DMEM 
(10%,v/v, FCS) for 4-5 days prior to harvesting 
(Section 2.4 6 ), washed twice m  DMEM and counted5(Section 2 4.9) They were resuspended at 2x10
cell/ml of complete DMEM (10%, v/v, FCS)
-4supplemented with 1x10 M 8-azaguanine2(2.0/jg/ml). 75cm flasks were each seeded with 
2 5x10** cells (12.5ml suspension per flask) and 
incubated for 3-5 days at 37°C in 5% Only
HAT-sensitive cells will grow in this medium.
Therefore, cells failing to grow under these
culture conditions were discarded and replaced 
with a known source of HAT-sensitive myeloma 
cells. NSO cells found to be HAT sensitive were 
washed in DMEM and then grown m  
8-azaguanine-free complete DMEM (10%, v/v, FCS) 
for 4-5 days prior to use m  cell fusions.
2.7.2
ISOLATION OF SPLEEN CELLS
Spleen cells are removed from immunised mice 3
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days after the final boost with antigen (day 28) 
Ideally they are used immediately after removal. 
However, if the myeloma cells are found to be
unsuitable for use m  a fusion experiment
(Section 2.7.5) on a particular day the spleen 
cells can be stored m  liquid nitrogen
(Section 2.4.10) until required. The main 
disadvantage of this methodology is that 
potentially valuable splenocytes may be lost 
during freezing and thawing of the cells.
The immunised Balb/c mouse was killed by cervical 
dislocation and placed m  ethanol. It was then 
pinned onto a dissection board on it's right 
side, placed in a laminar flow hood and sprayed 
with ethanol The spleen was aseptically
removed using sterile instruments and, after 
removal of fatty tissue, was placed in a 
petn-dish containing lOmls of serum-free medium 
(DMEM). Having dissected the spleen into small
pieces, the cells were forced into the medium 
using the barrel of a sterile 1 0ml syringe. 
Other methods of obtaining splenocytes involve 
either the use of a sterile tissue dissociation 
sieve (Sigma) or else flushing the cells out of 
an intact spleen by injection of serum-free 
medium (5mls). The latter requires that the 
spleen is held using a sterile blunt 
forceps. Serum-free medium is injected into the 
upper end of the spleen. The medium forced out 
of the other end of the spleen will contain 
splenocytes. The resulting cell suspension was 
washed three times in serum free medium and then 
counted (Section 2.4.9). Spleen cells were 
either used in a fusion experiment (Section
2.7.5) or stored in liquid nitrogen (Section
2.4.10) for use at a later date. Viability
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before freezing was usually >90% and each spleengyielded up to 1x10 splenocytes A blood sample 
was taken from the immunised mouse and the 
resulting serum used as a positive control in 
screening of hybndoma supernatants by ELISA 
(Section 2.6*2).
2.7.3
PREPARATION OF 50% (W/V) POLYETHYLENE GLYCOL 
(PEG)
PEG was used as the fusogen m  somatic cell 
fusion experiments (Section 2.7.5).
Solutions of 50% (w/y) PEG were prepared using
both of the following methods.
A.
5g of PEG (Riedel-de Haen; molecular weight 1540) 
were fully dissolved in 3-4mls of serum-free DMEM 
(with heating) and the final volume adjusted to 
lOmls. The solution was sterilised using a 
sterile 0.22/j filter (Gelman) and stored m  2.0ml 
aliquots at -20^C
B .
5g of PEG (M.W. 1540) were autoclaved at 121°C 
for 20 minutes to sterilise and dissolve the PEG. 
As it cooled, but before it solidified, (approx. 
40^0 , 5mls of sterile serum-free DMEM were
added (i.e. a volume of medium equal to the 
number of grams of PEG autoclaved) . As in the 
previous method, 2 .0ml aliuots were stored at
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2 7 4
PREPARATION OF MOUSE MACROPHAGE FEEDER CELLS
Peritoneal macrophages were used as a source of 
feeder cells The presence of these growth 
factor secreting cells greatly increases the 
ability of other cultured cells to grow at very 
low concentrations Feeder cells are essential 
when plating out newly formed hybndomas (Section 
2 7.5) and especially during the cloning of cells 
by limiting dilution (Section 2 7.7).
The method of preparation demands great care and 
attention as the macrophage feeder cells are very 
susceptible to contamination by intestinal 
bacteria during the extraction procedure. 
Therefore, the cells are usually prepared one day 
prior to the fusion experiment (Section 2.7 5) 
and are thoroughly examined for signs of 
bacterial contamination before being used
Six Schofield were sacnfied by cervical 
dislocation and immer3 ed in ethanol A mouse was 
pinned onto a dissection board, sprayed with 
ethanol and placed in a laminar flow hood The 
skin was then carefully cut away to expose the 
peritoneal membrane which was then sprayed with 
ethanol The peritoneal membrane was lifted with 
a sterile blunt forceps (to avoid puncture) and 
lOmls of either serum-free DMEM or sterile PBS 
were injected into the peritoneal cavity, taking 
care not to pierce the gut. The abdomen was 
gently massaged to bring macrophage cells into 
suspension. 5mls of the cell suspension were 
then carefully withdrawn and dispensed into a 
sterile universal (30mls). This procedure was 
repeated for each mouse. As these mice were not
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immunised, blood samples were taken and the
resulting sera were used as negative controls in
ELISA (Section 2.6,2) screening of hybndoma
supernatants Cells were pooled into three
groups (cells from two mice per group), washed
twice in serum-free medium and counted (Section
2.4.9) . It is not advisable to pool all the
cells together as one contaminated sample would
result in the loss of all the feeder cells. They
5were resuspended to 1x 10 cell/ml in complete 
DMEM (10%, v/v, FCS) and plated out m  sterile 
96-well tissue culture plates at a concentration4of 1x10 cells/well. After incubation overnight 
(37°C in 5%, v/v, ' the feeder cells were
examined for sitjns of bacterial contamination 
before proceeding with the fusion experiment.
2.7.5
CELL FUSION PROCEDURE
This method, to be successful, requires delicate 
manual dexterity and rigorous attention to 
detail. The state of growth and viability of
myeloma cells, the rate of addition and dilution 
of PEG and the fusion temperature are all 
critical faactors in the procedure. For a
successful fusion, hybndomas are usually visible 
as growing colonies after 7-14 days.
NSO cells, maintained in mid-log phase of growth 
for 7 days prior to fusion, and pre-tested for 
both HAT sensitivity (Section 2 7.1) and the
presence of Mycoplasma (Section 2.4.12), were 
pooled, counted (Section 2.4.9) and washed three 
times m  serum-free DMEM. Immunised spleen cells 
obtained either by spleenectomy (Section 2 .7 .2 ) 
or recovered from liquid nitrogen (Section
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2 4.11) were also counted and washed as above. 
Spleen cells and NSO cells, m  the ratio of 2 1 
spleen.NSO cells, were mixed and centrifuged at 
3500 r.p.m. for ten minutes to yield a hard 
pellet. Ratios of 10:1 (spleen:NSO) have also 
been used successfully. The supernatant was 
fully removed. Cells were fused in 50% PEG 
(Section 2.7.3) at 37°C as follows: 1ml of
PEG-1540 was added at a constant rate over one 
minute (0.1ml PEG/ 6.0 seconds) with gentle 
mixing. This was achieved by gently stirring the 
cell pellet with the tip of the pipette as the 
PEG was being added. The cell pellet and PEG
were then stirred for one minute The aim was to 
expose the cells to the PEG while maintaining as 
much cell contact as possible. PEG was diluted 
by dropwise addition of 3mls serum-free medium 
(DMEM at 37^C) over 3 minutes (lml/minute), 
followed by a further 8mls of serum-free DMEM
over 3 minutes (approx. 2.65mls/minute) The 
cells were gently spun at 1 0 0 0 r.p m for 10 
minutes to yield a soft pellet, then resuspended 
at 2x10 cells/ml m  enriched complete culture 
medium (DMEM with 20%, v/v, FCS) containing 
double strength HAT (Section 2.7.6). The cells4were plated out at a concentration of 2x10 
cells/well in sterile 96-well tissue culture
plates, precoated with macrophage feeder cells 
(Section 2.7.4), and incubated,undisturbed,at 
37°C in 5% (v/v) CO^ for 10 days. After this
time hybndomas were fed at regular intervals 
(apprx. after every 2 days) by replacing 100^11 of 
spent medium with 100/il of fresh medium. After 
approximately 14 days the cells were grown m  
complete DMEM (10%, v/v, FCS) containing HAT
(Section 2.7.6). After a further 14 days the 
cells were weaned off HT and thereafter were
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c u lt u r e d  i n  c o m p le te  DMEM (w it h  10%, v / v ,  F C S ) .
2.7 6
HAT AND HT-SELECTIVE MEDIA
Single strength (lx) HAT medium consisted of 
complete DMEM (10%, v/v, FCS) supplemented with 
lOOjiM hypoxanthine (H) , 1M a m m o p t e n n  (A) and 
16/jM thymidine (T) Twice these amounts were 
used to prepare double strength (2x) HAT HT 
medium, used to wean cells off HAT, consisted of 
complete DMEM (10%, v/v, FCS) supplemented with 
100/JM hypoxanthine (H) and 16jiiM thymidine (T) .
2 7 7
CLONING OF HYBRIDOMAS BY LIMITING DILUTION
A feeder layer of murine macrophage feeder cells 
(Section 2 7 4) was prepared one day prior to 
cloning. Cells producing antibodies of specific 
interest, as determined by ELISA (Section 2 6 2), 
were expanded from 96-well to 24-well sterile 
tissue culture plates as 1 0ml cultures When 
confluent, the cells were harvested (Section
2.4.6) and counted (Section 2 4.9) As a
precautionary measure a sample of cells was 
frozen for storage in liquid nitrogen (Section 
2 4.10) The remainder of the cells were diluted 
in serum-free medium (DMEM), then plated m  
complete DMEM (10%, v/v, FCS) in sterile 96-well 
plates at concentrations of 10, 5 and 1 cell per 
well The plates were incubated for seven days 
at 37 C in 5% (v/v) CO^ and then examined for
growth of clones It is often the case that no 
growth occurs m  the plates seeded with one 
cell/well This can occur as a result of errors 
in the procedure. For example, an overestimation 
in the initial cell count would lead to excess
65
dilution of cells, the result being that many of 
the wells would receive no cells at all Another 
possibility is that the macrophage feeder cells 
may not secrete sufficient amounts of growth 
factors required for early stages of cell growth. 
Therefore, it is essential that higher cell 
concentrations (5 and 10 cells per well) are 
seeded so as to prevent the loss of potentially 
valuable hybndomas. The most important plates, 
if growth occurs, are those with one cell per 
well, as they contain the least heterogeneous 
mixture of antibodies* Cells in these wells are 
expanded and rescreened for antibody 
production using ELISA (Section 2.6.2), Antibody 
secreting clones are recloned. Two
limiting-dilution subclonings are usually 
adequate to produce a fully monoclonal 
antibody-producing hybndoma However, it is 
advisable to reclone regurlarly in the first few 
months so as to test stability, expressed as 
continued ability to secrete antibody
2 7.8
GROWTH OF CLONES AS ASCITIC TUMOURS IN MICE
To obtain large quantities of antibody, clones 
were grown as ascitic tumours in Schofield mice.7Each animal was injected with 1x10 cells, having 
been primed 7 days earlier with 0. 5ml of 
immunostimulant (Pnstane or Freund's Adjuvant). 
The animals were observed daily for tumour 
growth. After 10-15 days the ascitic fluid was 
removed. The mice were sacrificed by cervical 
dislocation. The skin was cut away to reveal the 
peritoneal membrane. PBS (3-4mls) was injected 
into the peritoneal cavity and the stomach area
6 6
was gently massaged using a blunt forceps (to 
avoid puncturing the membrane). The purpose of 
the PBS injection was to dilute the viscous 
ascitic fluid, thereby facilitating it's removal. 
The fluid was carefully withdrawn (using a 
sterile needle and syringe) and then centrifuged 
at 3000 r.p.m. for 5 minutes to pellet the cells. 
Having removed the supernatant (rich in 
antibodies), thimerosal (a preservative) was 
added to a concentration of 0.001% (v/v) . The
ascitic fluid was dispensed into epmdorph tubes 
and stored at 4^C until required.
2 8
METHODS OF STATISTICAL ANALYSIS
2 8.1
TWO-SAMPLE STUDENT'S T-TEST
Statistical analysis using this test required use 
of Student's two-sample t-statistic To test a 
null hypothesis (HQ) which states that there is 
no difference between the two sample means 
requires the following form of the statistic.
Sp (l/n1 + l/n2)0-5
where and X^ are the sample means, 
n^ and n^ the sample sizes and 
Sp the pooled standard deviation
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S 2 = (n1-l)xS12+ (n0-l)xS 2P  1 1  A 4
nl+n2 " 2
and are the standard deviations
The rule is to reject Hq if the absolute value of 
t is greater than or equal to C, where C (the 
critical value) is obtained from Student's 
t-table for a two sided test and V= n1 +n2“2 
degrees of freedom, thereby accepting the 
alternative hypothesis (H^), which states that a 
difference does exist between the two sample 
means.
2.8.2
STUDENT'S T-TEST
A form of Student's t-Test was used to compare 
the magnitude of the change (usually an increase) 
in total serum NANA levels observed in the tumour 
group (LAT) with those of the PBS and Pnstane 
control groups. This was based on the comparison 
between the average changes in serum NANA levels
between day -1 (one day prior to injection) and
either day 3 or day 6 (3 or 6 days after
injection).
The null hypothesis (H^) stated that no
difference existed between the average change 
observed in serum from the LAT-bearmg mice and 
those of the control groups. The alternative 
hypothesis (H^) stated that a difference did
exist. Testing of this hypothesis required 
the following form of the t-statistic.
6 8
t = xr x2
Sp (l/n1+ l/n2 )0 '5
where and X2 are the average changes in total 
serum NANA levels over a specified time interval, 
n- and n0 are the sample sizes and S the pooled
1 6 P
mean square estimate of the standard deviation.
SP2 -  E * „ 2 *  a 2 l 2-  i r a 2 l ) 2/ » 2]
ni+n2-2
X^and X^^ are the changes in total serum NANA 
in individual mice over a specified time 
interval.
The rule is to reject if the absolute value of 
t is greater than or equal to C, where C (the
critical value) is obtained 
t-table for a two-sided test 
degrees of freedom
from Student's 
and V= n1+n2-2
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SECTION 3
The Evaluation of Total Serum Sialic Acid 
as an Indicator of Tumour Burden in Human Patients 
with Cancer of the Prostate.
3.1
INTRODUCTION
The aim of this research was to evaluate total 
serum NANA as a tumour marker for cancer of the 
prostate. An ideal tumour marker is a substance, 
the concentration of which varies solely as a 
result of changes in the extent of tumour 
burden. It must be highly sensitive (i.e. give a 
low % of false negative results), and highly 
specific {i.e give a low % of false positive 
results). Another desirable quality is that the 
marker can be determined both rapidly and 
economically. An ideal tumour marker has yet to 
be found. However, extensive research is 
constantly in progress to find a substance which 
best satisfies the above requirements.
NANA has been repeatedly investigated with 
regard to its potential as a tumour marker. 
Elevations m  serum NANA have been found not to 
be specific for any one particular tumour. Lodha 
et al (1979) found elevated NANA levels in a 
wide range of tumours, with the most significant 
elevations occurring m  cases of metastatic 
disease. Erbil et al.. (1986) found that NANA 
lacked the specificity required for early 
detection of prostatic cancer, but suggested its 
possible use as a marker of tumour activity, 
during follow-up under treatment m  cases of 
advanced disease. Khanderia et al. (1983, 1988), 
who found poor correlation between isolated NANA 
levels and stage of neoplastic disease, suggested 
that serial determination of serum NANA could be 
a more useful monitor of response to therapy in a
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range of neoplasms, including metastatic 
embryonal cell carcinoma, transitional cell 
carcinoma of the bladder, cancer of the colon and 
hepatocellular adenocarcinoma.
The reasons for this caution are well 
founded. O'Kennedy et al. (1991) stated that 
while significant elevations m  serum NANA "can 
occur in tumour-bearing individuals, the reason 
for these elevations is not solely tumour 
derived. There are substances known as 
acute-phase reactants, the concentrations of 
which are altered (usually in the form of an 
increase) m  response to any of the following, 
tissue injury, infection, trauma or inflammation. 
Bradley et al (1977) stated that the increase 
occurs within 12-36 hours. NANA itself is an 
acute phase reactant since NANA levels are also 
elevated by the above mentioned stimuli. For 
example, Berra et al. (1986) discovered that 
total serum NANA levels were greatly modified by 
different manipulations of patients. When blood 
samples were drawn after an operation, NANA 
was specifically increased. Shamberger et, al 
(1987) found elevated levels of NANA in several 
inflammatory diseases, including osteoarthritis, 
Crohn's disease and mucosal ulcerative colitis. 
Hogan-Ryan et al. (1981), in their study of serum 
NANA concentrations in malignant melanoma, 
purposely omitted patients from the study if they 
had infection, so as to exclude the non-tumour 
specific acute-phase production of NANA. These 
findings implied that NANA lacked the specificity 
required for use as a tumour marker because of 
the possible incidence of false positive results.
In this evaluation of total serum NANA as a
71
tumour marker for cancer of the prostate, the 
following questions were posed.
1 .
Is the tumour burden of a patient suffering from 
cancer of the prostate, at a specific time, 
reflected m  an isolated determination of total 
serum NANA?
2
Could serial determination of total serum NANA be 
used to monitor patient response to therapy?
3
Does total serum NANA demonstrate properties of 
an acute-phase reactant when used as an indicator 
of tumour burden for cancer of the prostate9
3.2
EXPERIMENTAL DESIGN
Ten patients suffering from cancer of the
prostate were examined. All patients initially 
had advanced disease, with some also suffering 
from metastases. Following initial diagnosis and 
therapy each patient regularly attended the Meath 
Hospital as part of routine follow-up and
clinical monitoring. At each visit to the
hospital a sample was taken. Total serum NANA 
levels were determined using the thiobarbitunc 
acid method of Warren (Section 2.3.4). The 
duration of NANA monitoring varied for each 
patient as follows:
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PATIENT*
NAME
DURATION OF STUDY 
(weeks)
PI 25
P2 36
P3 31
P4 27
P5 30
P6 25
P7 23
P8 18
P9 13
P10 11
* : To preserve patient anonymity, real names
were not used. Each of the ten patients were 
therefore given a coded name (P1-P10), where 
for example, PI = Prostate cancer patient 
No.l.
3.3
ANALYSIS OF RESULTS
Total serum NANA levels for patients P1-P10 are 
tabulated in the appendix at the end of this 
section (Tables 3.1-3.10, respectively).
Results for PI are shown m  Figure 3.1.
This patient presented with advanced disease, 
but later responded well to therapy and was 
diagnosed as being free of disease at the end of 
the study (week 25).
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Total serum NANA levels fluctuated very little 
over the entire 25 week period, ranging from 
1700 nmoles/ml to 1900 nmoles/ml Therefore, the 
readings were quite constant, and grouped around 
the centre of the normal range for total serum 
NANA (1117 nmoles/ml-2525 nmoles/ml)* In marked t 
contrast, the state of health of the patient 
varied considerably, from advanced disease 
initially, to total absence of disease after only 
six weeks. This dramatic decrease in tumour 
burden was not reflected in total serum NANA 
levels. No dramatic decrease in serum NANA was 
observed. Serial determination of NANA would 
have provided no indication of tumour regression.
Results for P2 are shown in Figure 3.2.
This patient presented with advanced disease, 
but later responded well to therapy and was 
diagnosed as being free of disease at the time of 
the last clinical examination (week 36).
Initial analysis of total serum NANA gave a value 
of 1950 nmoles/ml. The level progressively 
decreased over the following 9 weeks. Between 
weeks 10 and 14 there was a slight increase m  
total serum NANA levels, giving a maximum value 
of 1800 nmoles/ml at week 14. From that point 
until the end of the study serum NANA levels 
continued to decrease, with the exception of a 
very slight elevation at week 32, to give a final 
level of 1150 nmoles total serum NANA per ml of 
serum at week 36.
In this case there was very good correlation 
between tumour burden and total serum NANA. The
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general trend in NANA levels was downwards, 
coinciding with progressively decreasing tumour 
burden. The level of total serum NANA at week 
36, the time at which the patient was pronounced 
free of disease, was only 1150 nmoles/ml, that 
is, towards the lower end of the normal range. 
Very slight increases were observed between weeks 
10 and 14 and also between weeks 28 and 32 V  
(increases observed were 300 nmoles/ml and 200 
nmoles/ml, respectively). These elevations were 
probably the result of an acute-phase response, 
which could have occurred as a result of any of 
the aforementioned causes of such a reaction.
One indication of these results is that 
isolated NANA determinations must be interpreted 
with caution. For example, week 1 gave a total 
serum NANA level of 1950 nmoles/ml, a value well 
within the normal range, at a time when the 
patient was known to have advanced disease with 
metastasis However, a possible use for serial 
determination of total serum NANA as a monitor of 
response to therapy is indicated as there was a 
definite decrease m  NANA levels as therapy 
successfully reduced the tumour burden.
Results for P3 are shown in Figure 3.3.
In this case, advanced disease was followed by 
a positive response to therapy and gradual 
tumour regression.
A cursory examination of Figure 3.3 shows that 
serial determination of total serum NANA is m  no 
way indicative of the extent of prostatic cancer. 
Dramatic decreases in total serum NANA levels 
were observed between weeks 1 -6 , 1 2 - 2 0 and 22-31.
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However, dramatic increases also occurred 
between weeks 8-12 and 20-22. These increases 
were obviously not tumour-associated as the 
tumour was actually regressing during these 
times. Results showed no particular trend, 
with total serum NANA levels fluctuating, within 
the normal range, between 1250 nmoles/ml and 2250 
nmoles/ml.
Results for P4 are shown m  Figure 3.4.
This patient initially had advanced disease with 
metastasis. At first he responded well to 
therapy, but later had a relapse and died.
Serum NANA levels fluctuated erratically, within 
the normal range, during the course of the seven 
month study. There was no consistent pattern or 
trend. Decreases in NANA levels were observed 
between weeks 1-5, 15-19 and 23-27, whereas
levels were seen to increase between weeks 5-15 
and 19-23 A gradual increase m  NANA levels 
would have been expected, to coincide with
progression of the disease This did not occur.
In fact, towards the end of the study, serum NANA 
levels were approaching, albeit erratically, 
values towards the lower end of the normal range. 
This was at a time when the state of health of 
the patient was rapidly deteriorating. Serial 
determination of total serum NANA gave no
indication or warning of impending death.
Results for P5 are shown m  Figure 3.5.
In this case the patient, who initially had 
advanced disease, later responded very well to 
therapy.
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Between weeks 1 and 8 there was a considerable 
decrease observed in total serum NANA levels, 
from 1950 nmoles/ml to 1450 nmoles/ml. The 
levels then increased to a level of 2 0 0 0  
nmoles/ml after 18 weeks. After this time, total 
serum NANA levels gradually decreased. At week 
30 (final sample), a value of 1800 nmoles total 
NANA per ml of serum was obtained. At no point 
during the 30 week investigation did total serum 
NANA levels go outside the normal range. There 
was no decrease in NANA to coincide with the 
improvement in the state of health and well-being 
of the patient. The levels actually increased 
over a 10 week period (weeks 8-18) despite an 
improvement in the patient's status during that 
time As tumour burden was actually decreasing 
between weeks 8 and 18 it is possible to 
state with certainty that the observed increase 
in total serum NANA was not tumour-associated. 
Therefore, for this patient total serum NANA 
levels were not indicative of the extent of 
tumour burden.
Results for P6 are shown m  Figure 3.6.
This patient suffered initially from advanced 
disease but later responded to therapy and 
improved.
Between weeks one and seven there was a dramatic 
decrease in total serum NANA levels, from 2400 
nmoles/ml to 1500 nmoles/ml. There was only a 
slight increase in NANA levels between weeks 
7 and 17. The serum NANA content then increased 
by 500 nmoles/ml between weeks 17 and 21. Four 
weeks later (week 25:final sample) a value of
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1950 nmoles/ml was obtained
The presence of advanced disease was reflected m  
a high serum NANA level (2400 nmoles/ml). 
However, it must be noted that this value is 
still within the normal range (upper limit is 
2525 nmoles/ml) . As the patient improved there 
was a dramatic decrease in total serum NANA 
levels up to week 7. The patient continued to 
improve from week 7 until the end of the 
observation period (week 25) . However, this 
further improvement in the health of the patient 
was not reflected m  total serum NANA levels, 
which were actually seen to increase.
Results for P7 are shown m  Figure 3.7.
This patient initially had advanced disease with 
distant metastasis. There was no response to 
therapy and the unfortunate patient died later.
The initial level of total serum NANA was 
extremely high (3550 nmoles/ml at week 1). This 
value was over 1 0 0 0 nmoles/ml higher than the 
upper limit of the normal range (2525 nmoles/ml). 
After 3 weeks the value increased still further 
to 4200 nmoles NANA per ml of serum. 
While there was a decrease in NANA levels between 
weeks 3 and 9, the values were still extremely 
high (week 5: 4000 nmoles/ml, week 9: 3950
nmoles/ml) . From week 9 until the end of the 
study (week 23) there was a gradual increase in 
total serum NANA levels. The value obtained for 
week 23, the final sample, was 4500 nmoles/ml.
In this case there was very good correlation 
between tumour burden and total serum NANA
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levels. All values obtained were very high. 
There was also an increase in NANA levels as the 
patient's condition deteriorated (weeks 9-23) 
Therefore, for this patient, total serum NANA was 
a very good indicator of tumour burden.
Results for P8 are shown in Figure 3.8.
This patient initially suffered from advanced 
disease. He later responded to therapy and his 
clinical status improved significantly. At the 
last examination (week 18) the patient was found 
to be completely disease free.
Between weeks 1 and 5, total serum NANA levels 
were elevated, but constant (week 1 : 
2650 nmoles/ml, week 2: 2600 nmoles/ml, week 5: 
2650 nmoles/ml) . Between weeks 5 and 10, total 
serum NANA levels decreased dramatically from 
2650 nmoles/ml to 1950 nmoles/ml. NANA levels 
continued to decrease, giving a value of 1450 
nmoles/ml at the end of the study (week 18: 
patient free of disease).
For this patient, total serum NANA was found to 
be an excellent indicator of tumour burden. 
Initially the levels were high (above the upper 
limit of the normal range), coinciding with 
serious advanced cancer of the prostate. As the 
clinical status of the patient improved the 
levels of serum NANA decreased dramatically. By 
the time the patient was diagnosed as being 
completely free of disease, total serum NANA 
levels were approaching the lower limit of the 
normal range.
Results for P9 are shown m  Figure 3.9.
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This patient initially had advanced disease with 
metastasis, but later responded well to therapy 
However, by the end of the study (week 13) the 
patient was no longer responding to therapy.
Weeks 1 and 3 gave total serum NANA levels of 
1150 nmoles/ml and 1050 nmoles/ml, 
respectively. Weeks 5, 7 and 9 gave higher
levels, ranging from 1350 nmoles/ml to 1550 
nmoles/ml. Between weeks 9 and 11 total serum 
NANA levels dropped dramatically, but were found 
to be on the increase again at week 13 (end of 
study).
Total serum NANA levels did not correlate well 
with tumour burden. Levels approaching (and 
going below) the lower limit of the normal range 
(1117 nmoles/ml) were obtained for weeks 1 and 3, 
at a time when the patient had advanced disease 
Total serum NANA levels, while within the normal 
range, were actually elevated at a time when the 
patient was responding to therapy Only towards 
the end of the study was there any degree of 
correlation between tumour burden and NANA 
levels. A dramatic decrease was observed between 
week 9 (1450 nmoles/ml) and week 11 (800
nmoles/ml), coinciding with a further improvement 
in the state of health of the patient. By the 
end of the study the patient was showing symptoms 
of therapy failure. This was reflected in 
increased serum NANA levels.
The extent of disease varied considerably from 
advanced cancer initially, to reduced tumour 
burden, and finally to symptoms of a return to a 
more serious condition. This clinical
progression was not reflected in total serum NANA
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levels These results especially demonstrate the 
unsuitability of using an isolated, individual 
determination of serum NANA as an indicator of 
tumour burden The low levels of NANA obtained 
for weeks 1 and 3 would indicate that the 
the patient was not seriously ill, whereas other 
clinical parameters had shown the presence of 
advanced disease with metastasis.
Results for P10 are shown m  Figure 3.10.
This patient initially suffered from advanced 
cancer of the prostate with metastasis. The 
disease later stabilised and had not progressed 
at the time of the last examination (week 1 1 ).
Total serum NANA levels were extremely high for 
weeks 1 and 3 (3550 nmoles/ml and 3800 nmoles/ml, 
respectively), when compared with the upper limit 
of the normal range (2525 nmoles/ml). The levels 
decreased somewhat for week 5 (3000 nmoles/ml)
and week 8 (3150 nmoles/ml) , but were still
considerably elevated. Week 10 showed a dramatic 
decrease in serum NANA, giving a value of 1950 
nmoles/ml (a drop of 1 2 0 0 nmoles/ml).
In this case there was some correlation between 
tumour burden and total serum NANA, as advanced 
metastatic disease coincided with highly elevated 
NANA levels. It was only towards the end of the 
study that NANA levels were within the normal 
range (week 10: 1950 nmoles/ml, week 11: 2200
nmoles/ml). However, these results must be 
interpreted with extreme caution. The patient 
was diagnosed as having advanced disease with 
metastasis, which later stabilised and showed no 
signs of any further progression. Total serum 
NANA levels, if used as an indicator of tumour
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burden, would have indicated a more optimistic, 
and in this case incorrect, prognosis. NANA 
levels fell dramatically, from values well above 
the upper limit of the normal range, to values 
within that range, at a time when the disease had 
merely stabilised. Total serum NANA obtained 
would suggest that the disease had not merely 
stabilised, but significantly regressed.
3.4
DISCUSSION
Table 3.11 shows the degree of correlation 
between total serum NANA levels and extent of 
prostatic cancer tumour burden for all the 
patients studied.
This experiment, namely, the evaluation of total 
serum NANA as a marker for cancer of the 
prostate, produced conflicting results. It was 
not possible to give a definite answer concerning 
its clinical significance.
Patients PI, P2, and P8 all had identical
disease profiles. All initially had advanced
disease. Similarly, they all later responded 
well to therapy and were deemed to be completely 
free of disease at the last clinical examination. 
In the case of patient PI, total serum NANA 
levels hardly changed at all, despite dramatic 
changes in the extent of disease. However,
patients P2 and P8 both showed very good 
correlation between serial NANA determination and 
response to therapy. In both cases there was a 
definite downward trend observed m  serum NANA
levels as the state of health of the patients 
improved, thus suggesting that NANA could be
82
of use as a monitor of response to therapy 
Patients P3, P5 and P6 also had similar clinical 
histories, with good response to therapy 
resulting in gradual disease regression. Patient 
P5 showed no downward trend m  total serum NANA 
levels to coincide with tumour regression. The 
levels were actually seen to increase 
consistently, over a ten week period, during 
which time the patient was actually improving. 
This trend, of elevated serum NANA levels 
coinciding with decreasing tumour burden, was 
also observed in patient P6 . For patient P3, 
total serum NANA levels fluctuated, within the 
normal range, and showed very poor correlation 
with extent of disease.
Patients P4 and P7 could also be grouped together 
as both eventually succumbed to the disease. 
Results obtained for P7 strongly indicated that 
total serum NANA was a very good indicator of 
tumour burden. NANA levels were extremely high 
from the start and continued to rise still 
further as the disease progressed. These 
findings were totally contradicted by the results 
obtained for patient P4, where NANA levels 
fluctuated erratically within normal range 
values. There were no elevated NANA levels to 
coincide with the initial severely advanced 
disease. Neither was there a consistent increase 
in serum NANA levels as the patient suffered a 
relapse and approached death. NANA levels 
indicated that this patient was, at the very 
least, stable.
Patient P10 stood alone m  that he suffered from 
metastatic disease which remained stable, that 
is, there was no further progression. However,
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total serum NANA levels indicated a completely 
different scenario, namely that the patient was 
undergoing a dramatic improvement Whereas the 
extent of tumour burden remained constant, the 
levels of total serum NANA fell dramatically.
Despite these contradictory results, this 
experiment did produce some definite findings. 
One such finding is that individual isolated 
total serum NANA levels must be interpreted with 
extreme caution. A possible role for NANA in 
relation to prostatic cancer is the use of serial 
determination of total serum NANA levels as a 
tenuous indicator of response to therapy, and 
only if used in conjunction with other clinical 
parameters. No clinical or therapeutic decisions 
should be made solely on the strength of a sialic 
acid determination. NANA lacks the sensitivity 
required for screening purposes, that is, the 
detection of early stages of tumour development. 
It is also clearly lacking m  specificity, as 
results obtained for patients P3, P5, P6 and P9 
were indicative of a typical acute-phase 
reaction, where elevations in total serum NANA 
levels could not be attributed to the extent of 
prostatic tumour burden. Another consistent 
trend observed in this experiment was that 
elevated serum NANA levels were always present in 
cases of severely advanced disease.
Finally, the results showed one other interesting 
trend which may be of clinical significance. In 
6 of the 7 patients (8 6%) where initial NANA 
levels were within the normal range, there was 
very poor correlation between serial NANA 
determination and prostate tumour burden (PI, P3, 
P4, P5, P6 and P7), with only one patient (P2) 
showing good correlation. However, in the 3
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cases (P7, P8 and P10) where initial NANA levels 
exceeded the upper limit of the normal range, 
patients P7 and P8 (67%) were found to have 
excellent correlation between tumour burden and 
NANA levels.
3.5
CONCLUDING COMMENTS
Based on the results obtained in this experiment, 
it is possible to state the following:
Individual isolated NANA determinations do not 
necessarily reflect the extent of tumour burden 
m  patients with cancer of the prostate.
Total serum NANA levels are dramatically elevated 
m  cases of advanced metastatic disease.
Total serum NANA lacks the specificity necessary 
for its use as a marker of tumour burden, and 
shows properties of an acute-phase reactant. 
Elevated serum NANA levels are observed in cases 
where the cause (or causes) are clearly not 
directly associated with prostatic tumour burden.
Total serum NANA lacks the sensitivity required 
for use as a screening assay for cancer of the 
prostate.
NANA, as an indicator of tumour burden, is at its 
most useful when initial NANA levels exceed the 
upper limit of the normal range. This suggests a 
possible role for serial determination of total 
serum NANA levels as a means of monitoring 
patient response to therapy, if used m  
conjunction with other recognised clinical 
parameters.
85
TO
TA
L 
NA
NA
 
(n
m
o
l/m
l)
FIGURE 3 1
CHANGES IN TOTAL SERUM NANA WITH TIME
TIME (weeks)
86
TO
TA
L 
NA
NA
 
(n
m
o
l/m
’A-S&
FIGURE 3 2 
CHANGES IN TOTAL SERUM NANA WITH TIME
2600 
2400 
2200 
2000 
1800 
1600 
1400 
1200 
1000
0 3 6 9 12 15 18 21 24 27 30 33 36 39
TIME (weeks)
87
TO
TA
L 
NA
NA
 
(n
m
o
l/m
l)
FIGURE 3 3
CHANGES IN TOTAL SERUM NANA WITH TIME
TIME (weeks)
8 8
TO
TA
L 
NA
NA
 
(n
m
o
l/m
l)
FIGURE 3 4
CHANGES IN TOTAL SERUM NANA WITH TIME
2600
lower lim it 
(norm al range)
upper lim it 
(normal range)
0 12 15 18
TIME (weeks)
21 24 27 30
89
TO
TA
L 
NA
NA
 
(n
m
o
l/r
n
l
FIGURE 3 5
CHANGES IN TOTAL SERUM NANA WITH TIME
TIME (weeks)
9 0
TO
TA
L 
NA
NA
 
(n
m
o
l/m
l)
FIGURE 3 6
CHANGES IN TOTAL SERUM NANA WITH TIME
TIME (weeks)
9 1
TO
TA
L 
NA
NA
 
(n
m
o
l/m
l
TABLE 3 7
CHANGES IN TOTAL SERUM NANA WITH TIME
TIME (weeks)
92
TO
TA
L 
NA
NA
 
(n
m
o
l/m
FIGURE 3 8
CHANGES IN TOTAL SERUM NANA WITH TIME
TIME (weeks)
93
TO
TA
L 
NA
NA
 
(n
m
o
l/m
l)
FIGURE 3 9
CHANGES IN TOTAL SERUM NANA WITH TIME
TIME (weeks)
94
TO
TA
L 
NA
NA
 
(n
m
o
l/
m
l)
FIGURE 3 10
4000
3700
3400
3100
2800
2500
2200
1900
1600
1300
1000 2
CHANGES IN TOTAL SERUM NANA WITH TIME
TIME (weeks)
95
SECTION 3 
APPENDIX 
TABLES 3.1 - 3.11
CLINICAL HISTORY : Patient responded veil to
therapy. Disease free at last 
clinical examination (week 25)
SERIAL DETERMINATION OF TOTAL SERl> S\N\
TABLE 3 1
PATIENT £!
I IME 
(weeks)
TOTAL SERIM \V% - 
nmöles/ul
1 1700
5 1700
9 1900
13 1800
17 1900
21 1850
25 1750
SERUM NANA NORMAL RANGE *
1117 nmoles/ml-2525 nmoles/ml
9 6
TABLE 3 2
CLINICAL HISTORY .Patient responded well to
therapy. Disease free at last 
clinical examination (week 36).
SERIAL DETERMINATION OF TOTAL SERUM NANA
PATIENT £2
TIME
(weeks)
TOTAL SERUM NANA 
(nmoles/ml)
1 1950
8 1800
10 1500
12 1600
14 1800
16 1450
20 1400
24 1350
28 12 0 0
32 1400
36 1150
NAMA NORMAL RANGE.
1117 nmoles/ml-2525 nmoles/ml
9 7
TABLE 3 3
CLINICAL HISTORY: Patient responded well to
therapy and showed gradual 
disease regression.
SERIAL DETERMINATION OF TOTAL SERUM NAN^
PATIENT : P3
TIME
(weeks)
TOTAL SERUM NANA 
(nmoles/ml)
1 2250
6 1450
8 1450
10 1750
12 2050
18 1500
20 1250
22 2150
26 2000
31 1600
SERLM NWA NORMAL RANGE *
1 1 1 7  n m o le s /m l-2 5 2 5  n m o le s /m l
3 3
TABLE 3 4
CLINICAL HISTORY . Patient initially responded
well to therapy, but later 
had a relapse and died.
PATIENT P4
SERIAL DETERMINATION OF TOTAL SERUM NANA
TIME
(weeks)
TOTAL SERl*M NANA 
(nmoles/ml)
1 1900
5 1200
15 1750
19 1050
23 1550
27 1150
SERUM NANA NORMAL RANGE:
1117 nmoles/ml-2525 nmoles/ml
9 0
TABLE 3 5
CLINICAL HISTORY Patient responded very well to
therapy,
SERIAL DETERMINATION OF TOTAL SERUM NANA
PATIENT P5
TIME
(weeks)
TOTAL SERUM N\NA 
(nmoles/ml)
1 1950
8 1450
10 1750
12 1750
14 1950
18 20 0 0
22 1900
26 1900
30 1800
SERUM NANA NORMAL RANGE:
1117 nmoles/ml-2525 nmoles/ml
] JO
TABLE 3 6
CLINICAL HISTORY: Patient initially had very bad
metastatic disease, but later 
improved
PATIENT . P6
SERIAL DETERMINATION OF TOTAL SERUM NANA
TIME
(weeks)
TOTAL SERIM N\NA 
(nmoles/ml)
1 2400
5 20 0 0
7 1500
17 1600
21 21 0 0
25 1950
SERUM NANA NORMAL RANGE 
1117 nmoles/ml-2525nmoles/ml
1
TABLE 3 . 7
i
CLINICAL HISTORY Severe metastatic disease
No response to therapy 
Patient died. =
PATIENT -P7
SERIAL DETERMINATION OF TOTAL SERUM NANA
TIME
(weeks)
TOTAL SERUM NANA“ 
(nmoles/ml)
1 3550
3 4200
b 4U0U
y J4b0
4 JbO
± ^ 4 ¿i SO
¿6 4bOO
SERUM NANA NORMAL RANGE 
iii/ nmoles/ml-<¿b¿b nmoles/mi
TXBLE 3 . 8
CLINICAL STMlS Patient initially suffered from
severe fietastatic disease, but 
later responded to therapy. 
Disease free at time of last 
examination.
SERIAL DETERMIV VTIQN OF TOTAL SERUM NANA
PATIENT P I
TIME
(weeks)
TOTAL SERUM NANA 
(nmoles/ml)
1 2650
2 2600
5 2650
*7 2450
10 1950
12 1700
14 1600
18 1450
SERUM N\NA %QQ*AL RA_\:£
1 1 1 7  n m o le s /m l- 2 5 2 5  n ^ c le s /m l
TABLE 3 9
CLINICAL STATUS :Severe metastatic disease
initially. Later responded 
well to therapy. Patient 
was not responding to
therapy at end of study.
PATIENT .P 9
SERIAL DETERMINATION OF TOTAL SERUM NANA
TIME
(weeks)
TOTAL SERUM NANA 
(nmoles/ml)
1 1150
3 1050
5
t
1550
7 1350
9 1450
11 800
13 1250
*
SERUM NAVI NORMAL RANGE
1 1 1 7  n m o le s /m l-2 5 2 5  n m o le s /m l
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TABLE 3 10
PATIENT . P 1 0
CLINICAL STATUS : Patient initially had severe
advanced disease but later 
stabilised and h a d  not 
progressed at time of final 
examination.
SERIAL DETERMINATION OF TOTAL SERUM NANA
TIME 
(weeks)
TOTAL SERUM NANA 
(nmoles/ml)
1 3550
3 3800
5 3000
8 3150
10 1950
11 2200
SERUM NANA NORMAL RANGE*
1117 nmoles/ml-2525 nmoles/ml
1 0 5
TABLE 3 11
DEGREE OF CORRELATION BETWEEN TOTAL SERUM NANA 
AND TUMOUR BURDEN
PATIENT DEGREE OF CORRELATION
PI *
P2 * ft ft «
P3 ft
P4 ft
P5
P6 *
P7 ft * * * *
P8 ft ft a * *
P9 ft
P10 * ft
Symbols used to represent degree of correlation 
represent the following
SYMBOL DEGREE OF CORRELATION
ft POOR
ft ft REASONABLE
ft ft ft GOOD
ft ft ft ft VERY GOOD
ft ft ft ft ft EXCELLENT
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SECTION 4
A Critical Evaluation of Serum and Urinary Sialic Acid as 
Indicators of Tumour Burden in Human Patients with 
Cancer of the Bladder.
4.1
INTRODUCTION
The aim of this experiment was to evaluate serum 
and urinary total NANA as indicators of tumour 
burden m  human patients with bladder cancer, an 
aggressive disease which, m  the United States of 
America alone, can claim as many as ten thousand 
lives each year (Javadpour et al, 1984). One of 
the first symptoms of bladder cancer is blood in 
the urine, a condition known as haematuria. 
Unfortunately, in many cases the disease will be 
significantly advanced before haematuna occurs. 
This factor, combined with the limitations of 
other available clinical, roentgenographic and 
laboratory methods in the diagnosis of urological 
cancers, or in the determination of the precise 
extent of disease, have lead to the search for 
alternative tumour markers. Ideally the tumour 
marker, present in serum or urine, should be 
capable of detecting early stages of tumour 
development, thus allowing its use as a method 
of cancer screening. As elevated serum NANA 
levels have been associated with other types of 
cancer it was decided that serum and urinary NANA 
should be evaluated as possible markers for 
bladder carcinoma.
It had been found that elevated NANA levels are 
not specific for any one type of cancer. Lodha 
et al. (1979) found highly significant elevations 
m  serum NANA levels in a variety of malignant 
neoplastic conditions. Erbil et al. (1986), in 
their study of genitourinary malignancies 
(including bladder cancer), found that serum 
protein-bound NANA and LSA levels correlated very
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well with stage and grade in patients with 
advanced disease, and therefore had potential as 
indicators of response to therapy* However, the 
suitability of NANA for use as a method of 
screening has been questioned. Erbil et al.. 
(1985), who evaluated serum NANA and LSA levels 
as markers for colorectal cancer, found that they 
both lacked the sensitivity and specificity 
required for screening purposes. Silver et al. 
(1978), who studied serum NANA levels in 
malignant melanoma patients, also found that NANA 
lacked the sensitivity reqired for cancer 
screening, reflected in a high incidence (36%) of 
false negative results.
In this evaluation of serum and urinary total 
NANA as markers for bladder cancer, the following 
questions were being asked:
1
Is the tumour burden of a patient with bladder 
cancer, at a specific time, reflected in an 
isolated determination of total serum or urinary 
NANA?
2
Is the presence of advanced bladder cancer 
accompanied by significantly elevated levels of 
serum and urinary NANA levels?
3
Can total serum or urinary NANA be used as a 
marker for the presence of small tumour volume, 
thus allowing their use as methods of bladder 
cancer screening?
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4.2
EXPERIMENTAL DESIGN «
Five healthy volunteers were used as controls. 
Three subject groups were studied. The first 
group contained 13 patients who previously had 
bladder cancer but had no clinical or endoscopic 
evidence of disease at the time of study. The 
second group consisted of 7 patients who 
previously had bladder cancer and had small 
volume, superficial tumour recurrence amenable to 
transurethral fulguration or resection at the 
time of study. The third group contained 6 
patients with newly diagnosed tumours that were 
at least invasive of muscle. Samples of blood 
and urine were collected preoperatively. NANA 
levels were determined by the Warren assay 
(Section 2.3.4).
4.3
STASTICAL ANALYSIS
Normal levels of serum and urinary total NANA 
were defined using the mean levels obtained from 
5 healthy volunteers. The two-sample Student’s 
t-Test (Section 2.8.1) was used to compare 
normal levels of both serum and urinary NANA with 
the mean values of each of the three tumour 
groups.
4.4
DISCUSSION
Results are shown in Table 4.1.
No significant differences were found in either 
serum or urinary mean NANA levels between the 
control group and those who previously had cancer 
but who were free of disease at the time of study 
(tumour group 1). In the second tumour group,
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where patients previously had bladder cancer and 
now had small volume, superficial (non-muscle 
invasive) disease, it was again found that no 
significant elevation in serum or urinary NANA 
occurred, when compared to normal levels. Even 
m  cases of advanced muscle invasive disease 
(final tumour group) , it was only in serum NANA 
levels that significant elevations occurred 
(P<0.02). While urinary NANA levels were also 
elevated above normal levels, the observed 
increases were not statistically significant 
(P<0.2).
4 . 5
CONCLUDING COMMENTS
Based on the results obtained m  this experiment 
it is possible to state the following:
1
Tumour burden is not reflected m  either serum 
or urinary NANA levels m  cases of small volume, 
superficial bladder carcinoma.
2
Serum and urinary NANA levels are elevated, when 
compared to normal levels, in cases of advanced 
bladder carcinoma, with significant increases 
occurring only in serum levels.
3
As both both serum and urinary NANA levels lack 
the sensitivity required to detect small tumour 
burden, both markers are therefore unsuitable for 
use either as a method of cancer screening, or as 
a method for detecting small volume, recurrent 
tumours.
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Significantly elevated levels of serum total 
NANA, in cases of advanced disease, suggest that 
this marker may be suitable as a supplementary 
parameter in the follow-up of high stage bladder 
cancer, particurlarly with regard to the 
assessment of response to, and efficacy of, 
therapeutic procedures.
4
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\TABLE 4.1
SERUM AND URINARY MEAN NANA LEVELS IN NORMAL 
CONTROLS AND PATIENTS WITH CANCER OF THE BLADDER
TUMOUR EXP. SAMPLE NANA (nmoles/ml) CRITICAL (V)
MARKER GROUP SIZE MEAN +/- S.D. VALUE
SERUM CONTROL 5 1670.0 +/- 375.2 (-) (-)
NANA TUMOUR(1) 13 1857.7 +/- 314.1 1.07 (16)
TUMOUR(2) 7 1914.3 +/- 587.2 0.81 (10)
TUMOUR(3) 5 2400.0 +/- 316.2 3.34* (8)
URINARY CONTROL 5 184.0 +/- 98.9 (-) (-)
NANA TUMOUR(1) 13 213.8 +/- 71.1 0.71 (16)
TUMOUR(2) 7 191.4 +/- 76.0 0.15 (10)
TUMOUR(3) 6 326.7 +/- 147.7 1.82 (9)
S.D. = Standard Deviation
V represents the number of degrees of freedom for 
a particular t-Test and is determined by the 
sample size, where V = n^+ng-S.
Only one significant difference found.
* : significant difference ; P<0.02
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SECTION 5
The Evaluation of Total Serum Sialic Acid 
and Lipid-Bound Serum Sialic Acid as 
Indicators of Tumour Burden in Mice 
Bearing the Landschutz Ascites Tumour.
5.1
INTRODUCTION
The aim of this investigation was to evaluate the 
potential use of total serum NANA and serum LSA 
as indicators of tumour burden m  LAT-bearing 
mice. To achieve this, four separate experiments 
were performed. Three involved the measurement 
of total serum NANA levels while one measured 
serum LSA levels.
Erbil et al. (1985) suggested that increased
levels of total serum NANA found m  the sera of 
patients with tumours are due to an increased 
release and breakdown of sialoglycoconjugates 
from tumour cell membranes. Debray et. aJL. (1986) 
showed that there is an increase in highly 
branched oligosaccharides in transformed human 
tumour cells. Miller et al. (1963), who compared 
the NANA content of the mouse erythrocyte with 
that of the murine Ehrlich ascites tumour (EAT) 
cell, found that the density of NANA on the EAT 
cell surface was approximately four times that on 
the erythrocyte. It was our aim to discover if a 
similar phenomenon occurred m  the LAT 
cell, that is, increased synthesis of surface 
NANA, reflected in elevated levels of total serum 
NANA.
It has been suggested that serum LSA might be a 
more useful and discriminating marker for tumour 
detection than total serum NANA. The
potential use of LSA as an indicator of tumour 
burden has been evaluated in a range of animal 
model systems. Skipski et al. (1975) studied 
serum LSA levels m  rats bearing Morris hepatoma. 
The presence of tumour was accompanied by
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qualitative and quantitative changes in 
ganglioside patterns. Poll et al.. (1986) , who 
evaluated serum LSA as an indicator of 
tumour burden in dogs, found good correlation 
between effectiveness of therapy and LSA 
measurements. However, elevated serum LSA levels 
were also associated with chronic inflammatory 
and degenerative disease, thus implicating LSA as 
a possible acute-phase reactant. Kloppel et al.. 
(1981) studied serum LSA levels in horses with 
neoplasms. Their results showed that LSA could 
be used to detect neoplastic growth and also to 
monitor response to treatment. The specificity 
(% true negatives) of the test was high (91%), 
with false positive results occurring only m  
cases of acute infections. Kloppel et. al. (1977) 
also studied serum LSA levels in mice bearing 
transplantable mammary carcinomas. The presence 
of tumour was associated with elevated NANA 
levels, with the elevations occurring principally 
m  the ganglioside fraction. Increases in serum 
LSA levels were often seen to predate visual 
signs of tumour presence. Surgical removal of 
tumours was also accompanied by dramatic 
reductions m  serum LSA levels.
Tumour development is not always accompanied by 
increases m  NANA levels. Hakim (1980) studied 
levels of serum protein-bound, perchloric acid 
soluble NANA (PA-NANA), in rats bearing a mammary 
adenocarcinoma. In general, PA-NANA levels 
increased with tumour burden, and the magnitude 
of the increase varied with the number of 
implanted tumour cells. However, they also found 
that a maximum level of PA-NANA was obtained5twenty days after implantation of 10 tumour 
cells, and that levels progressively decreased in 
animals that lived for longer periods. Saha et
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al. (1988) measured LSA levels in the plasma of
mice bearing EAT. Plasma LSA gradually increased 
up to day 6 (6 days after mtrapentoneal
injection of tumour), but then rapidly declined, 
to values below normal levels, by day 10. The 
authors suggested that the observed decrease in 
LSA could be due to simplification in ganglioside 
synthesis, combined with a decrease in metabolic 
activity of the tumour.
5.2
EXPERIMENTAL DESIGN
Four separate experiments, three measuring total 
serum NANA and one measuring serum LSA, were 
performed in order to evaluate total NANA and LSA 
as indicators of LAT burden in an animal model 
system. The experiments had the following steps 
m  common. Male Schofield mice were used. LAT 
cells (Section 2.3.1), recovered from liquid 
nitrogen (Section 2.4.11), were counted
(Section 2.4.9) prior to injection. Mice m  
the tumour-bearing groups received either
lxl07or lxlO5 viable LAT cells (both m  1.0ml
PBS). Control groups received 1.0ml of either 
PBS or Pristane (2, 6, 10, 14-tetramethylpenta- 
decane; an immunostimulant). All injections were 
mtrapentoneal. Blood samples, obtained by 
tail-bleeding (Section 2.3.2), were taken before 
and after injection of LAT cells, PBS or
Pristane. Total serum NANA levels were
determined (experiments 1-3) using the Warren 
thiobarbituric acid method (Section 2.3.4). 
The Warren assay was also used to determine serum 
LSA levels (experiment 4), following extraction 
of gangliosides by the procedure of Katopodis and
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Stock (Section 2.3.5).
The details of each individual experiment can be 
summarised as follows.
SERUM
MARKER
EXP.
NO.
EXPERIMENTAL
GROUPS
MATERIAL
INJECTED
NANA
1 LAT GROUP 
CONTROL GROUP (1) 
CONTROL GROUP (2) 
MICE PER GROUP(6)
107 CELLS 
PBS
PRISTANE
NANA 2 LAT GROUP (1)
LAT GROUP (2) 
CONTROL GROUP 
MICE PER GROUP(4)
107 CELLS 
105 CELLS 
PBS
NANA 3 LAT GROUP 
CONTROL GROUP 
MICE PER GROUP(5)
107 CELLS 
PBS
LSA 4 LAT GROUP 
CONTROL GROUP 
MICE PER GROUP(4)
107 CELLS 
PBS
5.3
STATISTICAL ANALYSIS
The magnitude of average increases m  total 
serum NANA levels observed In LAT-beanng mice 
were compared to those of control groups using 
Student's t-Test (Section 2.8.2). This method 
of analysis required the monitoring of serum NANA 
elevations in each mouse.
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The two-sample Student’s t-Test (Section 2.8.1) 
was also used to compare normal serum NANA and 
LSA levels with those obtained after 6 days of 
LAT growth. Normal levels of NANA and LSA were 
defined using the mean values obtained from 
pre-mjectlon samples.
5.4
ANALYSIS OF RESULTS
5.4.1
EXPERIMENT 1
Results are shown in Figure 5.1. 7The large number of injected LAT cells (10 ) 
caused a rapid increase in tumour mass. 
Therefore, to minimise the distress caused to the 
animals, the maximum period of NANA monitoring 
was 11 days. However, even over this short 
period, it was obvious that NANA levels showed no 
correlation with tumour burden.
In the LAT tumour-bearing mice, mean NANA levels 
rose sharply from 1192 nmoles/ml to 1967
nmoles/ml between day -1 (one day before 
injection of LAT cells) and day 3 (three days 
after injection). This represents a 65% increase 
in serum NANA on resting (pre-injection) levels. 
Initial elevations were also observed m  the PBS 
and Pnstane control groups, after 3
days. Statistical analysis of the results showed 
that highly significant differences existed
between the average increase in NANA levels 
observed m  LAT-beanng mice and those which
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occurred in both the PBS and Pnstane control 
groups (Table 5.1).
The results obtained in this experiment are 
typical of those expected for an acute-phase 
reaction. The initial elevation in total serum 
NANA, in the tumour group was not caused by the 
tumour itself since further increases in tumour 
burden were not accompanied by further elevations 
in serum NANA. Between day 3 and day 7 there was 
an obvious increase in tumour burden whereas the 
level of total serum NANA actually decreased. 
The initial dramatic peak, observed in 
LAT-bearing mice, would appear to have been 
caused by the trauma of the injection process.
5.4.2
EXPERIMENT 2
Results are shown in Figure 5.2.
The results obtained for the first tumour group,7where each mouse received 1x10 cells, were very 
similar to those obtained in experiment 1. There 
was no correlation between total serum NANA and 
tumour burden. A dramatic increase m  mean total 
serum NANA was again obvious by day 3. The 
levels rose from 1538 nmoles/ml (day -1) to 2225 
nmoles/ml (day 3), representing a 45% increase on 
resting levels. This increase was followed by an 
even greater decrease over the next 2 days. The 
value obtained for day 5 was 1525 nmoles/ml total
serum NANA. Therefore, after 5 days of tumour
growth, the level of NANA was actually less than 
that obtained prior to injection of tumour.
An initial peak, although small, was also 
observed in the PBS control group. Analysis of 
the results showed that a statistically
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significant difference did exist between the 
average increase in serum NANA observed m  
the LAT group and that which occurred in the PBS 
control (Table 5*1).
In the second tumour group each mouse received 
5only 1x10 cells. The advantage of injecting 
fewer LAT cells is that tumour burden and 
associated serum NANA levels can be monitored for 
almost 4 weeks. As in the previous LAT group, 
mean serum NANA levels peaked after 3 days, but 
then fell dramatically after a further 2 days of 
tumour growth. Mean total serum NANA levels rose 
from 1338 nmoles/ml (day -1) to 2083 nmoles/ml 
(day 3) , an increase of 56% on resting levels, 
but then fell to 1688 nmoles/ml by day 5, a 
decrease of 19% compared to the level of day 3. 
The increase in serum NANA levels of LAT-bearing 
mice, between day -1 and day 3, was not 
significantly different from that which occurred 
in the control group over the same period (Table
5.1) .
A second peak in total serum NANA occurred in the 
LAT-bearing mice on day 14. However, a similar 
increase was also observed in the PBS control 
group on the same day, thus showing that the 
increase m  NANA levels was not directly due to 
the increased tumour burden.
5.4.3
EXPERIMENT 3
Results are shown in Figure 5.3.
In the tumour-bearing group, mean total serum 
NANA levels increased from 1760 nmoles/ml (day 
-1) to 2140 nmoles/ml (day 6) , representing an 
increase of 21.6% over resting levels. However,
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an increase of 17.2% in NANA levels was also 
observed m  the PBS control group over the same 
period. Therefore, the difference m  the 
percentage increases in mean total serum NANA 
levels from day -1 to day 6, between the two 
groups, was 4.2%. This means that, m  the LAT 
group, only 4.2% of the observed increase in mean 
total serum NANA levels can be attributed solely 
to the extent of tumour burden, with the 
remaining 95.8% being due to non-tumour 
associated effects. Statistical analysis, based 
on the comparison between the average increases 
in serum NANA, confirmed that no difference 
existed between the two groups (Table 5.1). 
However, when the mean level of serum NANA, prior 
to injection (i.e. normal level), was compared to 
the mean value after six days of tumour growth, a 
highly significant difference (P<0.001) was found 
to exist (Table 5.2).
5.4.4
EXPERIMENT 4
Results are shown in Figure 5.4.
In the tumour-bearing group, mean serum LSA 
levels rose from 513 nmoles/ml on day -1 to 757
nmoles/ml on day 6. This represents a dramatic
increase of 47.6% m  mean LSA levels when 
compared to resting levels, whereas the observed 
increase in the control group over the same 
period was only 20.5% (484 nmoles/ml on day -1 to
583 nmoles/ml on day 6). Statistical analysis,
based on the comparison between the average 
increases in LSA levels between day -1 and day 6, 
showed that no difference existed between the two
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groups (Table 5.1), whereas comparison of the 
mean levels on those days did show a small, but 
significant increase (P<0.02) m  LSA levels 
(Table 5.2).
No further increases in serum LSA levels were 
observed in the tumour-bearing mice after day 6, 
despite an obvious visual increase in tumour 
burden. A value of 691 nmoles/ml was obtained on 
day 9, representing a decrease of 8.7% in LSA 
levels, when compared to the value of day 6. 
After an additional 2 days of tumour growth the 
mean LSA level was found to be 690 nmoles/ml, 
further confirming that serum LSA was not 
increasing proportionally with tumour burden. 
Between days 6 and 9, at a time when mean LSA 
levels were decreasing m  the tumour-bearing 
mice, the levels were seen to increase in the PBS 
control group, from 583 nmoles/ml to 625 
nmoles/ml, a rise of 7.2% for the three day 
period. A negligable change in LSA concentration 
(3 nmoles/ml) was observed in the control group 
between days 9 and 13.
5.5
DISCUSSION
The principal aim of these experiments was to 
evaluate serum NANA and serum LSA as indicators 
of tumour burden in mice bearing LAT. Berra et 
al. (1986) found that serum NANA concentration
was modulated by hormonal conditions, therefore 
all mice used in these experiments were male. 
LSA has been extensively studied with regard to 
its tumour marker potential in a variety of 
animal model systems. The main emphasis in this 
investigation was therefore placed on the
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evaluation of total serum NANA as an indicator of 
LAT tumour burden.
The first of the three experiments used to
evaluate total serum NANA contained one tumour 
7group (10 LAT cells per mouse) , and two control 
groups, PBS and Pristane. The latter {Pnstane) 
is not a true negative control as it occasionally 
results in tumour formation. Total serum NANA 
showed no correlation with tumour burden. The 
rapid rise and fall in NANA levels observed m  
the LAT group suggested that NANA is an 
acute-phase reactant, with the dramatic 
elevation occurring as a result of the actual 
injection of tumour cells. Bradley et al. (1977) 
stated that levels of acute-phase reactants rise 
within 12-36 hours in response to various 
stimulants, including tissue injury and trauma.
The second experiment used two tumour-bearing 
groups and one PBS control group. Results for 
the LAT group, where each mouse was injected with71x10 cells, confirmed the findings of the 
previous experiment. No correlation was found 
between total serum NANA and LAT burden. 
Injection of LAT cells again resulted in a 
dramatic short-term increase in serum NANA5levels. As a result of injecting 1x10 cells 
into each mouse (the second tumour group) it was 
possible to monitor NANA levels for a longer 
period (26 days), thus allowing a more thorough 
evaluation of this possible tumour marker* In 
marked contrast to the previous group, no 
difference existed between the increase m  NANA 
levels of LAT-bearing mice and that observed in 
the control group, the likely cause being that,5in this group, fewer LAT cells were injected (107as opposed to 10 ). Further alterations in serum
1 2 2
NANA levels m  the LAT group were accompanied by 
very similar changes m  the PBS control group, 
indicating once again that tumour burden was not 
being reflected m  total serum NANA levels. 
Finally, after 26 days of LAT growth the mean 
level of total serum NANA was found to be almost 
identical to that obtained prior to injection of 
the tumour.
It was obvious that serum NANA levels were being 
affected by the injection process, as reflected 
by dramatic elevations in NANA levels after three 
days. Consequently, the design of the third 
(and final) experiment involving total serum NANA 
was slightly modified. The day three sample was 
omitted. Mice were injected with either PBS orn
LAT cells (1x10 cells per mouse) and then left 
undisturbed for six days, at which time serum 
samples were taken for NANA analysis. After six 
days of tumour growth, elevation m  mean total 
serum NANA was found to be highly significant 
(P<0.001), indicating that mean NANA levels are 
elevated as a result of LAT growth during the 
early stages of tumour development.
In the experiment used to evaluate serum LSA as a 
marker for LAT, the day 3 sample was also 
omitted. Initial results were encouraging, with 
mean serum LSA levels significantly elevated 
(P<0.02) after six days of tumour growth. 
However, this increase was not as dramatic as 
that observed m  serum NANA. Furthermore, LSA 
levels decreased between days 6 and 9 despite a 
further increase m  tumour burden. This trend in 
serum LSA levels has been observed elsewhere. 
Pennington et a^. (1988) , who studied serum LSA
levels m  human cancer patients (nature of cancer 
not specified), found that patients with
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exceptionally heavy tumour burdens tended to show 
declining levels in LSA in the final weeks
preceeding death. Therefore, while it has been
shown that serum LSA does not increase linearly 
with tumour burden, it is possible that serial 
determination of LSA could be of use in
monitoring the clinical status of a patient, 
whereby a reduction in serum LSA levels may be 
indicative of significantly increased tumour
burden.
It might be argued that the observed decreases in
mean NANA levels, observed between days 3 and 6
(experiments 1 and 2) , were caused to a certain
extent by the taking of blood samples, whereby
the loss of blood resulted in decreased levels of
circulating NANA. However, it is unlikely that
the process of tail-bleeding significantly
affected NANA (or LSA) levels. For example, in
5experiment 2, using 10 injected LAT cells (Fig.
5.2), total serum NANA levels increased between 
days 7-11 and 11-14, despite the taking of blood 
samples on days 7 and 11, respectively. 
Furthermore, in experiment 4 (Fig. 5.4), the 
taking of a blood sample on day 9 did not result 
in decreased serum LSA levels on day 11 (only two 
days later). Finally, the assays used in these 
experiments determined serum NANA and LSA 
concentrations. A reduction in the volume of 
blood in a mouse (caused by tail-bleeding), while 
decreasing the total amounts of NANA and LSA 
present, should not adversely affect their 
concentrations (the amount of NANA/LSA per unit 
volume of blood). However, it is possible that 
tail-bleeding could have a minor effect, whereby 
the process of regenerating the removed blood may 
have a short term dilution effect on circulating
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levels of NANA and LSA Therefore, since the 
overall effect (if any) of the tail-bleeding 
process on serum NANA and LSA levels is minimal, 
it is possible to conclude that serum NANA and 
LSA levels, as determined by the aforementioned 
assays, accurately reflect the true serum levels 
of these markers.
5 . 6
CONCLUDING COMMENTS
Based on the results obtained m  these 
experiments it is possible to state the 
following:
1.
The rapid increase m  total serum NANA m  
LAT-beanng mice strongly suggests that NANA is 
produced by the host m  response to the tumour's 
presence m  the form of an acute-phase reaction, 
caused by the trauma of the injection process.
2 .
The magnitude of the acute-phase reaction 
increases with increasing numbers of injected LAT 
cells.
3 .
Despite highly significant elevations in mean 
serum NANA levels during the early stages of 
tumour development, prolonged monitoring shows 
that NANA levels fluctuate erratically with 
further increases in tumour burden, thus making 
it unsuitable for use as a marker for LAT growth.
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4.
During early stages of growth serum LSA increases 
proportionally with LAT burden, with mean LSA 
levels significantly elevated when compared to 
normal levels. In marked contrast, later stages 
of LAT growth can be accompanied by decreasing 
LSA levels.
5.
Serial determination of serum LSA could be used 
to monitor response to therapy in LAT-bearing 
mice, thereby providing a means by which newly 
developed anti-tumour agents (immunological, 
radiometric or chemotherapeutic in nature), could 
be assessed in an animal model system.
6 .
While elevations in mean serum NANA levels were 
more significant than those of serum LSA during 
the early stages of LAT development, LSA was 
found to be a more reliable marker m  cases of 
prolonged tumour growth.
7.
The results of this investigation provide further 
evidence to suggest that serum LSA could be a 
more useful and discriminating indicator of 
tumour burden than total NANA concentration, and 
therefore may have a clinical role m  the routine 
follow-up and monitoring of patients suffering 
from neoplastic disease.
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TABLE 5.1
AVERAGE CHANGES IN SERUM NANA AND LSA LEVELS IN 
NORMAL CONTROLS AND LAT-BEARING MICE
TUMOUR
MARKER
EXP
NO
EXP
GROUP
AVERAGE 
CHANGE IN 
NANA 
(nmoles/ml)
CRITICAL
VALUE
SERUM (1) PBS* 266 6 M
NANA PRISTANE+ 90.0 (-)
107 LAT* 775 0 (3.91)1
107 LAT+ 775.0 (5.91)2
SERUM (2) PBS -50.0 <-)
NANA 107 LAT 750.0 (3.42)3
105 LAT 687.5 (2.56)
SERUM (3) PBS 337.5 (-)
NANA 107LAT 380.0 (0.317)
SERUM (4) PBS 91.3 (-)
LSA 107 LAT 306.0 (1.21)
The following P values represent the significance 
of average changes in total serum NANA and serum 
LSA levels relative to those of PBS (*) and
Pnstane ( + ) controls
3 significant differences were found
1 : significant difference ; P<0 005
2 : significant difference ; P<0.001
3 : significant difference , P<0.020
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TABLE 5.2
MEAN LEVELS OF SERUM NANA AND SERUM LSA IN 
NORMAL CONTROLS AND LAT-BEARING MICE
TUMOUR
MARKER
EXP
MO
EXP.
GROUP
MEAN + / -  S.D 
(nmoles/ml)
CRITICAL
VALUE
SERUM
NANA
(3) PBS
107LAT
1705.6 + / -  146.7 
2140.0 +/- 232.9
( - )
(4.325)*
SERUM
LSA
(4) PBS
107LAT
496.3 +/- 62.0
757.3 +/- 205.1
( - )
(3.268)^
The following P values represent the significance 
of elevations in mean total serum NANA and serum 
LSA levels relative to PBS controls levels.
* : significant difference ; P<0.001
# : significant difference ; PC0.020
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FIGURE 5 1
THE VARIATION OF TOTAL SERUM NANA (n m o le s/m l) FOR 
CONTROL AND TUMOUR-BEARING MICE WITH TIME (days)
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SECTION 6
The Development of the VGR Assay, a 
Modified Thiobarbituric Acid Method, for 
the Determination of Total Plasma NANA.
6 1
INTRODUCTION
In 1959, Leonard Warren developed the thiobarbituric 
acid (TBA) method for the determination of free 
(unbound) NANA (Warren, 1959) Despite
modifications by other researchers, including 
Aminoff (1961) and O'Kennedy (1979), the original 
method, as devised by Warren, has been extensively 
used over the last 32 years.
The importance of NANA as a biological marker has 
resulted in the development of a range of highly 
specific and highly sensitive methods of 
quantitation, including spectrofluorometnc (Hammond 
& Papermaster, 1976), chromatographic (Silver & 
Karim, 1981) and enzymatic methods of analysis 
(Teshima , 1988) These more recently
developed methods have several advantages over the 
Warren assay Chromatographic and
specrofluorometric methods are highly automated and 
are capable of detecting picomolar (10-12M) levels of 
NANA Enzymatic analysis, one of the most recent 
developments, has greatly reduced assay t ime 
However, these methods also have disadvantages For 
example, the instrumentation required for 
chromatographic and spectrofluorometric analysis can 
be very expensive, as are many of the enzyme kits 
currently available Additional problems associated 
with enzymatic methods include reagent instability, 
light sensitivity (exposure to light can increase 
blank O.D. readings) and interference from naturally 
occurring substituents of body fluids (especially 
pyruvate and ascorbic acid) Therefore, despite the 
genesis of these elaborate and more sophisticated 
methods, the Warren assay, which is economical (does
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not require expensive instrumentation), sensitive 
(can detect nmolar quantities of NANA) and 
reproducible (10% inter-assay variability), is still 
used as a routine method for the determination of 
NANA, However, the Warren assay itself has several 
disadvantages and limitations It is time consuming 
and laborious, lacks any degree of automation and 
requires the use of toxic reagents, including sodium 
arsenite (human poison and carcinogen, Sax and 
Lewis, 1989) and cyclohexanone (an organic solvent 
capable of dissolving plastic, thereby requiring the 
use of quartz cuvettes) 2-deoxyribose (2-DOR) 
interferes in the Warren assay to such an extent 
that a correction formula is required to negate its 
effect
The purpose of this research was to develop a new 
method for the determination of NANA, using the 
principles and procedures of the Warren assay as a 
foundation It was hoped that the modified assay 
would have the following characteristics
1 Reduced assay time
2 Reduced interference due to 2-DOR
3 A degree of automation
4. A greater element of safety.
The main prerequisite for acceptance of a particular 
modification was that it did not interfere with, or 
hinder in any way, the performance characteristics 
of the assay, namely its sensitivity and 
specificity It was crucial that the modified assay 
maintained the analytical "integrity" of the parent 
assay. '
134
6 2
EXPERIMENTAL DESIGN
Total plasma NANA levels were determined by the VGR 
assay (Section 2 3 6), referred to as "VGR-Macro" 
(since a large sample volume, 1.0 ml, was required 
for 0 D measurements) The stability of the VGR- 
Macro chromophore was determined by monitoring the 
O.D of a plasma sample over an 85 minute period. 
NANA levels were also measured using a modified VGR 
assay (Section 2 3 7) known as "VGR-Micro" (the 
method incorporated a micro-sample detection system 
whereby the O D s of samples, 180 |ll, were recorded
in 96-well microtitre plates) When using the VGR- 
Micro assay, 2 methods of incubation (50°C) were 
employed The first method required that the 
microtitre plates were placed in the incubator of 
the plate reader prior to 0 D measurements, whereas 
m  the second method, microtitre plates were 
incubated in a conventional oven incubator and then 
transferred to the plate reader, where 0 D s were 
recorded The standard incubation time was 25 
minutes However, to determine chromophore
stability, 50 minute incubations prior to 0 D. 
measurements, using both methods of incubation, were 
also employed Finally, in order to validate the 
VGR-Macro and VGR-Micro assays, total plasma levels 
were also determined using a commercially available 
enzymatic kit for NANA (Boehringer Mannheim, Cat 
No 784192) The principle of this enzymatic assay 
has already been discussed (Section 1 3)
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6 3
STATIS llC ftft M ALXSIS
The two-sample Student's t-Test (Section 2 8 1) was 
used to compare sample means, between experimental 
groups Where the t-Test (two sided) was employed, 
samples were assayed in triplicate (N* - N2 = 3) 
Therefore, all critical t-values were based on 4 
degrees of freedom (V) , where V = N^  + N2 - 2
6 4
ANALYSIS OF RESULTS
The ability to determine plasma NANA levels using 
the VGR-Macro and VGR-Micro assays is made possible 
due to the linear relationship between NANA 
concentration (over a range of 0 - 50 nmoles/sample) 
and 0 D at 560 nm Typical standard curves
obtained, using both methods, are shown in figures 
6 1 and 6 2 The strength of this relationship is 
reflected in consistently high correlation 
coefficients (R values) for the standard curves,
with these values in the range 0 995 - 0.999.
Since cyclohexanone, used in the Warren assay, had 
been replaced by a solution of 5% (v/v) HC1 in
ethanol, it was necessary to investigate the
stability of both the VGR-Macro and VGR-Micro 
chromophores Tables 6 1 shows 0 D values, 
obtained from a sample assayed by VGR-Macro, over an 
observation period of 85 minutes. The initial 
reading (0 178) increased to 0 183 after 85 minutes, 
representing a rise m  O . D. of 2.8%. During the
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same period, the difference between the highest and 
lowest O D values (0 183 after 85 minutes and 0 176 
after 18 minutes) was 4 0% These results confirmed 
that addition of the 5% (v/v) HC1 in ethanol
solution resulted in a stable VGR-Macro chromophore, 
whereby small variations in O.D. values occurred 
over an 85 minute period For the VGR-Micro
chromophore, O D s were recorded at regular 
intervals, during a 40 minute incubation period (in 
the incubator of the microplate reader) The 
results (Table 6 2) show decreasing 0 D. values, in 
all samples, during the first 15 minutes of 
incubation, whereas the values stabilised after 20 
minutes. These results are consistent with the 
following explanation The samples were turbid 
during early stages of incubation as a result of 
sample temperatures being less than the required 
temperature of 50°C As the samples approached 50°C 
the turbidity decreased, resulting in decreased 0 D 
readings O D stabilisation indicated that a 20 
minute incubation period was necessary for sample 
equilibration at 50°C Therefore, based on these 
results, an incubation period of 25 minutes, prior 
to recording of 0 D s, was chosen as the standard 
incubation period for the VGR-Micro assay, thereby 
ensuring sample equilibration at the required 
temperature.
Having confirmed chromophore stability in both VGR- 
Macro and VGR-Micro assay systems, it was then 
necessary to quantify inter-assay variation. Total 
plasma NANA levels were determined in 13 plasma 
samples (using both methods) and mean levels were 
then compared. The results (Table 6 3) showed that, 
in 12 of the 13 samples (92%), no statistically 
significant differences were found between mean 
levels of plasma NANA. in one sample (No. 11), a
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small, though statistically significant, difference 
was found to exist However, closer examination of 
the results for the sample shows that, in this 
particular instance, the calculated t-value was 
exaggerated due to the small value obtained for Sp 
(one of the terms m  the denominator of the two- 
sided Student's t-Test, Section 2 8 1) This in 
turn was a result of a standard deviation value of 
zero (a rare occurrence) obtained from the VGR-Micro 
determination
To further assess the stability of the VGR-Micro 
chromophore, the following experiment was performed 
Having determined plasma NANA levels, in 4 samples, 
using the standard VGR-Micro assay (incubation at 
50°C for 25 minutes), the samples were incubated for 
a further 25 minutes (total of 50 minutes), after 
which time the 0 D 's were again recorded Plasma 
NANA levels were then determined using the new 0 D 
readings Therefore, 2 values for mean plasma NANA 
were obtained for each sample, the first value 
determined after a 25 minute incubation period, the 
second after 50 minutes Analysis of the results 
(Table 6 4) showed no statistically significant 
differences between mean plasma NANA levels
Since the majority of ELISA plate readers do not 
have an inbuilt incubator, the possibility of using 
a conventional oven incubator, in the VGR-Micro 
assay, was also investigated Total plasma NANA 
levels were determined, in 5 samples, using two 
variations of the VGR-Micro assay, with both methods 
incorporating an incubation period of 25 minutes 
The standard VGR-Micro assay was used, whereby 
samples were incubated in the microplate reader 
The second method used a conventlonal oven 
incubator, with the plates being transferred to the
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microplate reader, after incubation, for immediate 
recording of 0 D ' s, In 4 out of 5 samples tested 
(80%), no statistically significant differences were 
found between mean levels of plasma NANA, as 
determined by the VGR-Micro assays (Table 6 5) . 
However, since a significant difference between mean 
plasma NANA levels was found in one of the samples, 
a second experiment (using new samples) was 
performed, in which samples were allowed a period of 
50 minutes in the conventional incubator prior to 
transfer and recording of O D ' s in the microplate 
reader The purpose of the longer incubation step 
was to facilitate sample equilibration at 50°C 
Mean plasma NANA levels determined by this modified 
assay were compared to those obtained using the 
standard VGR-Micro assay The results (Table 6 6) 
showed statistically significant differences in 2 of 
the 5 samples (40%) Furthermore, while no 
difference was found between NANA mean levels for 
Sample 1 (P < 0 5) , it must be noted that the
standard deviation obtained for that sample, using 
the modified VGR-Micro assay (conventional incubator 
for 50 minutes) , was very large (± 29%) , thereby 
preventing reliable statistical comparison of 
results
Finally, to validate the modified assay, total 
plasma NANA levels were determined in 16 samples, 
using the standard VGR-Micro assay and a 
commercially available enzymatic assay for NANA 
The results (Table 6 7) showed no statistically 
significant difference, between mean plasma NANA 
levels, in 13 of the 16 samples (81%) However, 
statistically significant differences were found in 
the remaining 3 samples
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6 5
DISCUSSION
The purpose of these experiments was to modify the 
Warren thiobarbituric acid assay Major deviations 
from the original method included an attempt to 
determine NANA levels from a standard curve and also 
the inclusion of a new solution for chromophore 
stabilisation For the VGR-Macro assay, correlation 
coefficients for standard curves (0 - 50 nmoles NANA 
/ std) were consistently in the range 0 995 - 0 998 
For the same assay, it was shown that the use of a 
5% (v/v) HCl in ethanol solution, in place of
cyclohexanone, did not adversely affect chromophore 
stability, with variations in 0  D readings of only 
4 0% occurring over an 85 minute period The next
stage was to miniaturise the VGR-Macro assay by
using a microplate reader for recording of 0 D s 
The VGR-Micro assay consistently produced standard 
curves with correlation coefficients in the range 
0 996 - 0 999 Furthermore, once the samples had 
equilibrated at the required temperature (50°C), the 
reproducibility of the VGR-Micro chromophore was 
also found to be superior to that of the VGR-Macro 
assay, with negligable changes in 0 D. readings over 
a period of 20 minutes (sufficiently adequate since 
the O D s of an entire 96-well plate could be
recorded in 30 seconds). When plasma samples were 
assayed for total NANA, using both methods (VGR- 
Macro and VGR-Micro), statistical analysis showed no 
difference between mean plasma NANA levels 
Therefore, subsequent experiments were designed 
solely to assess the VGR-Micro assay, since its 
automated 0 D recording ability, coupled with its 
superior performance characteristics (high quality 
standard curves and highly stable chromophore), made
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it the preferred method for NANA analysis To 
further evaluate the VGR-Micro assay, plasma NANA 
levels were determined in 4 samples, using 0 D s 
recorded after both 25 and 50 minute incubation 
periods Statistical analysis showed no difference 
between mean plasma NANA levels, thereby reaffirming 
the high degree of stability in the VGR-Micro 
chromophore The possibility of incorporating a 
conventional oven incubator into the VGR-Micro assay 
(a cost reducing step) was then investigated. 
Plasma NANA determinations, following an incubation 
period of 25 minutes, suggested a possible role for 
a conventional incubator However, when the 
incubation period was increased to 50 minutes (to 
allow samples a longer "warm up" time), mean plasma 
NANA determinations were significantly altered 
Therefore, the method of incubation, prior to 
recording O D s, has a definite effect on mean 
plasma NANA levels, as determined by the VGR-Micro 
assay The heater in the microplate reader is a 
heating plate, upon which the microplate rests 
This is an efficient method of heating since the 
plate and the source of heat are in close contact, 
thereby reducing the time required for sample 
equilibration at 50°C A heating plate is also a 
good source of homogeneous heat, thereby ensuring a 
minimal temperature differential across the plate (a 
crucial requirement for the VGR-Micro assay where 
variation in O D with temperature is significant) 
In contrast, the conventional incubator uses 
circulating heated air as the method of heating It 
is possible that temperature homogeneity in the oven 
incubator is inferior to that of the microplate 
reader heating plate apparatus, thereby resulting in 
fluctuating 0 D values Another possible cause of 
the inferior results obtained using the conventional 
incubator is that the 25 minute incubation period
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may have been inadequate to allow proper sample 
equilibration at 50°C Increasing the incubation
period to 50 minutes caused additional problems 
whereby O D reproducibility, in several cases, 
deteriorated significantly (possibly as a result of 
sample evaporation) Finally, when using the
incubator of the microplate reader, the 0 D s were 
recorded "in situ", with no disturbance of samples, 
whereas use of the conventional oven incubator 
required transfer of the plates to the microplate
reader, thereby making samples vulnerable to
problems of spillage and cooling
In the final experiment of this investigation, 
plasma NANA levels were determined by the VGR-Micro 
assay and a commercially available enzyme kit 
Statistical analysis showed no difference, between 
mean plasma NANA levels, in 81% of samples studied 
However, the existence of significant differences in 
the remaining 19% of samples indicated that the 
observed differences were caused by interference in 
either the enzymatic assay (from plasma pyruvate and 
ascorbic acid) or the modified TBA assay (from 2-
DOR) These results suggested that further
examination of 2-DOR interference was necessary 
Later research at D.C.U, lead to refinements in the 
VGR-Micro assay As a result of definite 
interference (by 2-DOR) it was necessary to re­
introduce a correction formula (with O.D s recorded 
at two wavelengths) . However, the use of the 
microplate reader, which is capable of reading the 
O D s of a 96-well plate at two wavelengths in less 
than 5 minutes, coupled with a computer programme 
designed to compute NANA levels from input 0 D 
readings, more than compensates for the introduction 
of the correction formula, thereby making the VGR-
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Micro assay a very viable method for analysis of 
plasma NANA
6 6
CONCLUSIONS
Based on the results obtained in these experiments,
it is possible to draw the following conclusions.
1 The use of a 5% (v/v) HC1 in ethanol solution
(as opposed to cyclohexanone), in the modified
assay, results in the formation of a highly
stable chromophore
2 The elimination of cyclohexanone from the TBA
assay has the following advantages
a) Cyclohexanone is moderately toxic by 
ingestion and inhalation It is also a skin 
and severe eye irritant (Sax & Lewis, 1989). 
Human systemic effects by inhalation includes 
changes in sense of smell and conjunctiva 
irritation, therefore requiring the use of a 
laminar flow hood The replacing of 
cyclohexanone, with a less toxic solution, 
therefore results in a more "operator 
friendly" assay, while also eliminating the 
need for a laminar flow hood This is very 
important in view of recent developments in 
legislation concerning safety at work.
b) The use of cyclohexanone (organic phase) in 
the original assay, as a chromophore 
stabiliser, required a centrifugation step,
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followed by removal of the organic phase 
(containing the chromophore) using a Pasteur 
pipette By replacing the cyclohexanone with 
a solution of 5% (v/v) HC1 in ethanol
(aqueous), thereby resulting in the formation 
of a one phase system, these laborious and 
time consuming steps are no longer necessary.
c) The elimination of cyclohexanone from the 
modified assay introduced a cost saving step, 
since the 5% (v/v) HC1 in ethanol solution
(unlike cyclohexanone) does not dissolve 
plastics, thereby eliminating the need for 
the use of quartz cuvettes
3) It has been shown by statistical analysis that, 
in the modified TBA assay, the method employed 
for recording of 0 D s does not effect NANA 
determinations, whether it be a conventional 
spectrophotometer, as in the VGR-Macro assay, or 
a microplate reader, as in the VGR-Micro assay
4) For accurate work, the VGR-Micro assay requires 
a microplate reader with an inbuilt incubator, 
thereby allowing the recording of 0 D s "in 
situ". The use of a conventional oven incubator 
is not advisable as NANA determinations, using 
this method of incubation, are less reliable
5) If a microplate reader with an incubator is not 
available, it is advisable to use the VGR-Macro 
assay, where 0 D .s are recorded in a 
conventional spectrophotometer with temperature 
control attachments
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6 The rapid 0 D recording ability of the
microplate reader greatly reduces the time 
required to perform the assay It also reduces 
fluctuations in O.D s, a problem often 
associated with instrumental drift (e g changes 
in light source emission intensity)
7 Results obtained during validation of the VGR 
assay indicated interference by 2-DOR However, 
this problem may be eliminated by dual 
wavelength analysis of results.
8 While further evaluation of the VGR assay is
required, initial results are very promising, 
with a definite possibility that this modified 
TBA assay could become a routine method of NANA 
analysis
9 If further validation of the VGR assay continues
to give positive results, another possible
future application of this assay could be in the
determination of plasma LSA levels, whereby the 
VGR assay would be coupled to a method for 
gangliosidic extraction
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Table 6 1 Variations in 0 D readings (at 560 nm)
with time in the VGR-Macro Chromophore
TIME (MINUTES) 0 D
0 0 178
12 0 180
18 0 176
23 0 177
35 0 179
45 0 184
60 0 182
85 0 183
0 D s are the mean values of 3 determinations
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Table 6 2 Variations in 0 D Readings (at 560 nm)
with Time in the VGR-Micro Chromophore
SAMPLE
(NANA)
(NMOLES/SAMPLE)
AVERAGE 0 D (560 nm) AFTER SPECIFIED 
INCUBATION PERIODS (MINUTES)
5 15 20 30 40
0 + 0 049 0 044 0 045 0 045 0 045
10 ++ 0 066 0 060 0 061 0 061 0 061
20 ++ 0 096 0 091 0 091 0 091 0 093
30 ++ 0 122 0 115 0 117 0 116 0 117
40 ++ 0 158 0 155 0 153 0 152 0 153
50 ++ 0 191 0 185 0 186
•
0 186 0 187
+ O D s are the mean values of 8 determinations 
++ 0 D s are the mean values of 4 determinations
0
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Table 6 3 A comparison of total plasma NANA levels 
determined by the VGR-Macro and VGR- 
Micro Assays
SAMPLE VGR -MACRO VGR--MICRO C R I T I C A L
NUMBER TOTAL NANA TOTAL NANA t--VALUE
(nmoles/ml) (nmoles/ml)
MEAN ± S D MEAN ± S D !
1 1500 0 ± 482 2 1516 7 ± 378 6 0 047
2 1875 0 ± 90 1 1933 3 ± 57 7 0 944
3 1316 7 ± 101 0 1400 0 ± 114 6 0 945
4 2666 7 ± 354 7 2708 3 ± 232 3 0 170
5 1566 7 ± 260 2 1641 7 ± 252 9 0 358
6 850 0 ± 175 0 908 3 ± 115 7 0 482
7 766 7 ± 62 9 675 0 ± 82 6 1 530
8 2316 7 ± 80 4 2300 0 ± 109 0 0 213
9 1383 3 ± 125 8 1508 3 ± 104 1 1 327
10 2391 7 ± 62 9 2266 7 ± 175 6 1 161
11 2741 7 ± 152 8 2475 0 ± 0 0 3 026*
12 2433 3 ± 52 0 2258 3 ± 115 5 2 395
13 2250 0 ± 150 0 2208 3 ± 175 6 0 313
S D « Standard Deviation
Only one significant difference was found
* significant difference, P < 0 05
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Table 6 4 Total plasma NANA levels determined by 
VGR-Micro assays incorporating 
incubation periods of 25 and 50 minutes
SAMPLE
NUMBER
TOTAL NANA 
(nmoles/ml) 
25 Minutes 
MEAN ± S D
TOTAL NANA 
(nmoles/ml) 
50 Minutes 
MEAN ± S D
CRITICAL
t-Value
1 1508 3 ± 104 1 1508 3 ± 275 4 0 000
2 2266 7 ± 175 6 2133 3 ± 128 3 1 063
3 2258 3 ± 115 5 2116 7 ± 80 4 1 745
4 2208 3 ± 175 6 2075 0 ± 139 2 1 031
S D « Standard Deviation
No significant differences found
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Table 6 5 Total plasma NANA levels determined by 
the standard VGR-Micro assay and a 
modified VGR-Micro assay incorporating a 
conventional oven incubation period of 
25 minutes prior to recording of 0 D.s.
SAMPLE
NUMBER
TOTAL NANA 
(nmoles/ml) 
Standard Assay 
Mean ± S D
TOTAL NANA 
(nmoles/ml) 
Mod Assay 
Mean ± S D
CRITICAL
t-Value
1 1641 7 ± 252 9 1550 0 ± 152 1 0 538
2 908 3 ± 115 7 983 3 ± 104 1 0 835
3 675 0 ± 82 6 591 7 ± 28 9 1 652
4 2300 0 ± 109 0 2041 7 ± 38 2 3 877*
5 2858 3 ± 137 7 2866 7 ± 125 8 0 077
S D = Standard Deviation
Only one significant difference was found
significant difference, P < 0 02
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Table 6 6 Total plasma NANA levels determined by 
the standard VGR-Micro assay and a 
modified VGR-Micro assay incorporating a 
conventional oven incubation period of 
50 minutes prior to recording of 0 D s
SAMPLE
NUMBER
TOTAL NANA 
(nmoles/ml) 
Standard Assay 
Mean ± S D
TOTAL NANA 
(nmoles/ml) 
Mod Assay 
Mean ± S D
CRITICAL 
t-Value
1 1508 3 ± 104 1 1475 0 ± 420 6 0 133
2 2266 7 ± 175 6 2175 0 ± 204 6 0 589
3 2475 0 ± 0 0 2291 7 ± 94 6 3 357*
4 2258 3 ± 115 5 2041 7 ± 62 9 2 856**
5 2208 3 ± 175 6 2083 3 ± 125 8 1 003
S D = Standard Deviation
Only two significant differences were found
* significant difference, P < 0 05
** • significant difference, P < 0 05
153
Table 6 7 A comparison of total plasma NANA levels 
determined by VGR-Micro and a 
commercially available enzymatic assay
SAMPLE TOTAL NANA TOTAL NANA C R I T I C A L
NUMBER (nmoles/ml) (nmoles/ml) t*-VALUE
VGR -M IC R O ENZYME ASSAY
MEAN ± S D MEAN ± S I>
1 2 1 9 3 5 ± 2 4 6 6 2 3 1 0 5 ± 2 7 2 0 8 1 7
2 2 1 8 3 3 ± 2 4 6 0 2 0 3 6 4 ± 5 4 9 1 0 1 0
3 3 1 7 7 5 ± 1 8 0 2 3 0 5 4 1 ± 6 1 1 1 1 2 4
4 3 1 4 6 8 ± 1 3 8 7 2 9 1 9 2 ± 6 3 8 2 5 8 4
5 3 4 6 4 5 ± 3 0 9 5 3 5 0 0 3 ± 1 9 8 0 2 0 0
6 3 0 3 4 0 ± 1 1 6 4 3 1 8 9 0 ± 9 8 4 1 7 6 3
7 3 4 9 5 3 ± 1 8 5 4 3 7 6 9 6 ± 2 7 5 2 5 3 8
8 2 8 7 0 0 ± 2 1 6 0 2 8 9 8 5 ± 5 3 7 0 2 2 2
9 2 2 5 5 0 ± 2 0 9 3 1 9 3 9 8 ± 1 3 3  8 2 1 9 9
1 0 1 5 5 8 0 ± 1 5 4 8 1 4 6 9 1 ± 2 1 2 0 9 8 7
1 1 2 2 6 5 3 ± 1 9 7 7 2 4 2 8 6 ± 2 5 9 1 4 2 0
1 2 2 3 7 8 0 ± 1 2 8 0 2 6 5 1 4 ± 2 8 4 3 9 0 5 *
1 3 3 5 1 5 8 ± 2 0 0 1 3 7 0 2 4 ± 3 4 7 1 5 9 2
1 4 2 4 2 9 3 ± 1 7 1 2 2 7 8 7 7 ± 5 4 7 3 4 5 6 * *
1 5 3 1 7 7 5 ± 2 0 9 3 3 3 6 9 4 ± 7 5 0 1 4 8 9
1 6 2 8 9 0 5 ± 2 1 5 3 3 2 9 5 4 ± 6 5 6 3 1 1 7 * * *
S D = Standard Deviation
3 significant differences were found
* significant difference, P < 0 02
** significant difference, P < 0 05
*** significant difference, P < 0 05
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SECTION 7
The Production of Monoclonal Antibodies 
against Human Bladder Tumour-Associated
Antigens
7 1
INTRODUCTION
Kohler and Milstein were the first to successfully 
fuse myeloma and antibody-producing cells (B 
lymphocytes), resulting in a set of single cells 
(hybridomas) that could be grown in large numbers 
and could secrete antibodies in large quantities 
(Kohler and Milstein, 1975) Each cloned cell 
secreted one antibody (Ab) type with a single 
binding affinity and specificity, hence the name 
"monoclonal" This first successful fusion of two 
cell types counts as one of the most significant 
experiments in the history of scientific research
/The genesis of monoclonal antibody (MAb) technology 
provided clinical researchers with an invaluable 
diagnostic and therapeutic tool, due to the unique 
specificity of these Abs It enabled clinical 
oncologists to investigate the surface components of 
tumour cells with an unprecedented degree of 
precision Due to the enormous impact of MAbs, 
Kohler and Milstein were awarded a Nobel prize in 
1984
Kohler (1985), in the Nobel lecture, compared MAbs 
to those obtained from conventional polyclonal 
antisera. The main disadvantages of the latter were 
stated to be the following
1 Low Ab titres.
2 Polyclonal antisera contain a heterogeneous 
population of Abs, with different affinities and 
avidities for the target antigen (Ag)
3. Ab supply is limited
4 Reproduction of identical Ab populations, using 
another animal, is impossible.
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In marked contrast, MAbs have the following 
advantages
1 Single specificity • each hybrid produces one 
Ab
2. Unlimited Ab supply the fusion procedure 
results in hybrid immortalisation.
3 Pure Ab reagents can be obtained from impure 
Ags.
4 Enrichment of specific hybridomas, whereby 
specific B cells are enriched 10 - 100 fold in 
hybridoma populations (relative to corresponding 
spleen cell populations)
Early MAbs were produced using animal model systems 
(usually rodents), with the most common fusogen 
being polyethylene glycol (PEG) The past 16 years 
has seen the development of novel methodologies, 
resulting in improved methods of MAb production and 
the development of new types of MAbs, including 
human MAbs (HMAbs) The attempt to produce HMAbs 
arose as a result of the limitations of rodent MAbs, 
coupled with the realisation that, where Abs were to 
be used in prophylaxis or therapy, those derived 
from human sources would be desirable (especially if 
repeated administration was involved) One of the 
main limitations of rodent MAbs is that, in certain 
situations, mice and rats might not recognise the 
relevant Ags against a background of immunodominant 
epitopes (Carlsson and Glad, 1989) Another problem 
which interferes with the in vivo use of rodent MAbs 
is that they can elicit an immune response when used 
in vivo in humans, resulting in the production of 
human anti-mouse antibodies, known as HAMA 
(Colnaghi, 1991) Problems associated with HAMA 
production include rapid removal of MAbs, 
immunocomplex formation and liver accumulation
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HMAbs have been produced using the innovative 
technique of electric field-induced cell fusion 
The process of elect rofusion is based on the 
observation that close membrane contact can be 
established between two cells in an alternating 
electric field Following cell alignment (which can 
be visualised using a microscope), application of 
high-intensity, short-duration pulses causes 
reversible increases in membrane permeability and 
fluidity which, if locally restricted, then leads to 
both electropermeabilisation and cell electrofusion 
(Zimmermann and Urnovitz, 1987) Refinements of the 
basic procedure have resulted in further 
improvements m  both the quality and quantity of 
Abs Lo ££. ¿1 (1984), using electrofusion, devised 
a method for selective fusion of B-cells secreting 
Abs of interest, based on the findings that B-cells 
express, on their surface, Ag receptor 
immunoglobulin (Ig) of the same specificity as the 
secreted Abs In this method the Ag, covalently 
conjugated to avidin, binds to the surface Igs on B- 
cells The complex (B-cell-Ag-avidin) binds to 
biotin covalently attached to the surface of myeloma 
cells, thereby resulting in close alignment of 
myeloma cells and B-cells secreting Abs directed 
against the target Ag. Fusion of these cells 
resulted in a population of hybridomas with a high 
proportion of highly Ag-specific Abs This method 
has also been used to increase the yield of Ag- 
specific Ab-secreting hybrids in PEG fusion 
experiments Reason ££. SlL (1987) used the avidin- 
biotin method of bridging specific B-cells to 
myeloma cells to increase the frequency of 
azobenzene arsonate-specific hybrids. Foung
(1989) produced a panel of HMAbs to human 
cytomegalovirus (by electrofusion), using as few as 
1 x 106 Epstein-Barr virus (EBV) activated B-cells
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Despite these positive developments, the majority of 
HMAbs produced to date have been disappointing, 
particularly those directed against tumour cells 
There have also been serious problems associated 
with the actual production of these Abs The 
ability to capitalise on the practical opportunities 
afforded by HMAb technology has been limited mainly 
as a result of difficulties experienced in 
generating stable human hybridomas secreting 
adequate amounts of Ab The availability of 
suitable sources of immune lymphocytes is limited, 
as are suitable fusion partners (James, 1989) 
Furthermore, HMAbs are usually of the IgM isotype 
and, therefore, show relatively low affinity for the 
primary epitope In t#ie case of anti-tumour Abs it 
has been found that many HMAbs react or cross-react 
with intracellular cytoskeletal proteins or nuclear 
Ags rather than membrane components (tumour-specific 
or otherwise), thereby limiting their clinical 
potential (Campbell ££. , 1987)
In an attempt to overcome these difficulties, 
recombinant DNA techniques have recently been 
employed to generate new types of MABs Using 
protoplast fusion and electroporation (using a 
series of pSV2 vectors), Nakatani et al.(1989) 
produced transfected-derived recombinant antibodies 
(RAbs) by introducing human cloned Ig genomic DNA 
into Ig non-producing mouse myeloma cells The 
genetically engineered Abs, and those secreted by 
the origin cells (transformed human B-cells), did 
not differ in either binding specificity or affinity 
for the target Ag (Pseudomonas aeruginosa exotoxin 
A) Bruggemann a 1 (1989) successfully
established stable hybridomas, from transgenic mice, 
following introduction of human Ig gene segments (in 
the unrearranged configuration) . Gillies
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al (1989) obtained stable clones that secrete HMAbs, 
following the introduction of DNA expression vectors 
(obtained from a mouse-human heterohybridoma 
secreting anti-tetanus toxin Ab) into a non-Ig 
producing murine hybndoma cell line. Glick (1990) 
stated that this radical approach, whereby MAbs can 
be isolated without pre-production of hybridomas, 
has numerous advantages over conventional hybridoma 
producing methodologies For example, bacteria 
cells (used as a source of MAbs) can be grown to a 
high cell density in 1 - 2 days (using readily 
available fermentation vessels), whereas hybridoma 
cells, in comparison, require several weeks of 
growth to achieve only moderate cell densities A 
major advancement, using recombinant DNA techniques, 
is that it may no longer be necessary to immunise 
animals in order to obtain MAbs directed against a 
particular Ag This will be a welcome development 
to many researchers, including McGuil and Rowan 
(1989), who expressed concern over the levels of 
stress (and distress) caused to animals by 
conventional hybrldoma-forming methods of MAb 
production
Recent developments in modifying Abs, using genetic 
engineering or fusion techniques, have also resulted 
in new types of reagents such as chimaeric Abs and 
quadromas (Reuveny and Lazar, 1989) Chimaerics are 
Abs consisting of mouse variable regions with the 
human constant region, thereby suitable for use in 
humans since they combine mouse Ab specificity with 
low immunogenicity of the human fraction Quadromas 
are bifunctional Abs with two different active sites 
generated by the fusion of two different hybridomas 
One potentially invaluable application of 
bifunctional Abs is in the treatment of cancer, 
where one of the "arms" of the Ab could bind to a
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tumour marker and the other to a drug, toxin or 
cytotoxic cell One of the most significant 
advantages of bifunctional Abs is that the Ab 
molecule is active in its native state and requires 
no chemical alteration in order to bind either the 
target cell or the functional agent (Nolan and 
O'Kennedy, 1990) Fanger &1.(1991) stated that 
results from recent clinical trials, using 
bifunctional Abs which bind to target cells and 
trigger molecules (such as T-cell receptors), 
demonstrated the potential of these reagents to 
redirect and focus natural immune mechanisms in the 
treatment of tumours and infectious disease without 
the side effects of drugs, radioisotopes or toxins
MAb technology, being all of 16 years old, is still 
in its infancy, with its full potential still to be 
realised The significant advances which have been 
made since the genesis of this technology, coupled 
with the extensive research presently in progress, 
indicate that MAbs will soon enter the frantic and 
fruitful phase of adolescence
Extensive research has shown that alterations in the 
cell surface components of bladder tumour cells 
greatly affects tumour behaviour (Richie r
1982) For example, the presence or absence of 
blood-group Ags (A, B and H) can be used to predict 
the biological behaviour of transitional cell 
carcinoma of the bladder (D'Elia jei. al r 1982) The 
concensus among clinical urologists is that the loss 
of blood-group Ags from the surface of neoplastic 
epithelial cells is correlated with aggressive 
tumour behaviour, whereas bladders with 
morphologically similar tumours, which retain these 
Ags, do not develop invasive disease (Vallancien £Lk
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al , 1983, Wiley fit al / 1982, Lange fit al , 1978,
Bergman and Javadpour, 1978)
Methods used to demonstrate the presence of these 
blood-group Ags have included immunofluorence, using 
polyclonal antisera (Hammou fit. al , 1982), and the 
specific red cell adherence (SRCA) test (Coombes fit. 
al. P 1956) MAbs have also been used to detect 
these Ags Stephenson fit. al (1985) produced a 
panel of MAbs directed against A, B and H Ags, 
thereby enabling greater sensitivity and specificity 
in the detection of these prognostic markers It 
has also been reported that expression of the 
normally cryptic blood group-related Thomsen- 
Friedenreich Ag (T-Ag) in bladder carcinoma, also 
heralds an unfavourable prognosis (Coon fit al , 
1982) Summers fit al (1983) found that bladder 
tumours, in which the T-Ag is undetectable after 
neuraminidase treatment, were also highly 
aggressive This important result provided direct 
evidence that surface NANA plays a major role in the 
determination of the metastatic potential of bladder 
tumour cells, whereby removal of NANA significantly 
alters the surface expression of blood-group Ags
Numerous attempts have been made to produce MAbs 
against tumour Ags that are unique for cancer of the 
bladder (Grossman, 1983, Gozzo et a 1 1977,
Trejdosiewicz fit al / 1985) . However, the results 
have been disappointing In fact, no significant 
marker of human bladder cancer has been consistently 
demonstrated (Huben, 1984). At best, MAbs detect 
differentiation Ags with various degrees of 
restricted expression (Lange and Limas, 1986). A 
tumour specific Ag, unique to human bladder cancer, 
has yet to be found (Steffens fitai., 1985) 
Eludication of the mechanisms involved in neoplastic
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transformation of the bladder remains a formidable 
challenge. George R . Prout Jr , an emminent 
clinical urologist, stated that, "there is more to 
learn about bladder carcinoma now than there was 
twenty five years ago" (Prout, 1982) Ogasawara fit 
al (1988) further implied a role for surface NANA 
in the antigenic properties of human tumour cells, 
whereby pretreatment of immunised human gastric 
cancer cells with neuraminidase, enhanced binding of 
tumour-specific MAbs
Based on our previous biochemical investigation of 
total NANA content m  the sera of patients with 
cancer of the bladder, and the aforementioned work 
of Summers fit (1983) and Ogasawara fit &I_
(1988), the aims of our immunoglocial investigations
were as follows
1 To produce a panel of murine MAbs directed
against human bladder tumour (EJ) cells, in the 
hope of finding a tumour-associated Ag unique 
for this particular cancer
2 To investigate the biochemical nature of any
such Ag, with particular regard to any 
structural contribution made by NANA.
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7 . 2
EXPERIMENTAL DESIGN
The sequence of methodologies used to generate MAbs 
against human bladder (EJ) cells were as follows:
Immunization of Balb/c 
mice with whole EJ celle 
(Section 2.5)
ELISA screening of mice 
sera for Ab production 
(Section 2.6.2)
NS0 myeloma cells tested 
for HAT sensitivity (Section 
2.7.1) and presence of 
Mycoplasma (Section 2 4.12)
Seeding of macrophage cells one 
day prior to fusion (Section 2 7.4)
Fusion of Ag-stimulated B lymphoctyes (derived from mouse 
splenocytes) with NS0 myeloma cells (Section 2.7 5)
ELISA screening of hybridomas for Ab production 
(against EJ cells)
Elimination of "sticky” Abs by ELISA screening against BSA
Expansion and cloning (by limiting dilution) of anti-EJ Ab 
secreting hybridomas (Section 2.7.7).
ELISA screening of c ones against EJ cells
Recloning of Ab-secreting clones (to ensure monoclonality)
ELISA screening of clones against normal blood leucocytes 
and tonsillar lymphocytes (to eliminate Abs reactive with 
non-tumour-associated Ags
Growth of EJ-specific Ab-secreting clones as ascitic tumours 
in Balb/c mice (Section 2.7.8)
Determination of specific Ab titre (in ascitic fluid) using
ELISA (Section 2.6.2)
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7 3
RESETS
A total of 15 fusions were performed during the 
course of this immunological investigation, The 
first 13 fusions were unsuccessful, resulting in no 
hybridoma formation The most likely causes of 
these failures were technical errors during the 
difficult fusion procedure, whereby the slightest 
deviation from the recommended protocol results in 
unsuccessful fusing of the parent cells (Fazekas de 
St Groth and Scheidegger, 1980)
The first successful fusion (No 14) yielded 
hybridomas However, the Ab-secreting abilities of 
these hybridomas were found to be poor A total of 
16 hybridomas secreted Ab, albeit weakly, when 
initially screened against EJ cells (in 96-well 
plates) Expansion of these hybridomas, into 24- 
well plates, was followed by rescreening. No 
hybridoma was found to secrete Ab levels which 
merited further investigation In fact, many 
hybridomas ceased to secrete Ab altogether This is 
a common problem encountered in MAb production, 
whereby unstable hybridomas lose the ability to 
secrete Ab during initial stages of expansion 
(Goding, 1980). The results obtained for ELISA 
screening of these hybridomas (in 24-we11 plates) 
are provided in Table 7 1.
Thankfully, the final fusion (No. 15) produced 
interesting hybridomas In this fusion, hybridomas 
were seeded in four 96-well plates After ten days, 
growth was observed in 62-we11s, representing a 
fusion success rate of 16% The first ELISA 
screening, after 11 days, showed Ab production in 28 
wells (45%) Following expansion (into 24-we11
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plates) and rescreening (using ELISA) Ab
production was found m  16 wells (57%) Due to time 
restrictions, it was decided to concentrate on the 
strongest reactor, 2AC2 (i e. the hybridoma showing 
the strongest reactivity with EJ cells, based on 
ELISA results) . The subsequent progress of this 
hybridoma is summarised in Table 7.2.
Examination of Table 7 2 shows that, ultimately, 
only two clones were generatd which showed Ab 
reactivity with human bladder cancer (EJ) Ags One 
of these potentially useful clones, A5F9, was grown 
as an ascitic tumour in Schofield mice Following 
removal of the ascitic fluid, the Ab titre was 
determined to be in excess of 1 7,000 (Table 7 3),
based on ELISA screening of a range of ascitic fluid 
dilutions (Figure 7 1 and Table 7 4)
7 4
DISCUSSION
The production of MAbs is a long and arduous task 
(Galfre and Milstein, 1981, Hurrell, 1982) The 
prerequisites for a successful experiment include
1 Correct Ag presentation and immunisation 
regimen
2 An efficient method of screening for Ab 
production
3 Good aseptic and cell culture techniques
4. Efficient safeguard procedures.
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The first stage in MAb production requires 
stimulating the immune system of a specific host 
with the Ag of interest (e g tumour derived Ags), 
resulting in Ab production Ags of very low 
molecular weight (M W , less than 1000), are 
generally very poorly immunogenic, but may evoke 
strong responses when coupled to larger (more 
immunogenic) carrier molecules, such as BSA or 
ovalbumin (Goding, 1983) Ags of higher M W  do not 
require conjugation.
The immune system of the host can also be primed by 
injection of immunostimulants (Sikora and Smedley, 
1984) The most commonly used imunostimulant is 
Freund's complete adjuvant (Herbert, 1973) Use of 
this adjuvant requires the mixing of equal portions 
of a diluent (such as saline) , in which the Ag is 
dissolved or suspended, with an emulsifier-mineral 
oil mixture (containing Mycobateria) However, the 
use of Freund's complete adjuvant (potentially 
hazardous) requires caution Accidental injections 
into humans can cause severe, chronic inflammatory 
reactions (Mishell and Shngi, 1980) With cell 
surface Ags (as was the case in our experiments), 
adjuvant is not necessary since these Ags are 
usually highly immunogenic when presented on intact 
(e.g EJ) cells (Goding, 1980) Having decided on 
an immunisation regimen, it is of critical 
importance that injections are performed on the 
specified days and that splenocytes are collected 3 
days after the final Ag boost, so as to ensure that 
B-cell clones of interest are maximally stimulated 
(Milstem, 1982) . As already stated, no tumour- 
specific Ags have been found for cancer of the 
bladder. Consequently, if such Ags exist on the EJ 
cell, they are unlikely to be very immunogenic. 
Furthermore, our search for MAbs, directed against
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bladder tumour associated Ags, required the 
injection of whole EJ cells The problem with this 
approach is that there are immunodominant components 
in the Ag (whole EJ cell), namely that of normal Ags 
(present of the surface of the EJ cells) over the 
weakly immunogenic tumour-associatd Ags (Mayer and 
Walker, 1987)
Therefore, it was necessary to have a sensitive and 
specific ELISA, capable of detecting a weak immune 
response (directed against tumour-associated Ags) 
against a high background of normal Abs
The ELISA assay plays a pivotal role in the process 
of MAb production, with its principal functions 
being the following
1 Evaluationof an imunisation regimen by testing
serum from an immunised mouse, prior to a
somatic cell fusion experiment, for Ab
production
2 Initial screening of all hybndomas to test for 
Ab production
3 Elimination of "sticky" Abs by screening against 
BSA
4 Elimination of non-tumour-associated Abs by
screening against normal cells.
5 The routine monitoring of clones for continued 
Ab secretion
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It is, therefore, essential that the assay is fully 
functional prior to the commencing of a fusion 
experiment, as a large number of samples may require 
screening over a limited time period (Pruslin fit 
¿1 , 1991)
As the process of MAb production is a lengthy one, a 
prerequisite for success is good asceptic technique. 
Care must be taken at all times to minimise the 
occurrence of microbial contamination. It is also 
advisable that all of the relevant cell culture 
methodologies are thoroughly practised, prior to the 
starting of an actual fusion experiment Finally, 
it is important that safeguard procedures are in 
place (to protect valuable clones), namely, back-up 
generators for all incubators, and efficient 
auxiliary CO2 supply
Overall, the results of this immunological 
investigation were extremely disappointing There 
was a very considerable input of effort before 
anything was gained The high failure rate for the 
fusions (86%) meant that when hybndomas were 
eventually obtained, there was very little time to 
do any clinically significant evaluation, since it 
was necessary to stop experimenting at a time when 
the really interesting work was only beginning. 
Hybridoma 2AC2 was cloned twice before its large 
progeny were screened against normal cells. It 
could be argued that this screening should have been 
performed at a much earlier stage, thereby 
eliminating a large number of uninteresting clones. 
However, since antibodies were raised against a 
whole tumour cell (containing many normal antigens), 
it was necessary to ensure monoclonality, prior to 
screening against normal cells, so as to prevent the 
loss of potentially valuable clones One such clone
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(A5F9), not reactive with normal cells, yielded a 
good titre, whereby it could detect the presence of 
EJ cells when diluted in excess of 1 7000
The major problem with all but two of the Abs 
obtained was that they reacted with normal Ags 
present on the surface of the EJ cell Furthermore, 
while the remaining two Abs, reactive with EJ Ags, 
were found not to react with normal Ags (present on 
either tonsillar lymphocytes or blood leucocytes), 
it would be necessary to carry out further extensive 
characterisation studies, by screening against a 
panel of both normal and tumour cell types, before 
they could be truly designaed as recognising 
uniquely bladder tumoiir-associated Ags
Since the existence of bladder tumour-associated Ags 
has yet to be proven (as discussed m  Section 7 1), 
it is possible that no uniquely bladder-specific 
tumour Ags exist on the surface of the EJ cell 
Nevertheless, this does not mean that the Abs are of 
no use It is not an essential prerequisite that an 
Ab should exhibit absolute specificity for a tumour, 
as against normal cells, m  order for Ab to be of 
use in the detection of cancer (O'Carroll, 1988) 
Abs demonstrating only very low levels of reactivity 
with normal cells (as opposed to tumour cells) can 
be of use in the detection and in vivo localisation 
of a tumour In other words, an Ab need only be 
"operationally specific" for the tumour cell (Feder 
fit. 3.1 / 1983) In relation to the bladder tumour
Ag, it is not stictly necessary that the specific 
marker is exclusive of the tumour it is sufficient 
that it is specific in the given situation (Cimino 
Bt_ a 1 , 1987) For example, an exclusively
embryonic Ag may be an absolute marker for tumour if 
found outside its normal situation
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7 5
CQMC W P ING CQMENHS
A monoclonal antibody (A5F9) was produced which 
reacted with the EJ human bladder carcinoma cell 
line, yet showed no reaction with either normal 
tonsillar lymphocytes or blood leucocytes Analysis 
of ascitic fluid showed a capability for E J 
detection at dilutions in excess of 1 : 7000 These 
results suggest that further evaluation of this 
antibody may be warranted to assess its clinical 
potential
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Table 7 1 Screening of Hybridomas against EJ 
Cells (Fusion 14)
HYBRIDOMA AVERAGE O.D AT 405 nm
BB2 N A.D .
BB4 0.100
BBC4 0 073
DB4 N A D
AB4 0.130
AB2 0 125
DDB2 0 140
DDB4 0 170
EB4 N A D
EC2 0 120
CCB2 0 120
CB2 N A D
BAB 2 N A D
BAB 4 N A D
DB3 0 060
DB4 0 080
Positive Control* 0 D (av ) = 0 621
Negative Control** • 0 D (av.) = 0 120
* Serum from EJ immunised mouse (neat)
** Serum from non-immunised mouse (neat)
N A D  : No Ab Detected
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Table 7 2 Results obtained from Immunological 
Investigation of Hybndoma 2AC2
I n i t i a l  R e a c t i v i t y  o f  
2 A C 2 w i t h  E J  C e l l s
A v e r a g e  0  D o f  2A C2 
-  0 3 6 4
A v e r a g e  0  D o f  n e g  c o n t r o l  
= 0 0 7 7
2A C 2 4 7
n e g .  c o n t r o l
W e l l s  w i t h  g r o w t h  a f t e r  
f i r s t  c l o n i n g  o f  2A C2 Iff <60%>
W e l l s  s e c r e t i n g  A b  
a g a i n s t  E J  c e l l s 2^ <26%>
W e l l s  s e c r e t i n g  A b  
a g a i n s t  E J  c e l l s  
f o l l o w i n g  e x p a n s i o n
7 5  (81%>
W e l l s  s e c r e t i n g  " s t i c k y ” 
A b 6 1  (2 6 % )
L o s s  o f  c l o n e s  
( i n c u b a t o r  s h u t d o w n ) S  <3 3 % >
W e l l s  w i t h  g r o w t h  
a f t e r  s e c o n d  c l o n i n g  o f  
B 5B 2  ( a  c l o n e  o f  2 A C 2 )
a  «">
C l o n e s  s e c r e t i n g  A b  
a g a i n s t  E J  c e l l s M 2  ( 7 % )
C l o n e s  f o u n d  t o  s e c r e t e  
A b  a g a i n s t  n o r m a l  A g s ( 8 9  5%)
N u m b e r  o f  s e c o n d -  
g e n e r a t i o n  c l o n e s  
s e c r e t i n g  a n t i b o d i e s  
a g a i n s t  E J  t u m o u r -  
a s s o c i a t e d  A g s
£  <10  5%) 
( A 5 F 9  a n d  B 1 F 7 )
172
Table 7 3 Calculation of Ab Titre for Clone A5F9
Cut-off O.D. Value 0,231 *
Corresponding Dilution 
of Ascitic Fluid
1 : 4255 ^
i
Dilution of Fluid
(by PBS) during removal
1 1.75
Actual Ab Titre 1 * 7446
* The cut-off 0 D value, used to determine Ab 
titre, was defined as the 0 D value 0 1 units 
greater than that of the control (PBS, 0 131)
i
i
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Table 7 4 0 D Readings for Determination of Ab
Titre for Clone A5F9
ASCITIC FLUID 
DILUTION
AVERAGE 0 D AT 450 nm
1 1 0 0 4 7 3
1 1 0 0 0 3 2 9
1 5 0 0 0 3 0 0
1 1 0 0 0 0 2 8 7
1 2 5 0 0 0 2 5 9
1 5 0 0 0 0 2 2 1
1 1 0 0 0 0 0 1 8 7
1 2 0 0 0 0 0 1 8 0
1 3 0 0 0 0 0 1 0 3
Ascitic Fluid diluent PBS
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